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Abstract 
 Amongst the plethora of organic compounds of selenium studied till date, bivalent 
organodiselenides have been of topical interest as validated from their potential anti-
infective and anti-carcinogenic properties. In due consideration, the present research work 
is primarily focused on the design and synthesis of versatile diselenides, in addition to 
other related chalcogen derivatives, with an aim to delineate their potential molecular and 
cellular modes of action.The most active organodiselenides were confirmed to induce 
caspase-mediated apoptosis in KB-3-1 cancer cells. A highly active quinoline-
functionalized organo-diselenide targeted the translational machinery in addition to a dual 
inhibition of the Raf/MEK/ERK and the PI3K/Akt/mTOR pathways of KB-3-1 cells. 
ERK2 was identified as its potential cellular targetin a DARTS experiment.Unlike the 
chalcophenes, the most active organodiselenides exhibited a poor radical scavenging and 
reducing ability. In contrast, the phenolic hydroxyl group was hypothesized as a probable 
antioxidant pharmacophore in the very active chalcophenes. This study also identified 
thioredoxin reductase as a potential cellular target of certain chalcogen-containing 
naphthoquinones which could possibly explain their ability to induce tumour cell death via 
ROS generation. Considering the unprecedented potential of organoselenium compounds 
to target important cellular proteins in tumour cells, future interdisciplinary studies are 
required for a more comprehensive elucidation of their chemical and biochemical modes of 
action against cancer and other life-threatening diseases. 
iii 
 
Zusammenfassung 
Von den zahlreichen Organoselenium-Verbindungen, die bis heute untersucht wurden, sind 
die Organodiselenide wegen ihrer potentiellen Wirkung als Anti-Infektiva und Anti-
Krebsmittelvon besonderem Interesse. Aus diesem Grund fokussierte sich diese 
Doktorarbeit in erster Linie auf die Synthese und Skizzierung der molekularen und 
zellulären Wirkmechanismen der Organodiselenide und verwandter Organochalkogen-
Verbindungen. Für die erste Gruppe konnte bestätigt werden, dass sie in KB-3-1-
Krebszellen eine Caspase-vermittelte Apoptose induziert. Ein hochaktives Chinolin-
funktionalisiertes Organodiselenidhemmte den Raf/MEK/ERK und den PI3K/Akt/mTOR-
Signalweg und wirkte auf das Translations system der KB-3-1-Zellen. ERK2 wurde in 
DARTS-Experimenten als das mögliche zelluläre Zielprotein identifiziert. Anders als die 
Chalkophene zeigten die aktivsten Organodiselenide eine geringe Aktivität als 
Radikalfänger und geringes Reduktions potential. In den in dieser Hinsicht sehr aktiven 
Chalkogenen wurde die phenolische Hydroxylgruppe als mögliches 
Pharmakophorangesehen. Diese Studie identifizierte die Thioredoxin-Reduktase als ein 
mögliches zelluläres Zielprotein einiger Chalgogen-enthaltender Naphtochinone, was 
möglicherweise ihre Fähigkeit erklärt, durch ROS-Generierung den Tod von Tumorzellen 
zu induzieren. Im Hinblick auf das beispiellose Potential der Organoselenium-
Verbindungen, zelluläre Proteine von zentraler Bedeutung in Tumorzentralen zu 
adressieren, sind in Zukunft interdisziplinäre Untersuchungen nötig, um ihre chemischen 
und biochemischen Wirkmechanismenbei Krebszellen und anderen lebensbedrohenden 
Krankheiten aufzuklären. 
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Chapter 1 
1.1 Selenium- a valuable micronutrient 
Selenium is an indispensable micro-nutrient that occurs in a low percentage in 
nature. In contrast to its availability in trace amounts in its elemental state, it is found 
more often as selenides of iron, lead, silver or copper. Most of the physiological content 
of selenium is derived from the diet, in addition to a fraction that constitutes important 
cellular proteins, in the form of selenocysteine, SeC. The selenium content in food 
varies with nature and location of cultivation of the forage. Broadly, seafood, nuts, 
poultry and grains are well-recognized sources of selenium. 
Before delving into the chemotherapeutic effects of selenium, it is pertinent to 
have a brief overview of selenium and the diverse chemical forms, in which this 
element exists in nature. In nature, selenium exists primarily intwo forms- seleno-
proteins and non-selenoproteins. The naturally occurring seleno-proteins like GPx and 
TrxR are cellular enzymes that exist, in varying amounts, in all forms of life and are 
characterized with a common selenocysteine (SeC) containing amino acid residue. To 
date, 25 different SeC-containing selenoproteins have been identified in mammalian 
cells. However, SeC that serves as an important structural unit of selenoproteins also 
finds its non-physiological source in a variety of foods of either animal or plant origin. 
In food, however, in addition to its primary availability in the form of selenomethionine 
(SEM), selenium is also found in the form of selenates and selenites [1]. Amongst the 
various food sources, Brazil nuts and sea-food have been widely considered as the 
richest source of selenium [2].  
Apart from seleno-proteins, several types of selenium-containing compounds 
are also available in nature and may also be prepared through synthetic methodologies. 
These can be broadly classified furtherinto two chemical forms-inorganic selenium and 
organic selenium which are available in four different oxidation states [1]. 
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Table 1.1 Representation of different chemical forms of selenium  
Group Members 
Diselenides/ 
monoselenides 
Ar2Sexor R2Sex; x=1/2; Ar = Aryl group, R = alkyl or alkynyl 
group (also includes metal diselenides/monoselenides like 
tungsten diselenide and iron(II) selenide) 
Compounds with Se
6+
 Selenates (M2SeO4) ; M = alkali metal  
Compounds with Se
4+
 Sodium selenite (Na2SeO3); Alkyl/Aryl seleninic acid; 
Selenous acid (H2SeO3); Selenium dioxide (SeO2) 
Se-heterocyclic 
compounds 
1,3-Selenazolin-4-one derivatives; 2,5-Bis(5-hydroxymethyl-
2-selenienyl)-3-hydroxymethyl-N-methylpyrrole;2-Phenyl-
1,2-benzisoselenazol-3(2H)-one(ebselen);1,2-[Bis(1,2-benz-
isoselenazolone-3-(2H)-ketone)]ethane (BBSKE); 2-Butyl- 
selenazolidine-4-(R)-carboxylic acid (BSCA); 2-Cyclo- 
hexylselenazolidine-4-(R)-carboxylic acid (ChSCA),Se4N4 
Selenocyanates Ar/R-SeCN ( Ar=aryl group; R= alkyl/alkynyl group); Ar-
Se2CN[7] 
Halogenated seleno-
compounds/ 
(electrophilic selenium-
containing molecules) 
RSeX (R= aryl/metal; X= halogen); selenonium ion (H3Se
+
or 
(CH3)3Se
+
) 
In addition, the availability of elemental selenium in minerals and as 
nanoparticles in soils has also been observed. The soils in the state of Punjab in 
Northern India, for instance, have been reported to be enriched with selenium 
nanoparticles by the reducing action of certain bacteria on water-soluble selenites [3]. In 
its elemental form, selenium exists in six natural isotopic forms and 24 unstable isotopic 
forms [4]. 
As can be seen in Table 1.1, representative examples of various inorganic and 
organic forms of selenium have been demonstrated. Briefly, the inorganic forms of 
selenium include selenites, selenates, halogenated selenium compounds, selenoacids 
and even potential explosives like Se4N4. Organic forms of selenium include selenides, 
diselenides, aryl/akyl functionalized seleno acids, selenocyanates and several selenium-
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containing heterocyclic compounds. Recently, a novel selenium compound called 
selenoniene has been identified a predominant form of organic selenium in the blood of 
tuna fish [5].This compound has been further characterised as a potential antioxidant 
with an ability of attenuating methyl-mercury induced toxicity [5, 6]. 
1.2 Etiology of Cancer  
In view of its significant anti-oxidant and anti-inflammatory properties, 
selenium is more popularly recognised to harbor potential efficacy in reducing the 
development and progression of cancer. Therefore, prior to a discussion regarding the 
role of selenium in combating cancer, an insight into this disease and its etiology 
become important [8]. 
1.2.1 What is cancer?        
Popularly referred to as the "King of maladies", cancer is generally 
characterized by an uncontrolled growth of cells in a specific region (benign tumour) or 
throughout the living body (metastasized tumour). Since all forms of cancer originate 
from cells, so the cells that are often termed as building blocks of life may also serve as 
building blocks of death. More than 100 different types of cancer have been reported so 
far, depending on the region or organ of the body being affected by it. The onset of this 
disease is often characterized by several physical symptoms that may or may not be 
specific to a certain type of cancer. An early diagnosis of cancer-related symptoms can 
therefore, be highly instrumental in curbing the disease before it metastasizes to other 
parts of the body. 
1.2.2 Why do people get cancer? 
“It’s all in the genes!”- A saying that is befitting to one of the plausible causes 
of cancer. Cancer can be the outcome of a genetic predisposition that is inherited from 
family members. This means anyone born with mutations in one copy of a damage-
controlling gene which normally protects against cancer has a genetic predisposition for 
one or more types of cancer. For instance, approximately 5% of all cases of colon 
cancer are due to genetic inheritance of corresponding mutated and cancer-causing 
syndromes [9]. Environmental factors in the form of carcinogens also play a prominent 
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role in enhancing the risk of cancer. This group of substances is widely responsible for 
inducing mutations in the cellular DNA that activates an unprecedented number of 
intracellular biochemical events, eventually leading to cancer. For instance, a big 
section of the population is under the influence of smoking-a major cause of cancer. 
Though harmless in physical appearance and regarded as a stress buster, the tobacco of 
a cigarette releases a lethal cocktail of approximately 70 carcinogens with hundreds of 
cumulative poisons including nitrosamines and polycyclic aromatic hydrocarbons that 
serve as neurotoxins and found to induce DNA-methylated lesions [10].Apart from 
smoking, sporadic exposure to high-energy radiations such as gamma and X-rays also 
promote melanoma via oxidative cellular damage and production of immune 
suppressive cytokines[11].Moreover, the increasing role of pathogenic agents in the 
etiology of cancer can be partially comprehended by recent reports recognizing HPV 
infection as a prominent cause of cervical cancer [12]. These and several other forms of 
viruses like hepatitis B and C suppress the immune resistance of the body, thereby 
making it vulnerable to carcinogens.  
1.3 Biochemistry of cancer       
In an attempt to circumvent as well as combat cancer, an unprecedented 
number of natural and synthetic selenium-incorporated compounds have been 
exhaustively investigated for their chemotherapeutic efficacy. Although numerous in-
vitro and in-vivo studies have reported the positive role of selenium in the fight against 
cancer, results obtained from various case studies and random clinical trials have given 
a rather mixed response regarding the futuristic fate of selenium as a chemotherapeutic 
agent. This response has been found to vary both on the basis of gender of the patients 
and source of selenium supplements given to them. Results from the NPCT and 
SELECT trials have also introduced questions regarding the probable toxicity from 
long-term exposure to selenium supplements [13].Therefore, in order to exploit the 
maximal chemotherapeutic advantage of selenium under a safe pharmacological profile, 
it is essential to strengthen and broaden the existing knowledge of the anti-carcinogenic 
mode of action of selenium-containing compounds under varying modes of dosage and 
chemical source. Prior to doing so, it is indispensable to understand the basics of the 
etiology of cancer and the biochemical role played by selenium in its combat against 
cancer. 
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1.3.1 Cancer cells versus normal cells 
Under physiological conditions, normal cells and tumorigenic cells monitor 
their biological activities including development, tissue repair, immunity as well as 
normal tissue homeostasis on the basis of their complex system of inter and intra-
cellular pathways of communication[14]. An important and striking difference in the 
functioning of normal cells and tumorigenic cells lies, therefore, in the extent of activity 
of their cellular signalling pathways. Mutation(s) in any of these pathways often lead to 
their abnormal and dys-regulated functioning, resulting in uncontrolled cellular growth 
and enhanced cell survival, accompanied by a disruption of intra-cellular redox 
homeostasis [15]. Such events individually or synergistically lead to cellular disparities 
that can be characterized in the form of ectopic hypertrophy,enhanced cellular motility 
and deformity of cellular tissues. An in-depth comprehension of the intricacies of these 
biochemical pathways and their relevance with respect to cellular insults like cancer has 
played an important role in opening new therapeutic windows in fighting cancer and 
several other degenerative diseases. Within the library of chemotherapeutic agents, a 
plethora of selenium-incorporated molecules, via a cascade of active metabolites, have 
been reported to exhibit anti-proliferative activity against tumour cells by targeting 
some of these crucial intra-cellular biochemical pathways [16]. However, the 
biochemical mode of interaction of selenium with these signalling modules has been 
observed to fluctuate with dose and chemical form. Due to the biological scope of the 
work done in this thesis, the content of discussion of selenium´s biochemical effects will 
be limited to the modulatory effects of organodiselenides towards twoparticular 
signalling pathways that have been frequently observed to be constitutively over-
activated in tumorigenic cells,in-vitro and in-vivo, and share a cross-talk with its intra-
cellular protein translational machinery. 
1.3.2 Hyper-activated protein translation in cancer cells 
In eukaryotes, in particular, protein translation is a tightly regulated and a 
highly energy-demanding process required for cellular survival and proliferation[17]. 
Playing a pivotal role in regulation of gene expression, mRNA translation is highly 
dysregulated and over-activated in tumour-struck cellular tissues as characterized by 
subsequent genetic alterations leading to abnormal cellular mass and irregular 
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morphology [18].Proceeding in three distinct, yet highly orchestrated steps, protein 
biogenesis basically involves the translation of mRNA into proteins in the cytoplasmic 
region of a cell by utilizing ribosomes as a template. In eukaryotic cells, the process of 
translation has been widely studied to operate mainly via a "cap-dependent process". 
However, another form of translation that is independent of the presence of intact 5' cap 
is called cap-independent translation or IRES-mediated translation. In approximately 
10% of eukaryotic mRNA, translation is initiated via this cap- independent mechanism 
and is the preferred method of protein synthesis when cap-mediated translation is 
partially or completely attenuated under conditions of patho-physiological cellular stress 
including hypoxia, genotoxic stress and apoptosis [19]. 
1.3.2.1  eIF4E-driven protein translation 
In context to this thesis, the discussion will be directed towards the more 
commonly observed cap-dependent process. Briefly, this involves the binding of eIF4E 
complex to the 5' end of all nuclear-encoded eukaryotic mRNAs, commonly referred to 
as the "cap structure". This complex consists of the cap-binding protein, eIF4E, the 
RNA helicase (eIF4A) and the scaffolding protein eIF4G [20, 21]. The process of cap-
dependent mRNA translation occurs in three stages: initiation, elongation and 
termination, all of which are highly regulated although the initiation phase is proposed 
to be the limiting step [18].  
Amongst the various translation-promoting factors mentioned above, the 
oncogenic role of eIF4E is perhaps the most well established [22]. Being a relatively lesser 
abundant translation factor, eIF4E which is highly expressed and widely recognised as an 
oncogene in various types of tumour is hypothesized to be a rate-determining component of 
the translational machinery [20, 23]. Hyper-activation of eIF4E is a consequence of its over-
expression and/or alterations in its regulatory cell signalling pathways [20]. Over-activation 
of eIF4E in tumorigenic cells has been reported to proceed mainly through two levels. One 
method involves the direct phosphorylation of eIF4Edirectly by MAPK kinase interacting 
Ser/Thr kinase 1 and 2 (MNK1 and MNK2). This is evident from the observation that non-
phosphorylated mutant of eIF4E have been reported to drastically impair oncogenic 
potential as compared to the wild-type eIF4E [24]. To further establish the role of the 
phosphorylation of eIF4E in tumorigenesis, knock-in mice expressing a non-phosphorylable 
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Figure 1.1 Regulation of translation by 
synergistic effect of the Raf-MEK-ERK 
and PI3K Akt-mTOR signalling pathway. 
Figure has been adopted from [29]. 
form of eIF4E were observed not to display any conspicous phenotypecontrary to that 
depicted by phosphorylated (activated) eIF4E [25]. 
An alternate mechanism of eIF4E regulation involves its availability to form the 
eIF4F complex. When eIF4E is bound to translation suppressor 4E-BP1, it is unavailable 
for binding with translation-promoting factor eIF4G. 4E-BP1 can only bind to eIF4E when 
it is hypo-phosphorylated. Therefore, when eIF4E is not bound to 4E-BP1 due to hyper-
phosphorylation, it is free to interact with eIF4G and promote translation [20]. 
1.3.3  Hyper-activated signalling pathways in cancer cells 
1.3.3.1 mTOR-mediated signalling: Promoting cancer via eIF4E-
driven protein translation 
It has been proposed that the mTOR gene is apivotal signalling module that can 
influence the rate of cellular translation by inactivating the translation suppressor gene4E-
BP1 via phosphorylation at residues Thr70 and Ser65 [26]. As a consequence, an enhanced 
disassociation of 4E-BP1 from eIF4E results in an increased availability of functional eIF4E 
for the formation of the eIF4F complex 
subsequently leading to enhanced protein 
translation [27]. Inactivation of such 
translation-initiation repressor proteins 
like 4E-BP1 by dephosphorylation has 
been thereby implicated in aberrant 
cellular protein biogenesis and 
consequently carcinogenesis. As can be 
seen in Figure 1.1, mTOR, which forms 
an important node of the PI3K-mediated 
signallingpathway, forms two complex 
esmTORC1 and mTORC2 out of which 
mTORC1, plays the most influential role 
in regulating translation. 
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mTORC1 complex includes mTOR that is in association with a scaffold protein, 
Raptor. The primary role of Raptor is to recognize and phosphorylate substrates carrying 
TOR signalling motifs including the translation repressor 4E-BP1 and rpS6K.   
Upon phosphorylation by TORC1 complex, activated S6K disassociates from 
eIF3 and phosphorylates its downstream substrates- rpS6 and eIF4B. Phosphorylation of 
eIF4B stimulates an association between eIF4B and eIF3 which boosts translation probably 
by activating eIF4A [28]. Therefore, an aberrant mTOR signalling as commonly observed 
in malignant cells promotes ectopic stimulation of oncogenic eIF4B, 4E-BP1 and ribosomal 
S6K1. This, in turn, facilitates uncontrolled cap-mediated protein translation that serves as a 
hallmark of cancer. The prominent oncogenic role of the mTOR-mediated pathway has also 
been observed in this study. In accordance with the obtained findings, 12 has been observed 
to antagonize the proliferation of KB-3-1 cells via inhibition of mTOR-mediated 
phosphorylation of 4E-BP1. This effect has been further reflected in the observation of a 
down-regulation of the translational efficiency in 12-treated KB-3-1 cells. 
1.3.3.1.1 Significance of mTOR in oncology: Evidence of success of 
mTOR inhibitors against cancer 
The predominant role of mTOR as a tumour-agonist has made way for the 
development of several mTOR-inhibiting small molecules. 
a) First-generation mTOR inhibitors 
The development of Sirolimus (also called rapamycin),for instance, as an 
anticancer agent, began after its isolation and identification as a macrocyclic triene 
antibiotic from the soil bacterium,Streptomyces hygroscopicus,in the mid-1970s.However, 
rapamycin has met with substantial pharmacokinetic challenges due to its poor lipophilic 
chemistry. Due to this, rapamycin has been used in combination with other 
chemotherapeutic drugs, to avoid side-effects [30]. In addition, various formulations of 
rapamycin have been analysed to improve its poor water solubility and bioavailability for 
clinical applications. Amongst these improvised rapamycin analogues, Temsirolimus and 
Everolimus have demonstrated a promising potential in the treatment of different lineages 
of cancer (Table 1.2). In view of its drug-like features, Temsirolimus has been recently 
approved by the FDA for treating renal-cell carcinoma [31]. Developed by Novartis, 
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Everolimus is another analogue of rapamycin that has been approved for the treatment of 
renal cell carcinoma in USA, in addition to breast cancer and tuberous schelorisis in the 
European Union [32]. A third and the latest analogue of rapamycin, Ridaforolimus (earlier 
called Deforolimus and developed by Merck) is currently being assessed for treatment of 
sarcoma and has yet to be approved by the FDA [30]. However, the success of rapamycin 
derivatives in clinical trials has been limited to a few types of cancer. This is because 
despite their partial mTOR inhibition, rapalogs (analogues of rapamycin) have been 
unsuccessful inrepressing a negative feedback loop that exists between mTORC1 and its 
upstream factor Akt in certain tumour cells thereby resulting in phosphorylation and 
activation of oncogenic Akt. 
b) Second-generation mTOR inhibitors 
In order to counter this problem, a second-generation small-molecule mTOR 
inhibitors (TORKinibs) have been generated that simultaneously inhibit the ATP-binding 
domain of mTOR and the catalytic activity of both mTORC1 and mTORC2. Therefore, the 
dual inhibition of both mTOR complexes with a higher degree of selectivity has led these 
agents to have stronger anti-proliferative potential than the naturally available mTORC1 
inhibitor-sirolimus [33]. A representation of several important mTOR inhibitors, assessed to 
date, can be seen in Table 1.2.  
Table1.2 Examples of rapamycin analogues and second generation mTOR inhibitors 
Compound Class Disease 
Temisirolimus 
(FDA approved) 
Rapamycin Renal cell carcinoma 
Ridafirolimus Rapamycin 
Breast cancer, Head and neck 
cancer, 
Soft tissue sarcoma, Colorectal 
cancer, Non-small cell lung cancer 
(NSCLC) 
Everolimus 
(FDA approved) 
Rapamycin Hormone receptor positive, HER2 
Negative breast cancer 
Agent OSI-027 2nd generation 
mTOR-inhibitor 
Lymphoma; solid tumour 
XL765 2nd generation 
mTOR-inhibitor 
Combinatorial therapy 
PP242 2nd generation 
mTOR-inhibitor 
Multiple myeloma 
Chapter 1 Introduction 
10 
 
1.3.3.2  Signalling via MAPK pathway: Another lead promoter of 
carcinogenesis 
In addition to mTOR -mediated signalling, the ERK-mediated MAPK pathway 
has also been reported to serve as an important contributor to cancer. The activity of the 
Ras-Raf-MEK-ERK cascade-mediate signalling which constitutes one of the streams of 
the overall mitogen-activated protein kinase (MAPK) cascade has been reported to be 
over-activated in about 30% of all human cancers. This is evident from several reports 
that have highlighted the contribution of active ERK as the other important promoter of 
carcinogenesis via uncontrolled intra-cellular protein translation and enhanced cellular 
survival [35]. This is partially evident from the report by Monick et al. that 
demonstrated the oncogenic role of  activated ERK in promoting protein biogenesis in 
human alveolar macrophages through activation of eIF2α [36].  
1.3.3.2.1  Protein kinase: general class of MAP kinases 
Owing to the importance of protein kinases, in general, and the ERK-mediated 
signalling cascade in particular, protein kinases represent bonafide drug targets that are 
receiving considerable attention from a large cadre of biomedical scientists for the 
treatment of several life-threatening diseases [37]. In order to comprehend the 
biochemistry of the Raf-MEK-ERK mediated MAPK signalling and its oncogenic role 
upon dys-regulation, an overview of the protein kinase family to which it belongs, 
therefore, becomes indispensable.   
Protein kinases are one of the largest and most influential amongst the gene 
families and constitute almost 2% of the entire proteome. Protein kinases, in general, 
play a predominant regulatory role in transmission of extracellular signals into their 
intracellular targets by a network of interacting proteins that regulate a large number of 
cellular processes. Comprising of a set of cytoplasmic serine/threonine kinases, protein 
kinases participate in the phosphorylation of substrate proteins and modify the activity, 
location and affinities of approximately 30% of all cellular proteins. These signalling 
modules which are highly conserved from yeasts to vertebrates, have been demonstrated 
to participate in the regulation of numerous cellular processes including cell adhesion, 
cell cycle progression, cell migration, cell survival, differentiation, metabolism, 
proliferation and transcription [38]. 
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Collective efforts from many research groups, over the past decade, have 
facilitated the elucidation of one such signalling mechanism that involves the 
stimulation of several signalling molecules followed by a sequential stimulation of 
several cytoplasmic protein kinases collectively known as mitogen-activated protein 
kinase (MAPK) signaling cascade. The MAPK signalling pathway contributes to the 
amplification and specificity of the transmitted signals that eventually activate several 
regulatory molecules in the cytoplasm and in the nucleus to initiate cellular processes 
such as proliferation, differentiation and development. Moreover, since many oncogenes 
have been demonstrated to encode proteins that transmit mitogenic signals upstream of 
this cascade, the MAPK pathway provides a common platform for the mode of action of 
most, if not all, non-nuclear oncogenes [39]. 
Due to the scope of the work done in relation to organoselenium compounds, 
emphasis will be directed primarily towards the first MAPK cascade that mediates its 
signalling via MEK and ERK, its cross talk with the Akt-mTOR pathway (that has been 
discussed above) and the modulatory effects exerted by compound 12 on the synergistic 
regulation of the ERK and mTOR-mediatedsignalling pathways in cervix carcinoma 
(KB-3-1) cells. 
1.3.3.2.2  General overview of functioning within the MAPK family  
All eukaryotic cells possess multiple MAPK pathways which coordinately 
regulate gene expression, mitosis, metabolism, motility, survival, apoptosis and 
differentiation. In mammals, MAPK can be activated by a plethora of stimuli but in 
general, activation of JNK and p38-kinasesis primarily due to stress-stimuli including 
ionizing radiation and inflammatory cytokines. Whereas JNK plays a role in the 
induction of apoptosis through extrinsic and intrinsic pathways, p38 MAPK is 
predominantly involved in inflammation by regulating cytokine production [40]. 
Conversely, activation of ERK-mediated MAPK is largely dependent on mitogenic 
stimuli like growth factors and phorbol esters that drive cellular proliferation via cell 
cycle regulation, in addition to various cell- survival mechanisms (Figure 1.2).Although 
each member of the MAPK family has distinct functions, they share some common 
characteristics as well. All pathways that collectively constitute the MAPK signalling 
have a sequence of events consisting of at least three components, a MAPK kinase 
kinase (MAP3K/MKKK), a MAPK kinase (MAP2K/MKK), and the MAPK. At the top, 
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MAP3Ks are often activated through phosphorylation and/or as a consequence of their 
interaction with a small GTP-binding protein of the Ras/Rho family, in response to 
extracellular stimuli. These serine/threonine kinases phosphorylate and activate the 
downstream MAP2Ks which in turn phosphorylate and activate MAPKs through dual 
phosphorylation on threonine and tyrosine residues. These activated MAPKs 
subsequently phosphorylate a plethora of substrate proteins that are involved in the 
regulation of cellular transcription and translation.  
 
Figure 1.2 Representation of different tiers of the MAPK family in the eukaryotic 
system. Figure adopted from [28]. 
Therefore, phosphorylation serves as a basic mechanism by which the activity 
of MAPK proteins is turned "on" or "off" across a wide array of biological processes 
from cell growth and differentiation through apoptosis to disease. 
The over-activation of the MAPK pathways has been frequently implicated in 
the etiology of several diseases like Alzheimer’s, Parkinson’s, ALS and cancer, thus 
making them potential targets for therapeutic intervention. For instance, over-activated 
JNK and p38 MAPKs have been proposed to mediate neuronal cell death in 
Alzheimer’s, Parkinson’s and ALS. On the other hand, constitutive activation of the 
ERK pathway is believed to play a pivotal role in tumorigenesis through cell 
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proliferation and cell survival mechanisms. Therefore, the Raf-MEK-ERK signalling 
cascade shall be discussed in more detail, with due relevance to its modulation by anti-
carcinogenic selenium-containing compounds. 
1.3.3.2.3 Raf-MEK-ERK- mediated signalling pathway  
In an attempt to outline the pivotal nodes of the Raf-MEK-ERK cascade, at the 
level of MAP3Ks, the Raf genes are categorized into A-Raf, B-Raf and Raf-1 (or c-
Raf). These three different isoforms constitute the first tier in the MAPK cascade. These 
three isoforms differ in their ability to activate their immediate downstream substrate, 
MEK1/2. Amongst them, A-Raf is a relatively less-characterized isoform amongst the 
Raf members and is apparently a poor activator of MEK1/2 [41]. Ser432, Thr452 and 
Thr455 sites in A-raf are the important phosphorylation sites, responsible for its 
catalyticactivity. In addition to these sites, Zhu and colleagues have reported that 
phosphorylation of c-Raf at Ser471 is required for its interaction with its protein 
substrates, namely MEK1/2 [42]. 
B-Raf,on the other hand, has also been found to be widely expressed but more 
predominantly in neuronal tissues [43]. Amongst these Raf members, B-raf has been 
observed to play a more prominent role in activating the downstream substrate, MEK. 
To summarize, within the Raf family, B-Raf is considered to be the most potent and A-
raf has been found to be the weakest activator of its MAPK pathway. However, in 
context with the content of thesis, the relation and implications of c-Raf with respect to 
its oncogenic role will be considered in more detail in this study. 
a) c-Raf: Role in promoting oncogenesis 
c-Raf (Raf-1) is a well-studied and pivotal member of the growth factor 
signalling molecules at the MAP3K level of the cascade. It is a 70-75 kDa 
serine/threonine kinase which upon stimulation by various mutagens undergoes a rapid 
and transient activation via phosphorylation. Extensive research has provided sufficient 
evidence that Raf-1 is located downstream of RAS, which seems to interact directly 
with the NH2- terminal portion of Raf-1 on stimulation [44]. In addition to Ras, several 
other kinases like PKC and tyrosine kinases have also been proposed to activate Raf by 
distinct mechanisms [45].Although several proteins and peptides have been reported to 
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serve as substrates for Raf-1, current studies suggest that it has very selective substrate 
specificity, highly preferring the native form of MEK over a list of other proteins and 
peptides. Constitutive activation of Raf-1 due to oncogenic mutations in upstream Ras 
genes has been implicated in the onset and progression of solid tumours [46]. This has 
been observed in Ras-mutated NIH-3T3 ﬁbroblasts that activate its downstream 
substrate, Raf-1, during metastasis in mice [47]. In addition, RKIP, a member of the 
phosphatidylethanolamine-binding protein family, has also been proposed as a 
suppressor of metastasis in prostate cancer, thereby indicating the potential oncogenic 
role of c-Raf. The high incidence of activating c-Raf mutations in melanoma cells has 
made it an ideal target for cancer therapy. Of the various chemotherapeutic agents 
targeting Raf, sorafenib is apparently the most promising as it is at the most advanced 
stage of clinical development. 
b) MEK1/2: Downstream of Raf-1 
Downstream of Raf, there exists MAP2Ks in the form of MEKs. Bearing an 
approximate molecular weight of 45kDa, MEK1 and MEK2 constitute the two isoforms 
of the MEK family. They are commonly referred to as MEK1/2. MEK1 and MEK 2 are 
expressed ubiquitously in mammalian cells, although in mice MEK2 appears to be more 
expressed during development with MEK1 being more highly expressed in adult 
animals[48]. MEK1 and MEK2 share approximately 85% similarity in their amino acid 
sequence. Although it is commonly assumed that the two isoforms are functionally 
equivalent, several lines of evidence indicate that they are regulated differently and may 
exert non-redundant functions [49]. This feature has been highlighted by the 
translocation of its downstream substrate, ERK2, to diﬀerent regions of the cell upon 
stimulation by activated MEK1 and MEK2 [50]. In addition, MEK1 has been reported 
to down regulate MEK2-dependent ERK1/2 signalling, suggesting that MEK1 and 
MEK2 may not be completely interchangeable [51].This suggests that MEK1and 2 
provide a specificity towards the activation of its downstream substratesERK1 and 
ERK2, in addition to an amplification of the MAPK.  
This, thereby, justifiesMEK1/2 as an important regulatory component of the 
mitogenic signaling cascade. The role of both MEKs in angiogenesis is indicated by 
their over-expression in a significant percentage of tumours. Stimulated by various 
stimuli, dephosphorylation of MEK1/2 proteins at two serine residues at positions 217 
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and 222 in the activation loop has been reported to inhibit in-vitro and in-vivo 
proliferation of a variety of tumour cell models, including HCC [52, 53]. 
c) ERK1/2: Critical promoters of carcinogenesis 
As mentioned earlier, MEK1/2 has been found to catalyze the activation of 
human ERK1/2, via phosphorylation, in a sequential reaction at Tyr204/187 and then 
Thr202/185. A subsequent activation of the ERK isoforms results in a further activation 
of a plethora of transcriptional factors promoting cellular protein synthesis and survival. 
Until hitherto, ERK has been characterised by a bag of mixed roles as far as 
stimulation of apoptotic cell death is concerned. Although there are many reports that 
highlight the pro-apoptotic role of ERK [54,55], a good number of reports have also 
demonstrated the opposite as well [56]. However, here again, in context to the work 
done, the anti-apoptotic role of ERK shall be primarily discussed, as has been observed 
in regard to the mode of action of 12 against cancer. 
1.4 ERK and cancer 
The ERK proteins have been widely reported to regulate the proliferation and 
survival of cancer cells in several ways. Although ERK has been demonstrated to behave 
either as a promoter and suppressor of apoptosis in tumour cells, the role of ERK in 
suppressing apoptosis shall be primarily discussed in view of the scope of this thesis. Before 
discussing the distinct mechanisms of ERK-mediated suppression of apoptosis in cancer 
cells, a brief outline of the biochemical events leading to cellular apoptosis is necessary.  
1.4.1  What is apoptosis? 
Apoptosis is a systematic cell-death pathway which is important not only in normal 
cellular development, but also in cellular maintenance and monitoring the extent of 
cellular damage induced by external sources. Apoptosis, often termed as a "programmed 
cell-death process", is elicited by several unique cellular processes including the 
activation of caspases, release of mitochondrial cytochrome C, cleavage of PARP, the 
appearance of a distinctive DNA ladder, and a distinct and characteristic cellular 
morphology (Figure 1.3) [57]. 
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Figure 1.3 Mechanistic mode of apoptotic cell death. Figure has been adopted from [16]. 
In addition to apoptosis, necrosis is also a form of cell death which is, however, 
characteristically distinct from apoptosis. Necrotic cell death is initiated by 
mitochondrial inhibition and is associated with the breakdown of the cytoskeleton, 
cellular swelling and progressive increases in plasma membrane permeability [58]. 
Apart from morphological differences as mentioned earlier, whereas apoptosis is a 
synchronized and frequently energy-driven process, involving the stimulation or 
suppression of multiple genes and kinases, necrosis does not involve gene expression 
and is a passive externally-driven process that results in cell death in the absence of any 
metabolic activity [59]. In short, apoptosis mechanism removes the specific cell with a 
minimum of risk or damage to nearby cells.  
Amongst the various factors that suppress apoptotic cell death, the ERK-
mediated MAPK pathway plays a significant role via different mechanistic pathways. In 
tumorigenic cells, in particular, over-activation of the ERK-mediated pathway is 
responsible for suppressing apoptosis, thereby resulting in uncontrolled proliferation 
and enhanced cell survival. Many ways that ERK-mediated MAPK signalling adopts in 
suppressing apoptosis has been elucidated in the following section.   
1.4.2 Role of ERK in disablingapoptosis  
The mechanisms by which ERK1/2 activation inhibits apoptosis are intricate 
and vary, depending on the cell and tissue type involved and the cellular regulatory 
inﬂuences that the cell receives. In mammalian cells, ERK 1/2 activation can suppress 
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apoptosis at levels which are either upstreamor downstream or unrelated to the process 
of change in mitochondrial trans-membrane potential and cytochrome-c release [60]. 
1.4.2.1 ERK-mediated inhibition of apoptosis via BAD phosphorylation 
 Several signalling pathways have been demonstrated to regulate protein 
tyrosine phosphorylation of the pro-apoptotic protein BAD at specific serine residues 
[61]. In addition to phosphorylation at Ser136 by phosphoinositol 3-kinase/AKT 
signalling, ERK2-activated p90 ribosomal S6 kinase p90RSK has also been reported to 
induce BAD phosphorylation at Ser112and its subsequent sequestration by 14-3-3 
chaperon proteins from the mitochondria. In contrast, dephosphorylation of BAD by 
ERK1/2 inhibitors, as depicted in Figure 1.4, is characterized by its translocation into 
mitochondria and its heterodimerization with pro-apoptotic proteins lke Bcl-2, thereby 
inducing apoptosis [62]. This highlights a pivotal role played by ERK-mediated 
signalling pathway in preventing BAD-mediated apoptosis. 
p90RSK
P
PP BAD
Bcl-2/Bcl-xLApoptosis
heterodimerization
BAD
ERK1/2
 
Figure 1.4 ERK-mediated inhibitions of apoptosis via BAD phosphorylation 
1.4.2.2 ERK-mediated upregulation of anti-apoptotic Mcl-1 
Apart from suppressing the activity or expression of pro-apoptotic proteins, 
ERK1/2 can also promote cellular survival by enhancing the activity of anti-apototic 
molecules like myeloid cell leukemia-1 (Mcl-1). Mcl-1 protein, homologous to the Bcl-
2 family, is another of the most over-expressed genes in cancer cells [63]. Mcl-1 
promotes cell survival by disrupting the release of cytochrome-c from mitochondria 
Chapter 1 Introduction 
18 
 
thereby, suppressing apoptosis.It has been reported that phosphorylation and activation 
of Mcl-1 by ERK1/2 proceeds at two residues Thr92 and Thr163 resulting 
instabilization of Mcl-1. This is evident from the report that paclitaxel, a 
chemotherapeutic drug, has been reported to induce apoptosis by down regulation of 
Mcl-1 by ERK1/2inhibition in breast cancer cells [64]. 
1.4.2.3 ERK-mediated cellular survival via proteosomal degradation 
of pro-apoptotic BIM protein 
The Bcl-2 homology 3(BH3) domain only protein, BIM, is a potent pro-
apoptotic protein belonging to the Bcl-2 protein family.BIM acts like a tumour 
repressive gene and is positively and negatively regulated by transcription, 
phosphorylation and degradation [65]. Multiple BIM phosphorylation sites have been 
identiﬁed which are linked to both suppression and induction of apoptosis. In recent 
years, advances in basic biology have provided a clearer picture of the mechanism by 
which BIM kills tumour cells 
and how BIM expression and 
activity are repressed by growth 
factor signalling pathways. In 
the presence of ERK1/2 for 
instance, BIM undergoes 
polyubiquitination and 
subsequent proteosomal 
degradation, upon 
phosphorylation at multiple 
sites (Figure 1.5). 
This is evident from blockage of BIM phosphorylation sites by MEK 
inhibitors, thereby conﬁrming that ERK1/2 is a probable BIM-regulatory kinase. 
Another report has demonstrated the role of ERK-mediated p90RSK in mediating the 
phosphorylation and degradation of BIM-EL at Ser69hence blocking caspase-mediated 
apoptosis in K562 cells [66].Therefore, a decreased availability of pro-apoptotic BIMvia 
ERK-mediated proteosomal degradation results in attenuated levels of apoptosis and 
thereby, enhanced cellular survival [67]. 
Figure 1.5 ERK-mediated cellular survivals via 
proteosomal degradation of proapoptotic BIM 
protein 
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1.4.2.4 ERK-mediated stimulation of anti-apoptotic transcription 
factors-CREB and STAT3  
CREB is a post-translationally activated transcription factor that has been 
implicated in numerous brain functions including cell survival. This is evident by the 
observation that inhibition of CREB phosphorylation at Ser133 triggers neuronal 
apoptosis [68].In addition, the anti-apoptotic role of CREB has been demonstrated by its 
loss resulting in triggering a Bax-mediated apoptosis [69]. 
In response to both mitogenic and stress-related signals, ERK-activated 
p90RSK phosphorylates and stimulates the transcription factor CREB, by allowing the 
recruitment of its co-activators- CBP and p300 [70].In particular, MSK-1, a p90rsk 
family member with 45% sequence similarity torsk-2, phosphorylates CREB with high 
stoichiometry [71].Relative to other risk family members, MSK-1 seems to have a 
higher affinity for CREB, indicating that MSK-1 might have a primary function in 
regulating CREB activity in response to mitogen/stress stimuli [72]. In addition, ERK1 
has also been reported to single-handedly direct phosphorylate CBP in-vitro and 
increase its transcriptional activity, thereby resulting in attenuated apoptosis [73]. 
In addition to CREB, STAT3 is a latent cytoplasmic transcription factors that is 
uniquely activated at the plasma membrane by tyrosine and serine phosphorylation and 
translocate into the nucleus to activate anti-apoptotic factors. Another evidence of the 
anti-apoptotic role ofERK comes from the upregulation of STAT3 via phosphorylation 
at Ser727in both in-vitro and in-vivo experiments [74]. 
1.4.2.5 ERK-mediated stimulation of oncogenic MCT-1 
Additionally, multiple copies of oncogenic T-cell lymphoma-1 (MCT-1) have 
been demonstrated to require ERK-mediated phosphorylation at Thr81 for stability [75]. 
MCT-1 promotes malignant transformation of normal cells and inhibits apoptosis, 
potentially through Akt activation and dysregulation of the cell cycle. SinceERK is 
required for MCT-1 stability, inhibition of ERK activity could potentially render 
transformed cells susceptible to therapeutic agents. Accordingly, the use of ERK1/2 
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inhibitors in MCT-1-expressing cells could potentially attenuate cellular proliferation 
and lead to apoptosis. 
1.4.2.6 ERK-mediated stimulation of AIFs 
Interestingly, it has been suggested that ERK can regulate apoptosis induction 
via apoptosis inducing factor (AIF) in breast cancer cells.AIFs are flavoproteins that are 
that are involved in triggering cellular apoptosis via a caspase-independent pathway 
[76].Originally localized in the mitochondrial membrane, AIFsare translocated to the 
nucleus upon activation of death stimuli. This results in pro-apoptotic effects like 
chromatin condensation, fragmentation as well as PARP cleavage that serve as typical 
hallmarks of apoptosis [77]. The role of ERK inhibition in inducing apoptosis inducing 
factor (AIF)-mediated apoptosis in epithelial breast cancer cells is evident from the 
nuclear translocation of AIF induced by ERK- inhibitors likePD98059, thereby resulting 
in apoptosis in MCF-7 cells. Thus, the effect of PD98059 provides evidence that 
suppression of ERK-mediated MAPK can result in apoptosis via disruption of 
mitochondrial membrane with the release of AIFs. 
1.4.2.7 ERK-mediated regulation of pro-apoptotic caspases 
Belonging to a family of cysteine proteases, caspases are observed to play a 
distinct role in the initiation and execution of apoptotic cell death, failure of which leads 
to tumorigenesis and various other auto-immune diseases [78]. Of the 12 caspases that 
have so far been identified in humans, more than half of them serve as proapoptotic cell 
death inducers.Amongst the commonly studied pro-apoptotic caspases, caspase-2, 8, 9 
and 10 serve as apoptotic initiators whereas caspase-3 and 7 serve as executioner 
caspases.There is direct evidence of the inhibition of caspase-mediated apoptosis upon 
ERK1/2 stimulation (Figure 1.6). There have been reports highlighting the regulation of 
pro-apoptotic caspase 9 by ERK2. Caspase 9 is inhibited by phosphorylation at Thr125 
in a MEK1/2-dependent manner in cells stimulated with EGF or TPA. Phosphorylation 
at Thr125, a conserved MAP kinase consensus site targeted by ERK2, in- vitro, is 
suﬃcient to block caspase-9 processing and subsequent caspase-3 activation thereby 
preventing apoptosis. 
Chapter 1 Introduction 
21 
 
  
ERK1/2
p90RSK
BAD Mitochondria
cytochrome c
caspase 9
caspase 3
Apoptosis
P
P
 
Figure 1.6 Anti-apoptotic mode of action of ERK1/2 via caspase inhibition 
In summary, ERK1/2 has been demonstrated to suppress apoptosis by down 
regulation of pro-apoptotic molecules via a decrease in their activity or their protein 
expression by transcriptional repression. Conversely, ERK1/2 can also promote cell 
survival by upregulating anti-apoptotic molecules via enhancement of their activity or 
their transcription. Evidence to support the role of ERK in antagonizing the extent of 
apoptosis in KB-3-1 cells has also been observed in this study. In accordance with the 
findings, compound 12 that has been demonstrated to induce apoptosis in KB-3-1 
cellshas also been observed to inhibit the activation of ERK1/2 in KB-3-1 cells. This 
further corroborates the notion of the anti-apoptotic effects of ERK1/2 in mammalian 
cells.     
1.4.3 ERK asstimulator of protein translation in cancer cells 
The higher eukaryotic ribosomes are composed of two subunits that are 
designated as 40S (small) and 60S (large) subunits. The mammalian 40S subunit is 
composed of a single RNA molecule, 18S ribosomal (r) RNA and 33 proteins whereas 
the 60S subunit consists of three RNA molecules: 5S, 5.8S and 28S rRNAs and 46 
proteins [82]. Ofallribosomal proteins, it is ribosomal protein S6 (rpS6) that has 
attracted much attention since it was the first protein that was shown to undergo 
inducible phosphorylation. Ribosomal protein S6 (rpS6) is a key component of the 
translational machinery in eukaryotic cells and is essential for ribosome biogenesis.This 
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is evident from a study that demonstrated that a 33kDa protein, later identified as rpS6 
protein and residing in the small ribosomal subunit undergoes phosphorylation in rabbit 
reticulocytes.This has led to a number of reports validating the susceptibility to its 
phosphorylation by a range of stimuli rps6 is phosphorylated on five evolutionarily 
conserved serine residues with Ser236 being the primary site of phosphorylation. 
The S6Ks were initially reported to phosphorylate several proteins that are 
associated with mRNA translation, including rpS6 by an Akt-mediated pathway (Figure 
1.7). According to this mechanistic pathway, activatedAkt phosphorylates TSC2within 
theTSC1–TSC2 tumour suppressor dimerat multiple sites [83]. This phosphorylation 
blocks the ability of TSC2 to act as a GTPase-activating protein (GAP) for Rheb 
thereby allowing Rheb–GTP to accumulate and to operate as an activator of the 
rapamycin-sensitive TOR complex 1 (TORC1) [84].It is TORC1 that finally activates 
S6Ks that phosphorylate rps6.However, the Akt-mTOR mediated signalling is not the 
only mechanistic pathway involved in protein translation via rps6 phosphorylation. 
Initial hints to the role of the ERK-mediated signalling in promoting protein biogenesis 
came from a report highlighting that RSK-mediated rpS6 phosphorylation contributes to 
cellular mRNA translation (Figure 1.7). 
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Figure 1.7 ERK promotes protein translation via an Akt-mTOR-independent pathway 
This is evident fromRSK-mediated rpS6 phosphorylation that was reported 
to facilitate assembly of translation pre-initiation complex and to correlate with 
cap-dependent translation [85].In addition, RSK mediated phosphorylation of 
GSK3β at Ser9 causes a subsequent stimulation of translation factor eIF2B that 
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contributes to cap-dependent translation [86].Several reports have detected low 
levels of phosphorylation ofrpS6 at Ser235 and Ser236 in cells lacking both S6K1 
and S6K2.This phosphorylation is abolished by treatment by either U0126 
(ERK/MEK inhibitor) or PD184352 (ERK inhibitor), indicating the involvement of 
a MEK/ERK-dependent kinase [87]. Likewise,arecentstudywithHEK293Ecells has 
shown that Ser235 and Ser236 remained partially phosphorylated in cells treated 
with rapamycinwhich completely inhibits mammalian target ofrapamycin (mTOR) 
and thereby its downstream target S6K indicating the presence of an mTOR-
independent pathway leading to rps6 phosphorylation.In addition, 
in TSC2
+/−
 tumour cells, activated ERK has also been reported to directly repress 
post-translational activation of TSC2 at sites that are distinct from those that are 
phosphorylated by Akt thereby resulting in suppression of TSC1-TSC2 complex 
formation and a subsequent attenuation of protein translation [88].In contrast, 
wild-type TSC2 appeared to be ineffective in suppressing tumorigenecity in the 
presence of activated ERK. Therefore, ERK1/2, in addition to its direct substrates-
RSKs servesto mediate the phosphorylation of ribosomal protein rpS6 by an 
mTOR-independent pathway, thereby contributing to intra-cellular protein 
translation. An evidence of a cross-talk between the ERK-mediated MAPK 
pathway and protein translation has also been observed in this study. In 
experiments carried out to delineate the cellular mode of action of 12 against 
mammalian cells, the synergistic down-regulation of the ERK-mediated signalling 
pathway and rate of intra-cellular protein translation in 12-treated KB-3-1 cells has 
been observed.   
1.4.4 Small-molecule inhibitors of MEK/ERK as 
chemotherapeutic agents 
As mentioned earlier, MEK1/2 are the only known proteins to 
phosphorylate ERK 1/2 [89]. As a consequence, targeting MEK also facilitates a 
subsequent inhibition of its downstream substrates, particularly ERK. During the 
past decade, the design and analysis of MEK inhibitors like PD98059 and U0126 
have become instrumental in widening the therapeutic window for treatment of 
cancer and related disorders [90]. However, since ERK is recognised to affect a 
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plethora of vital cellular proteins necessary for cellular survival, an indiscriminate 
modulation of the MEK-ERK mediated pathway has resulted in unwarranted 
cellular toxicity in both normal and tumorigenic cells. As a consequence, such 
inhibitors have been characterised with a poor pharmacological profile that raised 
questions about their clinical efficacy. Until hitherto, some representative 
examples of MEK/ERK inhibitors analysed for their clinical efficacy against 
tumorigenesis have been listed in Table 1.3. 
1.4.5 Structural and biochemical differences between ERK 1 and 
ERK 2 
In a majority of research papers, ERK1 and ERK2 isoforms are generally 
grouped together as ERK1/2. This implies that the structure and functions of both 
these isoformsare apparently interchangeable. 
However, during the past couple of years, several animal studies have 
reported critical differences in ERK1 and ERK2 isoforms on the basis of their 
relative cellular abundance, structure and vitality. For instance, Saba-El-Leil et al. 
reported a not-so similar effect of the vitality of ERK1 and ERK2 in a mouse 
model. According to them, ERK1 gene was indispensable for the development of 
mice but a depletion of the ERK2 gene served lethal to the mouse embryo due to 
impairment in development of the mouse embryonic trophoblasts [79].These 
findings clearly highlight a difference in the vitality and functions of ERK1 and 
ERK2, irrespective of their similar homology. Results from such experiments 
indicate that deficiency or inhibition in ERK2 activity apparently exerts more 
severe consequences on biological mortality relative to ERK1. This hypothesis is 
further evident from the invalidation of ERK2 in the central neural system (CNS) 
leads to anomalies in multiple aspects of social behaviors, decreased anxiety-
related attitude, and impaired long-term memory [80]. 
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Table 1.3 Representative small molecules serving as MEK/ ERK inhibitors 
Compound Molecular 
Target 
Tumour 
Type 
Trial 
Phase 
FDA 
Approval 
Structure 
PD98059  MEK 1/2    N/A Disapproved 
 
PD0325901  
 
MEK 1/2 Breast; 
Colon; 
Melanoma; 
NSCLC  
I/II Disapproved 
 
U0126 MEK 1/2    N/A Disapproved 
 
CI-1040  
 
MEK 1/2 Breast; 
Colon; 
Pancreatic; 
NSCLC  
 
I/II Disapproved 
 
XL518  MEK 1/2 Advanced 
solid 
tumours   
 Disapproved 
 
AZD6244/ 
ARRY-
142886 I  
MEK 1/2 Advanced 
solid 
tumours 
I/I Disapproved 
 
76  ERK2  N/A Disapproved 
 
FR180204  ERK 1/2   N/A  Disapproved 
 
Chapter 1 Introduction 
26 
 
Inhibition of ERK1 and ERK2 is a frequently observed feature of several 
chemotherapeutic agents. However, the degree to which some of these compounds 
inhibit the activation of these ERK isoforms either by repression of its catalytic activity 
or direct binding to these kinases has been found to vary. For instance, FR-148083 has 
been earlier reported to be a potent and selective ERK2 inhibitor. The compound has 
been revealed to bind to the ATP-binding site of ERK2 by making a hydrogen bond 
with Met108 in the hinge region [81]. However, a similar extent and nature of binding 
has not been observed in case of ERK1. Such examples of selective binding preference, 
of certain small molecules, towards a specific isoform of ERK underscores a certain 
degree of distinct structural and biochemical activity of the different ERK isoforms. In 
regard to this upcoming topical aspect, the varying roles of ERK isoforms demand 
further investigation and confirmation in terms of their potential, individualistic 
interactions with chemotherapeutic selenium-containing compounds. An attempt to 
identify and distinguish between the individualistic interactions of 12 with ERK1 and 
ERK2 isoforms has been made in a DARTS experiment using a HeLa cell line that shall 
be discussed in its corresponding section. Nevertheless, future studies in underscoring 
the distinct biochemical roles of the ERK isoforms could be helpful in filtering out the 
characteristic roles of selenium-compounds on the basis of their varying interactions, if 
any, with the ERK isoforms. 
1.5 Identiﬁcation of protein targets of anti-cancer molecules 
In our age of ever-rising diseases of known and unknown origin, the need for 
more efficacious drugs is on the rise. In order to develop any potent drug of either 
natural or synthetic origin, a very important parameter has always been to assess the 
ability and nature of interactions of the drugs with specific cellular targets of interest, 
inside the biological system.Basic research focused on comprehending the molecular 
mechanism of action of small molecules has proved to be a goldmine for 
comprehending the role of importance of pivotal cellular proteins in the etiology of 
biological disorders. A large fraction of potent compounds have been, till date, filtered 
out successfully from primary screening methodologies involving in-vitro and in-vivo 
experiments, in addition to phenotypic and molecular read-outs. While the opportunity 
of hunting novel compounds from such assays is great, the utility in further pushing 
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these compounds to the clinic still remains largely limited. This is primarily due to the 
paucity of information regarding the compounds´ actual physiological behaviour with 
potential cellular targets. An identification and validation of the same is apparently the 
most challenging and time-consuming job, in addition to its utmost importance for 
labelling potential molecules as "drugs". Moreover, the small molecules, screened for 
analysing their ability to speciﬁcally modulate activity of a given protein of interest, 
often have been observed to bind with non-specific proteins also, many of which may 
not be predicted conveniently by sequence or structural homology [91]. Although 
mechanistic studies towards analysing the mode of drug action has a long history, 
identiﬁcation of direct drug-targets has its origin in state-of-the-art techniques like 
afﬁnity chromatography, biochemical fractionation and radioactive ligand binding 
assays. Puriﬁcation of enzymes, on the basis of their relative binding affinities with 
small molecule inhibitors, was ﬁrst initiated in the mid-1900s by Leonard Lerman and 
subsequently employed for novel identiﬁcations by the McCormick and Anﬁnson 
laboratories in the 1960s[92]. During the same period, several other research teams had 
begun the use of radioisotope-labelled compounds and biochemical fractionation to 
enrich drug-binding proteins from crude tissue extracts and cell lysates. A nicotinic 
acetylcholine receptor was the ﬁrst neurotransmitter receptor to be puriﬁed, using a 
radioactive snake toxin in a binding assay [93].  
Amongst the many prominent target-identiﬁcation techniques deployed so far 
including radioafﬁnity and photoafﬁnity approaches, afﬁnity chromatography is still 
apparently the most sought-after technique [94]. However, due to its several limitations, 
an alternative approach called DARTS has been recently adopted for a convenient 
identification of cellular targets of potential drugs and drug-like molecules.  
1.5.1 DARTS - an alternative target-identification approach  
Given the limitations of current target identiﬁcation methodologies, a target 
identiﬁcation strategy referred to as "DARTS “relies only identifying a possible 
interaction of the compound with a target protein without any chemical modiﬁcations of 
the former. Therefore, such an approach could potentially identify any protein target of 
a small molecule, with no limitations posed by chemical-modifying strategies or 
mechanism of action. In addition, the concept that a small molecule would stabilize its 
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target protein’s structure and result in a protease resistance has offered a possible 
solution to the problem of target identiﬁcation. Stabilization of a protein upon substrate-
binding is a well-known phenomenon that offers enhanced resistance to cellular proteins 
against structural disruption and subsequent denaturation by heat and chaotropic agents. 
This enhanced stability has been proposed to result from a shift in the protein's 
thermodynamic stability in order to favor its ligand-bound state which restricts the drug-
bound protein’s original ﬂexibility and movement. One recent example that lends 
support to this concept comes from the ﬁnding that Tacrolimus has been observed to 
protect the immunoenzyme FKBP1A from proteolytic degradation in a DARTS 
experiment. It actually leads to stabilization of a high-energy backbone conformation of 
the enzyme that is otherwise not commonly observed in the native conformation of 
unbound FKBP12 [95].In accordance with a similar DARTS experiment carried out in 
this study, 12 has been observed to exhibit a concentration-dependent and selective 
protection of ERK2 from pronase-mediated proteolytic degradation in a KB-3-1 cell 
model. This finding could,therefore, open a new window towards a more 
comprehensive understanding of the cellular mode of interaction of chemotherapeutic 
organodiselenides like 12 with potential oncogenes like ERK2.  
1.5.1.1 Advantages of DARTS over chromatography techniques 
With respect to the relatively few reports regarding small molecule-induced 
protease resistance, there has been, however, an insufficient realization regarding the 
generalisation of this scheme as a discovery approach for identifying unknown drug-
targets. DARTS offers an unprecedented ability to identify new proteins targeted by 
small molecules by exploiting this approach. It is similar to afﬁnity chromatography in 
terms of its afﬁnity-based methods that employ complex protein samples and selectively 
enrich the target protein(s) while removing all non-target proteins. However, whereas 
afﬁnity chromatography utilizes a positive enrichment approach by selectively pulling 
out the target proteins and leaving behind non-targets, DARTS uses a negative 
enrichment methodology by digesting non-target proteins while retaining the target 
proteins on account of their  resistance to proteolysis (Figure 1.8). In case of the affinity 
chromatography approach, a primary limitation is the extensive binding of non-speciﬁc 
proteins to the matrix that restricts the isolation of true targets. Although extensive 
washing of the matrix can help decrease the number of non-speciﬁc binders, weaker 
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specific binding agents will often be lost during the process. In contrast, DARTS does 
not require washing and can, therefore, be used to analyse lower afﬁnity interactions 
too. DARTS is also novel since it can screen and identify putative protein-binding small 
molecules without the need for their chemical derivatization or chemical identification. 
This is a tremendous advantage over afﬁnity chromatography and other prior methods.  
 
Figure 1.8 Schematic representation of drug-target identification approach (DARTS) 
1.5.1.2 Improvisation of DARTS: introduction of gel-free approach  
The success and reliability of DARTS primarily depends on the abundance of 
the target-proteins to be identified, in addition to their sensitivity (or resistance) towards 
proteolytic degradation. In certain cases, the level of target proteins within the cell is not 
sufficient enough to be stained for visualization. Even in case it is, its enrichment in the 
biological sample is susceptible to masking due to its co-migration with many other low 
or moderately abundant proteins of the same molecular weight on the gel.To counter 
such limitations, Lomenick etal. have attempted to improvise the DARTS approach by 
the introduction of a more sensitive gel-free proteomics approach. Briefly, this approach 
involves the enrichment of protein samples upon dialysis after protease treatment, by 
elimination of unwanted non-tryptic peptides from the sample (generated during the 
protease treatment [95]. This has been proposed to attenuate sample complexity, thereby 
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facilitating the convenient gel-free proteomic analysis of complex protein mixtures. 
This involves the subjection of digested protein samples to a MudPIT analysis that is 
based on separation of tryptic peptides by strong cation exchange and reversed-phase 
HPLC for analysing complex protein mixtures by mass spectrometry. This gel-free 
proteomics approach has been proposed to be more sensitive than a gel-based approach, 
in addition to its compatibility with all the mentioned label and label-free quantitative 
techniques. 
In conclusion, DARTS offers a novel proteomic approach to circumvent the 
restrictions in the way of target-identification of drugs and drug-like molecules by 
invalidating the need for chemical modiﬁcation of the screened molecules. This 
approach shall not only strengthen the basic concepts of chemical genetics but also 
facilitate a wider impact of the same on cellular biology and medicine.  
1.6 Effects of chemical speciation on chemotherapeutic 
efficacy of selenium-containing compounds by modulation 
of biochemical pathways 
1.6.1  Metabolism of selenium   
The physiological pathways contributing to the metabolism of selenium are 
intricate and involve the formation of a plethora of many intermediate metabolites. A 
schematic diagram showing basic selenium metabolism is presented in Figure 
1.9.Selenium is incorporated into its combined form either as an inorganic form 
(selenite, selenate) or as an organic form (SEM or SeC). Further, these are rapidly 
metabolized into broadly two groups of metabolites- the hydrogen selenide pool and the 
methyl selenol pool. In animals, hydrogen selenide is a critical selenium metabolite 
which can be formed from inorganic selenite via selenodiglutathione or from selenium-
containing amino acids via enzymatic activity (Figure 1.9). However, hydrogenselenide 
is relatively toxic but excess of it is susceptible to varying degrees of methylation and 
excretion. Monomethylated forms are the primary excreted products at normal selenium 
levels but in cases where large quantities are ingested, trimethyl selenonium ions have 
also been reported to be excreted in the urine [96]. 
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Figure 1.9 The metabolic cycle of selenium in the eukaryotic system 
1.6.2  Biochemical effects of different chemical pools of selenium 
Numerous in-vitro studies have shown that the monomethylated selenium pool 
induced numerous cellular, biochemical and gene expression responses that were 
distinct from those induced by the forms of selenium that enter the hydrogen selenide 
pool. Together, these findings support the presence of these two different pools of Se 
metabolites that induce distinct types of biochemical and cellular responses and exert 
differential impacts on angiogenic processes. It has been proposed that the active 
chemotherapeutic metabolite of selenium is apparently a monomethylated species 
(presumably methylselenol) and that the chemopreventive efficacy of a given selenium-
containing compound might depend on the degree of its metabolic conversion into that 
form [97]. Supporting evidence to strengthen this hypothesis was obtained by 
comparing the in-vivo cancer-preventing efﬁcacy of these different forms of active 
selenium metabolites. Methyl selenol displayed greater preventing efﬁcacy than 
hydrogen sulfide or dimethyl selenide in the chemically induced rodent mammary 
carcinogenesis model [98]. Moreover, it was found that sodium arsenite which retards 
the conversion of hydrogen sulfide to methyl selenolled to an attenuation of the overall 
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anticancer activity whereas an inhibition of further methylation of methyl selenol 
increased the efficacy [99]. 
Both inorganic and organic forms of selenium can be utilized as nutritional and 
supplemental sources of selenium. Amongst the inorganic forms, sodium selenite was 
the ﬁrst compound to be assessed for its chemopreventing studies. Found in low 
concentrations in nature, this compound is reduced into hydrogen selenide in the 
presence of GSH, by a number of intermediate steps (Figure 1.9). On the other hand, 
organic selenium is represented by selenoamino acids likeSeC and SEM. The main 
nutritional form SEM is not an oxidizing agent, however its metabolites like hydrogen 
selenide have strong oxidant potential [100, 101]. SEM is transformed into its active 
metabolite hydrogen selenide either through the trans-selenation pathway into SeC 
followed by β-lyase reaction into methylselenol, followed by demethylation reaction 
(Figure 1.9.) 
1.6.2.1 Chemotherapeutic effects of selenium incorporated 
compounds: Role in apoptosis  
The molecular basis of chemotherapeutic efficacy of selenium-incorporated 
compounds has been extensively studied to depend on their contribution in predisposing 
tumour cells toapoptosis. As mentioned earlier, the first studies linking selenium to 
apoptosis came out in the early 1990s when Pence et al. demonstrated the cytotoxic 
effects induced by selenite and selenocystamine in mouse keratinocytes, via apoptotic 
induction [102]. Since then there have been several studies investigating the relationship 
between selenium and apoptosis [103, 104 and 105]. 
In contrast to sodium selenite (an inorganic representative of selenium), the 
effects of organoselenium compounds on apoptosis are far more consistent (Figure 
1.10) 
For instance, there is substantial evidence that MSA can induce apoptosis in 
multiple cell types including breast cancer cell lines, hepatoma cell lines, prostate 
cancer cell lines, and in the same type of vascular endothelial cells we use as controls.  
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Figure 1.10 Representative examples of organoselenium compounds inducing caspase-
mediated apoptotic inducers in tumor cells. 
Among the recently identified organoselenium compounds, D-501036 induces 
apoptosis through an increase in the activities of caspase-9 and -3 in a dose and time 
dependent manner. An analogue of ebselen, BBSKE is a TrxR inhibitor that has 
demonstrated inhibition in the growth on the tongue cancer Tca8113 by induction of 
apoptosis via caspase-3 [106].Since the main compound of study in this study (12) is 
amethylenated diselenide and bears a close resemblance with recognised precursors of 
methy selenol, it is assumed that the potency of 12 could be attributed to its methyl 
selenol-like metabolites. As a result, the biochemical effects of methyl selenol shall be 
taken into account in more detail. As has been reported in numerous articles, methyl 
selenol is widely considered to be a critical metabolite and a potent apoptotic inducer in 
carrying out the chemotherapeutic effects of selenium [107, 108]. 
This is evident from its precursors like SeMCandMSA that have been 
demonstrated to be more effective in their chemopreventing efficacy compared to 
several other selenium-containing compounds [109]. In in-vitro systems, precursors of 
methyl selenol,likeMSA have beenshown to block progression of cell cycle, induce 
apoptosis and inhibit angiogenesis of cancer cells. The mechanisms by which these 
effects are obtained may involve redox cycling linked to oxidative stress-induced 
apoptosis and include changes in the expression of genes that control the cell-
cyclecheckpoint and regulate signalling pathways and caspase-mediated apoptosis. For 
instance, Wang et al. have demonstrated that methyl selenol induces apoptosis and cell-
Chapter 1 Introduction 
34 
 
cycle arrest via caspase stimulation in prostate and leukemia cells [110].SeMC, a 
naturally occurring organoselenium compound, has been shown to cause caspase-
dependent apoptosis of HL-60 human leukemia cellsand mouse mammmary epithelial 
tumour cells [111].Specifically, apoptosis has been observed to involve cell detachment, 
the activation of multiple caspases, mitochondrial release of cytochrome c, cleavage of 
PARP and DNA nucleosomal fragmentation [112]. This is evident from the apoptotic 
action of MSA in DU-145 and PC-3 human prostate cancer cells that is reported to be 
mediated by caspase-8 activation and cell detachment [103]. 
Caspase-12, an ER-resident caspase which is essential for ER-stress-induced 
apoptosis is also stimulated during MSA-induced apoptosis in PC-3 cells suggesting a 
probable role for ER stress in apoptosis induced by methyl selenol [113].Several 
groupshave also demonstrated the relation between the activation of intracellular 
signalling pathways like the ERK and AKT-mediated pathways as a consequence of 
caspase stimulation [104]. 
1.6.2.2 Modulator effects of selenium-incorporated compounds on 
intracellular biochemical pathways   
As described earlier, mutations in genes that encode components of the 
PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways occur at high frequency in a 
majority of cancers. In fact, a concurrent activation of the AKT and ERK-mediated 
pathways by separate mutations has been extensively observed in a significant portion 
of human tumours [114]. Abnormal activation of these pathways has, therefore, led to 
aberrant levels of protein translation and enhanced tumour cell survival as a result of 
decreased apoptosis.Inthis regard, attempts to delineate the mode of action of 
organoselenium compounds against cancer led to several reports that highlighted the 
inhibitory effects of a series of methyl seleno-imidocarbamates synthesized by Plano et 
al. against mTORC1 which is a critical protein within the PI3K-mediated pathway [16]. 
In addition, a concomitant downregulation of the ERK pathway was also observed by 
the same set of compounds. A little later in 2012, Plano etal. again observed this effect 
by inhibition of the PI3K and MAPK pathways by quinolinimidoselenocarbamates 
(another methyl selenium precursor) [115]. MSA,a prominent organoselenium 
compound and a potent source of methyl selenol has also been reported to effectively 
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inhibit the angiogenic factor-stimulated DNA translation (G1 to S progression) in 
tumour cells in the lower micromolar range [116].Methyl selenol which has been 
implicated on numerous accounts to be a critical selenium (Se) metabolite for its 
anticancer activity has demonstrated a significant inhibition of migration and invasive 
potential of HT1080 tumour cells at sub-micromolar doses  and a potent inhibition of 
the ERK-mediated MAPK pathway in breast cancer cells [110, 117]. In 2009, Zeng et 
al. reported the direct inhibition of the anti-apoptotic ERK signalling by methyl selenol 
thereby inducing caspase-stimulated apoptosis. The same group also reported the down-
regulation of several other oncogenic and anti-apoptotic genes in cells treated with 
methyl selenol [108]. These findings clearly highlight the anti-oncogenic and pro-
apoptotic behaviour of methyl selenol against tumour cells.  
1.7 Selenium: A janus-faced entity  
A body of evidence indicates that selenium harbors a split personality in terms 
of its role in monitoring cellular proliferation and cell survival. This feature is further 
evident with variation in its chemical speciation and dosage at physiological levels 
[118]. Supra-nutritional levels of selenium have been apparently the main contributors 
in the prevention of several types of cancer, including lung, colon- rectum and prostate 
cancers by its regulatory effects on cell cycle and apoptosis [119].This also reflects that 
the observation of inhibitory effects of organo-selenium compounds, as described 
above, upon the corresponding intracellularsignalling pathways in tumour cellshave 
been observed mostly at higher doses.At relatively lower doses, these compounds 
behave in quite an opposite manner. Low doses of selenium from SEM, for instance, 
have been reported to stimulate ERK-mediated protein translation and, therefore, 
enhance cellular survival [120].In addition, only supra-nutritional doses of selenium 
have been proven to be effective in preventing tumour in animal models. Such doses are 
at least ten times greater than those required to prevent clinical signs of deﬁciency and 
are considerably higher than most human selenium intakes [99]. This observation also 
reflects a plausible cause of the negative findings observed in the SELECT and NPCT 
clinical trials in assessing the chemotherapeutic efficacy of selenium- supplementation 
in humans [23].However, an unregulated intake of dietary or pharmacological selenium 
supplements mainly in the form of SEM has a potential to expose the body tissues to 
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toxic levels of selenium with subsequent negative consequences on DNA integrity. 
Therefore, in order to cater to the broad interests to exploit the beneficial effects of 
selenium for better health and against chemotherapy, studies investigating the 
appropriate dose and suitable chemical form of selenium uptake are highly warranted to 
minimise the selenium-induced negative effects like toxicity and DNA damage. 
1.8 Role of thioredoxin reductase in cancer     
It has been widely observed that in addition to hypoxia, tumour cells 
thrive on enhanced levels of oxidative stress, compared to normal cells. These 
conditions can partly be attributed to a growing tumour mass that quickly outgrows 
its vascular networks and therefore lacks sufficient oxygen and essential nutrients 
[121]. In response to hypoxia, specific proteins like HIF-1 protein are stabilized in 
tumour cells that induce the expression of specific oncogenes that function to 
improve oxygenation through angiogenesis and erythropoiesis. Paradoxically, the 
HIF-1 protein in particular is regulated by oxidative stress-inducing factors like 
free radicals such as the superoxide anion, H2O2 and NO, in addition to many other 
factors including ontogenesis, growth factors and hypoxia [122]. As a 
consequence, the tumour-cell environment is characterised by levels of oxidative 
stress that are relatively higher when compared to those in normal cells. However, 
when oxidative-stress levels exceed their critical threshold, these tumour cells are 
also susceptible to oxidative damage. In order to maintain these levels to an extent 
that are sufficient for their proliferation without posing any risk of cellular suicide, 
tumour cells have adopted certain biochemical pathways including the over-
expression of the natural cellular antioxidant enzymes like thioredoxin reductase 
(TrxR). This is quite evident from the abnormally enhanced levels of TrxR found 
in highly invasive and metastatic tumours [123]. Furthermore, high levels of TrxR 
have been implicated with increased resistivity of tumour cells towards 
chemotherapeutic agents including doxorubicin, cisplatin, docetaxel and 
tamoxifen. For example, in one study, breast cancer cells with high TrxR 
expression showed a significantly lower response rate to docetaxel than those with 
low TrxR expression.In addition to TrxR, over-expression of thioredoxin (TR), a 
direct substrate of TrxR, has also been observed in several primary cancers  [124].  
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To date, TrxR is the only selenoprotein that can reduce the TRox in a NADPH-
dependent manner. Three isoforms of TrxR have been identified in mammalian cells 
with all these isoforms containing the conserved active site. They are TrxR1, a 
cytoplasmic protein; TrxR2, a mitochondrial protein and the testis-specific TrxGR [125, 
126 and 127]. 
1.8.1 Thioredoxin reductase: A potential chemo-therapeutic target 
While TR itself has been regarded as a potential target, TrxR has been the 
focus of most TR system inhibitors [128]. An inhibition of TrxR leads to oxidation of 
TR and, therefore, an altered functionality of the entire TR system (Figure 1.11). A 
number of TrxR inhibitors have been tested in clinical trials with some approved by the 
FDA for use as cancer therapeutic reagents [129]. Curcumin is an example of a 
naturally occurring compound commonly found in turmeric that, in part, exhibits 
anticancer effects and irreversibly inhibits TrxR function [130]. Recently, both green 
and black teas have been found to contain antioxidant components that can inhibit TrxR 
and are capable of inhibiting HeLa cell growth in-vitro [131].  
NADPH TrxR(ox) Trx(red)
TrxR inhibitor
DNA synthesis
Trx peroxidase
H2O2 H2O
HIF-1 anti-apoptosis
 
Figure 1.11 ROS-scavenging and anti-apoptotic role of the mammalian thioredoxin 
system 
1.8.2 Role of selenium-containing compounds towardsthioredoxin 
reductase: substrate or inhibitor? 
Chapter 1 Introduction 
38 
 
Mammalian TrxR can reduce a number of small molecule substrates in addition 
to their role in maintaining TR in their reduced form. These substrates include small 
molecules like ascorbic acid, lipid hydroperoxides, α-lipoic acid, and hydrogen peroxide. 
In addition to these molecules, mammalian TrxR also bear specificity towards reducing 
inorganic and organic forms of selenium. Most of the selenium-containing compounds 
investigated so far have extensively served as excellent substrates of TrxR. There have 
been plenty of reports citing the potential effects of selenium-containing compounds on 
the thioredoxin system. Poerschke et al. studied the behavior of several 
selenocompounds derivativesin lung cancer cells and observed that TrxR-1 modulated 
the cytotoxic effects of these compounds by modulation of mitochondrial dysfunction 
[132]. Similar effects were also observed in colon cancer cells with SeM and MSA 
[133]. Gundimeda et al.have also suggested that the employment of selenium-
incorporated compounds, for example MSA, with agents that target TrxR-1 could 
influence their efficacy against malignant cells [134, 135]. 
Amongst the recently identified non-selenoproteins serving as TrxR inhibitors, 
ethaselen (also called BBSKE) has been reported to serve as a potent selenium-
containing inhibitor of mammalian TrxR, subsequently inducing apoptosis in lung 
cancer cells (Figure 1.12) [136]. It must be specified that BBSKE is one of the 
derivatives of ethaselen with a relatively better pharmacological profile compared to 
ethaselen. Ethaselen, on the other hand, is marred by poor solubilityfeatures in water 
and commonly available organic solvents. In addition, bioavailability of ethaselen after 
oral administration has also been reported to be considerably less. Therefore, the 
formulation and successful chemotherapy with ethaselen as a TrxR inhibitor still 
remains a challenge. Moreover, the addition of selenites has been proposed to enhance 
cell- sensitivity towards some chemotherapeutic agents, such as acylfulvenes or illudin 
S by inhibition of TrxR-1 [137]. Recently, supranutritional doses of selenite have been 
demonstrated by Huang et al. to inhibit the TR system by directly modifying the thiol 
groups of TrxR, thereby predisposing SW480 cells to selenite-induced apoptosis [138]. 
Pathogenic parasites like Trypanosoma brucei that cause African 
Trypanosomiasis,possess a cellular enzyme calledtrypanothione reductase that serves as 
an analogue of mammalian TrxR.  
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Figure 1.12 Representative examples of selenium-containing compounds serving as 
TrxR inhibitors 
The sulfur analogue of ebselen, ebsulfur, has been recently demonstrated to 
potently inhibit this TryR in these tropical parasites, thereby resulting in their 
eradication by ROS-mediated apoptosis. Ebselen, itself, which serves as an excellent 
substrate of mammalian TrxR is a competitive inhibitor of TrxR of E.Coli in the sub-
micromolar range. This can also partially explain its bacteriocidal effects against E.Coli 
and other bacterial agents like MRSA [139]. Taking the aforementioned discussion into 
account, TrxR is considered to be an important anticancer drug target due to its pivotal 
role in promoting both carcinogenesis and cancer progression. 
In addition to the existing small library of selenium-incorporated TrxR-
inhibiting molecules, the present study presents a first-hand evidence of two additional 
chalcogen-incorporated molecules (16 and 17) serving as potent inhibitors of 
mammalian TrxR. 
Overall, the chemistry and biology of organic selenium compounds has been a 
topical area of research, particularly in due recognition of its potentialanti-proliferative 
effects against cancer,as observed in both in-vitro and in-vivo experimental models. 
This has been observed to be a consequence of an unprecedented number of 
biochemical interactions of organo-selenium species with indispensable intra-cellular 
bio-enzymes of known and unknown origin. However, the mystery surrounding the 
frequently observed split-personality of organic selenium, in terms of its diverse 
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therapeutic effects in general and anti-cancer mode of action in particular, still remain to 
be solved. This could partially be achieved by analysing the individualistic interactions 
of selenium-containing compounds with pivotal switches in the cellular biochemical 
pathways that may aid in framing a clearer picture in comprehending the true potential 
of organo-selenium species against cancer. 
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Aim and Strategy  
Despite its trace levels in humans, selenium plays an essential and distinct role 
in the physiological system. From being an important constituent in mammalian cellular 
enzymes like glutathione peroxidase (which contains a selenocysteine) to being isolated 
from several organisms in a diverse chemical and biochemical format, selenium has 
emerged as an issue of topical interest both in terms of basic and applied research. 
Amongst the divergent biological roles discharged by this element, its promising anti-
cancer properties have been an area of prime focus in this study and elsewhere. With 
regard to the extensive information that exists regarding the potential chemotherapeutic 
properties of several prominent selenium-containing compounds and their metabolites, 
there still exists a wide scope for a deeper investigation into the precise biochemical 
mode of action in a particular selenium-selenium bridge containing molecules. 
Considering the relatively poor natural access to such selenium-containing compounds, 
their chemical synthesis is yet another challenge in this area. 
In view of these considerations, the first objective of this project was focussed 
towards the chemical synthesis of a diverse set of selenium-containing organic 
compounds as a tool for a subsequent biological evaluation at the comparative and 
individual scale. This part involved the chemical synthesis and physical characterisation 
of several monoselenides (1-9) and organodiselenides (10-15) followed by a biological 
analysis of the differences in their chemotherapeutic efficacy. With regard to the 
synthesis of the organodiselenides, apart from multiple benzene-substituted 
organodiselenides which have been extensively synthesized previously by several 
research groups, this study focussed towards the chemical synthesis of a rather less 
commonly investigated group of heteroarene-substituted diselenides.In view of N-
containing heterocyclic systems like pyridines or quinolines in several synthetic and 
naturally-occurring biologically active molecules, the conjugation of N-containing 
heterocyclic rings with the redox-active diselenide moiety was carried out in an attempt 
to synergize the biological efficacy of these heterocyclic pharmacophores with those of 
the diselenide moiety [140-142]. With regard to aryl monoselenides, although such 
compounds have been reported previously and display a rather average anti-cancer 
activity, synthetic attempts were carried out to impart a certain degree of lipophilicity 
into these molecules for a probable enhancement in their biological activity [153]. This 
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has been based on the assumption of a probable enhancement in their cytotoxicity via a 
probable increase in their bioavailability and also uptake into tumour cells. In addition, 
on a relatively small scale, few previously studied chalcogen-containing 
naphthoquinones (16 and 17) were re-synthesized with a primary motive to elucidate the 
hidden biochemical reasons responsible for their chemotherapeutic mode of action using 
an array of sophisticated techniques for "intra-cellular diagnostics" now available at the 
HZI and its partner institutes in Braunschweig. 
The second and main objective of this project involved the biochemical and 
biological analysis of several organodiselenides, some of which were used as 
benchmarks or controls.  The monoselenides and diselenides synthesized were also 
compared for their anti-cancer activity relative to a lesser investigated set of 
organoselenium compounds called selenophenes. More importantly, an identification of 
potential cellular targets of organodiselenides and chalcogen-containing 
naphthoquinones was made to elucidate their mode of action against cancer. 
Therefore, in a nutshell, the ultimate aim of the project has been the 
identification of novel organo-selenium compounds as promising chemotherapeutic 
candidates followed by a delineation of their mechanistic mode of action against tumour 
cells, both at the molecular as well as at the cellular level. A combination of chemical, 
biochemical and analytical techniques have been employed to synthesize and evaluate 
the anti-tumour efficacy of these organoselenium compounds. The studies have been 
multi-disciplinary in nature and involved the use of electrochemical methods, in-vitro 
bioassays, cell culture techniques and cutting-edge biological techniques like DARTS in 
attempts to identify potential intra-cellular targets of the most active compounds in 
tumour cells.     
As part of the synthetic strategy, some previously established synthetic 
methodologies were employed to synthesize a range of heteroarene-containing 
organodiselenides (10-15) in substantial yields and in high purity [140-142]. 
Furthermore, attempts to enhance the cytotoxicity of organo monoselenides (1-9) 
against tumour cells were made to lend a higher degree of amphiphlicity to their 
chemical structure via a functionalization of heteroarene-substituted monoselenides with 
hydrophobic alkyl chains of varying carbon chain-length. Such synthetic endeavours 
were carried out with the assumption of a possible improvisation in the uptake of 
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monoselenides in tumour cells via an enhanced lipophilicity.The purity of the 
organoseleniums, prior to biological analysis was checked. Prior to an in-depth 
biological evaluation of the most active organodiselenides (10-12), their detailed 
physico-chemical studies namely 
1
H, 
13
C, 
77
Se NMR and mass analysis werecarried out 
to re-confirm their synthetic purity. 
To the best of my information, there is still a paucity of basic research focussed 
towards the identification of potential cellular targets of chemotherapeutic 
organodiselenides. In basic cancer research, it is imperative to obtain a comprehensive 
understanding of the precise mode of action of drug-like molecules at the molecular and 
cellular level. Therefore, as a preliminary step to underscore the vitality of 
organodiselenides in the futuristic design of anti-cancer molecules, a primary 
cytotoxicity screening of the synthesized organoselenium compounds was carried out 
using a standard MTT assay. Following an identification of the most active 
organoselenium compounds, several biochemical assays like the ATP assay, ELISA 
assay and the caspase 3/7 assay were performed to highlight the basic bio-molecular 
mode of action of such compounds against a particular KB-3-1 cancer cell line. 
Amongst the screened organoselenium compounds, a representative example (12) 
amongst the most active group of organodiselenides was subjected to a deeper analysis 
for a more comprehensive investigation into its molecular and cellular mode of action 
against KB-3-1 cells. In due recognition of a well-documented link between apoptosis-
mediated tumour cell death and intracellular protein translation, in-vitro and in-cell 
translation assays were carried out to assess the modulatory effects exerted by 12, if 
any, in the translational machinery of KB-3-1 cells. Furthermore, due to sufficient 
evidence which has highlighted the individualistic and/or synergistic role of several 
cellular signalling pathways in regulating the protein translation and hence proliferation 
of tumour cells, the modulatory effects of 12 on the oncogenic ERK-mediated and 
mTOR-mediated signalling pathways were also assessed via Western Blot analysis. 
Finally, in attempts to identify potential cellular targets of 12 in KB-3-1 cells, a 
relatively new yet highly advantageous drug-target identification approach called 
DARTS was carried out. Based on the principle of an altered susceptibility of specific 
cellular proteins towards proteolysis when bound to drug-like molecules, this approach 
can provide valuable insight into the selective affinity of compounds towards oncogenic 
proteins like ERK2, as in this study. In addition to anti-cancer effects, the cytotoxicity 
Chapter 1 Aims and Strategy 
44 
 
of the most active organoselenium compounds were also analysed at a primary level 
against several pathogenic strains.Further, in attempts to identify the biochemical 
reasons responsible for the ROS-mediated induction of tumour cell death by 
representative examples of chalcogen-containing naphthoquinones (16 and 17), a 
thioredoxin reductase (TrxR) inhibition assay was carried out to assess the modulatory 
effects of 16 and 17 on mammalian TrxR. The TrxR enzyme was selectively analysed 
since the very same enzyme has been identified as a prime target of various ROS-
inducing chemotherapeutic molecules in several previous reports [151]. In addition, 
several non-cell based redox assays like electrochemistry in addition to the DPPH and 
FRAP assays were performed in order to investigate into a possible cross-talk between 
the anti-cancer activity and anti-oxidant features of the organoselenium compounds 
which have displayed the highest anti-cancer effectsin-vitro.   
In summary, the objective and strategy of this thesis has involved a 
comparativeanalysis of the anti-cancer activity of a chemically and structurally distinct 
range of organoselenium compounds followed by a partial elucidation of the 
biochemical mode of action of a representative example (12) amongst the group of 
organodiselenides, and representative examples (16 and 17) of chalcogen-containing 
naphthoquinones for their futuristic applications against cancer. 
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Chapter 2 
Materials and Methods 
As a part of this project, a range of organoselenium compounds were 
synthesized to investigate their anti-carcinogenic and anti-microbial efficacy. The 
synthetic protocols employed for this purpose were based on two biological objectives. 
The first objective involved an investigation into the biological efficacy of 
heteroarylselenoalkanes that have not received as much attention as the more popular 
selenium-containing compounds like methyl selenol and ebselen. Within this approach, 
variations in the alkyl side chain were introduced to investigate any probable 
modification in their corresponding biological efficacy. The second strategy was based 
on the synthesis of heteroaryldiselenides as a mean of comparative analysis of their 
biological activity with mono-selenoalkanesthat were synthesized in accordance with 
the first approach. 
On the basis of these objectives,in addition to the re-synthesis of certain 
previously published compounds, several new heteroaryl group-conjugated 
monoselenides and diselenideswere synthesized using previously established synthetic 
procedures, for a broad and comparative biological analysis [140-142]. A part of the this 
work was carried out in the research group of Prof. K.K. Bhasin (Department of 
Chemistry, Panjab University, Chandigarh, India). 
Upon primary cytotoxic screening of various heterocyclic organo-
monoselenides, diselenides and chalcophenes against tumour cell lines, 12was identified 
as the most active compound in terms of its anti-proliferative potential against selected 
tumorigeniccell lines. The isomeric diselenides 10 and 11 also demonstrated 
considerable anti-tumour efficacy in comparison to the otherdiselenides (13-15). As a 
result, the focus of this study was eventually diverted towards a detailed investigation of 
the biological efficacy of the most potential (di)aryldiselenides (10-12).It is important to 
mention that during thiswork; only aryl-functionalized diselenides were included in the 
Chapter 2              Materials and Methods 
46 
 
panel of the synthesized organodiselenides due to their higher chemical stability and 
lower toxicity profile, in comparison to the dialkyldiselenides.                                       
In accordance with the results obtained from a preliminary cytotoxicity 
analysis, a deeper investigation into the cellular mode of action of a significantly active 
compound 12 was carried out. The cyclic framework of the diselenide moiety endows 
this compound 12 with unique properties of both an aryl and alkyl diselenide. As a 
result, an in-depth biological analysis of 12 was performed together with an evaluation 
of the more general anti-carcinogenic and anti-microbial potential of the other two 
significantly potent compounds 10 and 11. 
2.1 Chemicals for synthesis 
Sodium borohydride, hydrazine hydrate (monohydrate), elemental selenium, 
diphenyldiselenide, diphenylditelluride, 6-bromohexane, 2-bromopropene, bromo-
methane, 2-chloro-quinoline-3-carbaldehyde, pyridine-3-carbaldehyde, pyridine-4-
carbaldehyde, anhydrous magnesium sulfate, ammonium chloride, 2,3-dibromo-
naphthalene-1,4-dione, 2-bromo-3-methylnaphthalene-1,4-dione, uracil, 2-bromo-
pyridine, urea, piperidine hydrochloride, barbituric acid and organic solvents (technical 
grade)were purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Barbituric 
acid was stored in a dessicator prior to use. Deionised water (Millipore, Darmstadt, 
Germany, 18.2 MΩ.cm-1) was used in all experiments, unless stated otherwise. Melting 
points have been uncorrected. TLC analysis was performed on aluminium TLC plates 
(silica gel 60G F254, Merck, Darmstadt, Germany). All experiments were carried out 
under nitrogen or an argon atmosphere. 
2.2 Chemical Synthesis 
2.2.1 Synthesis of 4-methyl-2-(methylselanyl)pyridine(1), 2-
(allylselanyl)-4-methylpyridine (2) and 2-(hexylselanyl)-4-
methylpyridine (3) 
To a vigorously stirred solution of 1,2-bis(4-methylpyridin-2-yl)diselane      
(3.1 g, 8.8 mmol) in THF under a N2 atmosphere, sodium borohydride (0.7 g,           
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18.6 mmol) was added. The mixture was stirred at room temperature for 15 min until 
the solution turned colourless. Afterwards, 1-bromomethane (2.1 g, 22.1 mmol) or 3-
bromoprop-1-ene (2.6 g, 21.7 mmol) or 1-bromohexane (3.6 g, 21.8 mmol) respectively 
were added dropwise via a septum to the colourless solution. The final mixture was 
stirred for approximately 1 h without exposing the reaction mixture to atmospheric 
oxygen. The formation of the product was assessed periodically using TLC. Upon 
disappearance of the reactant spot on the TLC plate, the reaction was quenched by 
addition of a saturated aqueous solution of ammonium chloride.   
The crude product (containing 1, 2 or 3) present in the organic phase was 
washed repeatedly with distilled water. Ethyl acetate was used for extracting the crude 
product from the aqueous phase. Subsequently, the combined organic layers were dried 
over anhydrous magnesium sulfate and the solvents were removed under reduced 
pressure. 
Silica gel chromatography was used for the separation and isolation of the 
desired compounds obtained from the organic phase. For this, the crude mixture was 
dissolved in a minimum amount of dichloromethaneand silica to form homogenous 
slurry of silica and the sample. This was then loaded onto a silica gel column, followed 
by elution with a mixture of ethyl acetate and hexane (5 : 95) to obtain the products as 
yellow oily liquid in moderate yield (around 61 %, 53 % and 43 % for compounds 1, 2 
and 3 respectively). 
2.2.2 Synthesis of 3-methyl-2-(methylselanyl)pyridine(4), 2-
(allylselanyl)-3-methylpyridine (5) and 2-(hexylselanyl)-3-
methylpyridine (6) 
To a vigorously stirred solution of 1,2-bis(3-methylpyridin-2-yl)diselane      
(3.2 g, 8.9 mmol) in THF under a N2 atmosphere, sodium borohydride (0.7 g, 
18.6mmol) was added. The mixture was stirred at room temperature for 15 - 20 min 
until the solution became colourless. Afterwards, 1-bromomethane (2.2 g, 22.5mmol) or 
3-bromoprop-1-ene (2.7 g, 22.1mmol) or 1-bromohexane (3.7 g, 22.5mmol), 
respectively was added via a septum dropwise to the colourless solution. The final 
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mixture was stirred for approximately 1 h without exposing the reaction mixture to 
atmospheric oxygen. The formation of the product was assessed periodically using 
TLC. Upon disappearance of the reactant spot on the TLC plate, the reaction was 
quenched by addition of a saturated aqueous solution of ammonium chloride. 
The crude product (containing 4, 5 or 6) present in the organic phase was 
washed repeatedly with distilled water. Ethyl acetate was used for extracting the crude 
product from the aqueous phase. Subsequently, the combined organic layers were dried 
over anhydrous magnesiumsulfate and the solvents (THF/ethyl acetate) were removed 
under reduced pressure.   
N Se N Se- Na+ N Se
Methyl-substituted 
2,2'-dipyridyl diselenide
CH3 CH3
R
1, R = methyl
2, R = allyl
3, R = hexyl
4, R = methyl
5, R = allyl
6, R = hexyl
- NaBr
+ RBr
ethanol
2
NaBH4 CH3
 
Figure 2.1 Scheme for the synthesis of methyl-functionalized (alkylselanyl)pyridines 
Silica gel chromatography was used for the separation and isolation of the 
desired compounds from the organic phase. For this, the crude mixture was dissolved in 
a minimum amount of CH2Cl2 and silica to form homogenous slurry of silica and the 
sample. This was then loaded onto a silica gel column followed by elution with a 
mixture of ethyl acetate and hexane (5 : 95) to obtain the products as yellow oily liquids 
in moderate yield (around 49 %, 58 %and 51 % for compounds 4, 5 and 6, respectively).  
2.2.3 Synthesis of 2-fluoro-3-(methylselanyl)pyridine (7), 3-
 (allylselanyl)-2-fluoropyridine (8) and 2-fluoro-3-
(hexylselanyl)pyridine (9) 
To a vigorously stirred solution of 1,2-bis(2-fluoropyridin-3-yl)diselane (3.0 g, 
8.5 mmol) in THF under a N2 atmosphere, sodium borohydride (0.7 g, 18.6 mmol) was 
added. The mixture was stirred at room temperature for 15 min until the solution 
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became colourless. Afterwards, 1-bromomethane (2.2 g, 22.5 mmol) or 3-bromoprop-1-
ene (2.7 g, 22.1 mmol) or 1-bromohexane (3.7 g, 22.5 mmol), respectively was added 
via septum dropwise to the colourless solution. The final mixture was stirred for 
approximately 1.5 h without exposing the reaction mixture to atmospheric oxygen. The 
formation of the product was assessed periodically via TLC analysis. Upon 
disappearance of the reactant spot on the TLC plate, the reaction was quenched by 
addition of a saturated aqueous solution of ammonium chloride. 
The crude product (containing 7, 8 or 9) present in the organic phase was 
washed repeatedly with distilled water. Ethyl acetate was used for extracting the crude 
product from the aqueous phase. Subsequently, the combined organic layers were dried 
over anhydrous magnesium sulfate and the solvents (THF/ethyl acetate) were removed 
under reduced pressure. 
N
Se
2
N
Se-Na+
N
Se R
1,2-bis(2-fluoropyridin-3-yl)diselane
F F
F
+ RBr
- NaBr
7, R = methyl
8, R = allyl
9, R = hexyl
NaBH4
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Figure 2.2 Scheme for the synthesis of 2-fluoro-3-(alkylselanyl) pyridines 
Silica gel chromatography was used for the separation and isolation of the 
desired compounds from the organic phase. For this, the crude mixture was dissolved in 
a minimum amount of CH2Cl2 and silica to form homogenous slurry of silica and the 
sample. This was then loaded onto a silica gel column followed by elution with a 
mixture of ethyl acetate and hexane (3 : 97) to obtain the products as yellow oily liquids 
in moderate yields (around 36 %, 43 % and 37 % for compounds 7, 8 and 9, 
respectively). 
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2.2.4 Synthesis of 1,2-bis{(pyridin-3-yl)methyl}diselane (10) 
and1,2-bis{(pyridin-4-yl)methyl}diselane (11)  
Compounds 10 and11 were synthesized according to a previously established 
protocol as described by Bhasin et al. withminor modifications [142]. As displayed in 
Figure 2.3, the key step of this synthetic methodology involved the reduction of 
pyridine-3-carbaldehyde or pyridine-4-carbaldehyde by sodium hydrogen selenide 
which was prepared in- situ from elemental selenium. This reaction was carried out in 
the presenceof piperidine hydrogen chloride. The corresponding pyridine-3-
selenoaldehyde or pyridine-4-selenoaldehyde thus formed was subsequently oxidized to 
yield the desired products (10 or 11).  
N N
2
piperidine hydrochloride
NaHSe, ethanol
N
CHO
Cl
piperidine hydrochloride
NaHSe, ethanol
N
Se
Se
12
10 or 11Pyridine carbaldehyde
CHO CH2 Se
 2-chloroquinoline-3-carbaldehyde  
Figure 2.3 Scheme for the synthesis of heteroarene-conjugated diselanes 
Absolute ethanol (100 ml) was added slowly to mixture of sodium borohydride             
(2.7 g, 73.2 mmol) and elemental selenium (2.4 g, 30.4 mmol) in a round-bottom flask 
followed by magnetic stirring at room temperature under N2 atmosphere. To this 
ethanolic solution of sodium hydrogen selenide (around 30 mmol) prepared in-situ, 
piperidine hydrochloride (2.5 g, 20.7 mmol) was added followed by an addition of 
pyridine-3-carbaldehyde or pyridine-4-carbaldehyde (1.9 g, 17.8 mmol) respectively. 
The reaction mixture was refluxed for 1 h under N2 atmosphere followed by cooling to 
room temperature to yield a brown-coloured solution. The progress of the reaction was 
assessed periodically by TLC until the disappearance of the starting reagents. After 
completion of the reaction, the reaction mixture was diluted with distilled water and 
extracted with chloroform (3 × 100 ml). The organic layer was filtered and dried over 
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anhydrous magnesium sulfate. Subsequently, the solvents (ethanol/chloroform) were 
removed under reduced pressure to obtain the crude product (10 or 11) in solid phase. 
The product was subjected to purification using silica gel chromatography using a 
mixture of chloroform and methanol (1:1) as eluent. Compounds 10 and 11 were 
obtained as lemon to orange coloured solids in a moderate yield of around 43 % and     
39 % respectively. 
2.2.5  Synthesis of 3H-[1,2] diselenolo [3,4 -b] quinoline, (12) 
The methodology as employed previously for the synthesis of 10 or 11 was 
utilised for the preparation of 12 from 2-chloroquinoline-3-carbaldehyde. Such a 
compound has been selected due to its unique diselenide bond that constitutes a part of a 
closed ring system. In addition, the electronic environment of the two selenium moieties 
constituting this diselenide bridge apparently has been asymmetric and may, therefore, 
provide an interesting biological reactivity. It may also be hypothesized that due to a 
probable ring strain, the diselenide bridge could react rather rapidly and hence may 
cause a significant biological activity, in part due to an apparently facile cleavage under 
physiological conditions. Compound 12 was synthesized according to a previously 
established protocol as described by Bhasin et al. with some minor modifications [142]. 
Absolute ethanol (100 ml) was added slowly to mixture of sodium borohydride (2.7 g, 
73.1 mmol) and elemental selenium (4.7 g, 59.5 mmol) and the resulting solution was 
stirred at room temperature under a N2 atmosphere. After 2 h of stirring, piperidine 
hydrochloride (6.1 g, 50.1 mmol) and 2-chloroquinoline-3-carbaldehyde (9.4 g,         
49.4 mmol) were added in succession. The reaction mixture was refluxed for 1 h and 
cooled to room temperature to yield a red coloured solution. An addition of sodium 
borohydride (0.5 g, 13.3 mmol) in small amounts resulted in a vigorous reaction. After 
the completion of the reaction, the reaction mixture was diluted with 250 ml of distilled 
water and the product was extracted with dichloromethane (3 × 50 ml). The organic 
layerwas separated and the solvent was removed under reduced pressure to obtain the 
crude solid product. The product was subsequently subjected to purification using silica 
gel chromatography eluting with a mixture of hexane and ethyl acetate (2:1). The 
isolated pure product was obtained as a reddish-orange coloured solid in a moderate 
yield of around 37 %. 
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2.2.6  Synthesis of 1,2-bis(4-chloropyrimidin-2-yl)diselane (13 ), 
 1,2-bis(4,6-dimethylpyrimidin-2-yl)diselane (14) and 1,2-
 di(pyridin-2-yl)diselane (15) 
Compounds 13, 14 and 15 were synthesized according to a previously 
established protocolwith minor modifications [140, 141]. To a vigorously stirred 
solution of sodium hydroxide (3.1 g, 77.4 mmol), elemental selenium (3.9 g, 50.1 
mmol) and N,N-dimethylformamide (20 ml), 100% hydrazine hydrate (0.6 g,            
11.8 mmol) was added drop wise under an inert N2 atmosphere. After 4 h of stirring, 
elemental selenium appeared to be completely dissolved, a solution containing 
approximately 80 mmol of 2,4-dichloropyrimidine (11.8 g) or 2-chloro-4,6-
dimethylpyrimidine (11.4 g)or 2-bromopyridine (12.6 g) in DMF, respectively was 
added dropwise to the reaction mixture. The reaction mixture was allowed to reflux 
accompanied by a periodic monitoring of the progress of the reaction via TLC analysis. 
Upon maximal disappearance of the reactant spot on the TLC plate, the reaction was 
quenched by addition of distilled water. This was followed by extraction of the crude 
product from the aqueous phase with dichloromethane. 
N
X
Cl
NaOH, Se, DMF
N
X
Se
2
NH2NH2-H2O ,  reflux
X = C or N
R´, R" = CH3 or Cl or H
X = N, R´ = Cl, R" = H        (13)
X = N, R´= CH3, R" = CH3 (14)
X = C, R´= H,  R" = H         (15)
R´
"R
R´
"R
 
Figure 2.4 Scheme for the synthesis of heteroarene-conjugated diselanes 
Subsequently, the combined organic fractions were dried over anhydrous 
magnesium sulfate and the solvents (dichloromethane/DMF) were removed under 
reduced pressure to yield a crude solid (13 or 14 or 15 respectively). Silica gel 
chromatography was used for the separation and isolation of the desired compound 
using hexane as the eluent. The pure compound (13 or 14) was obtained as a red 
crystalline solid in a yield of around 44 % and 67 % respectively. Compound 15 was 
obtained as a green-coloured solid in a yield of around 73 %. 
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2.2.7 Synthesis of 2,3-bis(phenylselanyl)naphthalene-1,4-dione 
(16)and 2-methyl-3-(phenyltellanyl)naphthalene-1,4-dione 
(17) 
Compounds 16 and 17 were synthesized according to a previously established 
protocol and described by Jacob et al. with some minor modifications [143]. Briefly, an 
aqueous solution of sodium borohydride (0.6 g, 16.1 mmol) was added dropwise to a 
solution of diphenyldiselenide (2.1 g, 6.7 mmol) or diphenyl ditelluride (2.6 g,            
6.3 mmol) in THF, respectively, and stirred vigorously in a round-bottom flask, under a 
constant inert atmosphere of argon. This was followed by continuous stirring for 
another 30 min to allow the formation of phenyl selenolate/tellurolate in-situ as evident 
by the discolouration of the solution mixture. Subsequently, a solution of 2,3-
dibromonaphthalene-1,4-dione (2.1 g, 6.6 mmol) or 2-bromo-3-methylnaphthalene-1,4-
dione (3.2 g, 12.9 mmol) in THF were added via a septum (i.e.,without exposing the 
reaction mixture to atmospheric oxygen) with continuous stirring for approximately 3 
h.The conversion of reactant was assessed periodically through TLC. Upon 
disappearance of the reactant spot on the TLC plate, the reaction mixture was left to stir 
in the open for another 1 h. 
X
2
NaBH4/ THF
H2O, Ar, r. t.
X
-
(prepared in- situ)
X = Se, Te
A = 2,3-dibromonaphthalene-1,4-dione   
B = 2-bromo-3-methylnaphthalene-1,4-dione
XPh
XPh
O
O
XPh
O
O
THF
X = Se    (16) X = Te    (17)
A, B
 
Figure 2.5 Scheme for the synthesis of chalcogen-containing naphthalene-1,4-diones 
The reaction was quenched by addition of a saturated aqueous solution of 
ammonium chloride.  The crude product (16 or 17) present in the organic phase was 
repeatedly washed with distilled water. Ethyl acetate was used for extracting the crude 
product from the aqueous phase. The combined organic layers were dried over 
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anhydrous magnesium sulfate and the solvents (THF/ethyl acetate) were removed under 
reduced pressure. 
Silica gel chromatography was used for the separation and isolation of the 
desired compounds from the organic phase. For this, the crude mixture was dissolved in 
minimum amount of dichloromethane and silica to form homogenous slurry of silica 
and the sample. This was then loaded onto a silica gel column followed by elution with 
a mixture of ethyl acetate and petroleum ether (3 : 97) to obtain the products as black-
coloured solids (16 and 17) in moderate yield (around 53 % and 47 %, respectively). 
2.3 Physico-chemical characterization of chalcogen 
containing compounds  
2.3.1 Spectroscopic analysis  
The chalcogen containing compounds which have been synthesized as part of 
the current study were soluble in common organic solvents like methanol, chlorinated 
hydrocarbons, DMSO and ether. The purity of the compounds was confirmed via 
1
H 
and 
13
C NMR spectroscopic analysis and was judged to be greater than 95%.
1
H and 
13
C 
NMR spectra were recorded either on Bruker Avance DRX-500 (500.0 MHz, 
1
H; 125.8 
MHz, 
13
C) or Bruker Avance III-HD (700.0 MHz, 
1
H; 176.1 MHz, 
13
C) spectrometer. 
Deuterated dimethyl sulfoxide (d6-DMSO) or deuterated chloroform (CDCl3) were used 
as solvents to obtain the 
1
H and 
13
C NMR spectra which were calibrated against their 
residual solvent peaks for 
1
H NMR (2.5 ppm, d6 -DMSO; 7.2 ppm, CDCl3 ) and 
13
C 
NMR (39.5 ppm, d6 -DMSO; 77.2 ppm, CDCl3 ppm). The NMR spectra corresponding 
to the re-synthesized compounds were in accordance with published literature values. 
Due to a prime focus on organodiselenides, in general, and compounds 10-12, 
in particular, 
77
Se NMR analysis of these compounds was carried out in CDCl3 solution 
using  dimethylselenide as the external reference on a Jeol 300.0 MHz spectrometer at 
57.0 MHz. In addition, an elemental analysis of compounds 10-12 was also carried out 
on a Perkin-Elmer 2400 CHN Elemental analyser. The electron impact (EI) mass 
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spectra of the main compounds of study (10-12) were obtained using a Q-TOF micro 
mass spectrometer by direct injection. 
2.3.2 X-ray structure analysis of compound, 11   
Orange coloured crystals of diffraction quality were grown by the slow 
evaporation of the compound 11 after dissolution in dichloromethane: hexane (1: 4). 
The data collected from the single crystal x-ray crystallographic studies of 11 has been 
illustrated in Table 2.1.  
Table 2.1 X-ray crystallographic structural information of compound, 11 
Parameters 
Empirical formula C12H12N2Se2 
Formula weight 342.16 
Temperature 273(2) 
Radiation used, Wavelength 0.71073 Å 
Crystal system, Space group Monoclinic, P2(1)/c 
Unit cell dimensions a = 13.569(3) 
b = 7.8407(15) 
c = 11.984(2) 
α = 90.00 
β = 109.101(4) 
γ = 90.00 
Volume 1204.8(4) 
Z 2 
Absorption coefficient 6.144 mm
-1
 
F(000) 864 
Crystal size 0.18 x 0.16 x 0.14 mm
3
 
Theta range for data collection 3.05 to 28.39º 
Index ranges -17 h 18 
-10 k 10 
-15 l  15 
Reflections collected 10284 
Independent reflections 3004 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3004 / 0 / 227 
Goodness-of-fit on F2 1.900 
Final R indices, 1708  
reflections [I>2 σ (I)] 
R1 = 0.1480,wR2 = 0.5680 
R indices (all data) R1 = 0.2510, wR2 = 0.6316 
CCDC No. 1008607 
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2.4 Biological studies 
2.4.1 Materials and devices 
2.4.1.1 Equipments and devices 
Various equipments and devices used throughout this study are listed in Table 2.2. 
Table 2.2 List of equipments/devices employed forthe cellular and non-cellular 
biological assays  
Equipment/ device Manufacturer 
Bacterial incubator Memmert 
Cell culture incubator CO2-Auto-Zero (Heraeus) 
Gel electrophoresis system Mini PROTEAN system (Bio-Rad) 
Semi-dry Transfer system Biometra 
X-ray processor Optimax (Classic X-ray) 
Light microscopy Axiovert 35 (Zeiss) 
UV spectrophotometer UV 1000 (Shimadzu) 
Plate reader Infinite® 200 PRO (Tecan) 
Centrifuges 5810R (Eppendorf) 
Electrochemical work station CHI 604D (CH Instruments) 
Laminar airflow Maxisafe 2020 (Thermo Fisher 
Scientific) 
Cell counter Cedex XS (Innovatis) 
Shaker Titramax 1000 (Heidolph) 
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2.4.1.2 (Bio)Chemicals and antibodies 
All chemicals and biochemicals were obtained from Carl 
Roth (Karlsruhe, Germany), Gibco® Life Technologies (Darmstadt, Germany), 
Invitrogen (Karlsruhe, Germany), Merck (Darmstadt, Germany), Roche Diagnostics 
(Manheim, Germany), Thermo Fisher Scientific (Dreieich, Germany), Promega 
(Manheim, Germany), Bio-Rad (Munich, Germany) or Sigma-Aldrich Chemie 
(Steinheim, Germany). The antibodies required for the Western Blot analysis and 
DARTS experiment were purchased from Cell Signalling Technology (New England 
Biolabs, Frankfurt, Germany).  
2.4.1.3 Assay Kits / Reagents 
The respective assay kitsused for the cellular assays are listed in Table 2.3. 
These kits were purchased from commercial sources.  
Table 2.3 List of commercially available biochemical kits/ reagents for cell-based in- 
vitro assays, with their relevant commercial source 
Assay/ Reagent Manufacturer 
Caspase-Glo® 3/7 Assay Promega (Manheim, Germany) 
Cell Titre Glo
®
 ATP assay  Promega (Manheim, Germany) 
Cell-Death detection ELISA Roche Diagnostics (Manheim, Germany) 
Flexi Rabbit Reticulocyte Lysate system 
(Nuclease treated) 
Promega (Manheim, Germany) 
BCA Protein Assay kit Pierce (Thermo Fisher Scientific, 
Dreieich, Germany) 
2.4.2 Cell Culture studies 
Several cell-based assays were carried out in-vitro to determine the 
biological activity of three distinct categories of organoselenium compounds, 
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namely organomonoselenides (1-9), diselenides (10-15) and chalcophenes        
(ARS-01 to ARS-06). A standard MTT assay was carried out initially in order to 
assess and compare the anti-proliferative activities of these compounds against 
several tumour cell lines [144].  
On the basis of this comparative analysis, the most active compounds (10, 
11 and 12) were further analysed for their molecular mode of action against a 
human cervix carcinoma (KB-3-1) cell line. For this, an ELISA and caspase 3/7 
assay were employed to determine the ability of 10, 11 or 12 to induce apoptosis in 
KB-3-1 cells.  
For a considerably active compound 12, cell-free and in-cell translation 
assays were also carried out in order to investigate the modulatory effects exerted 
by the compound (12) on the translational machinery of KB-3-1 cells. In due 
consideration of a widely discussed relationship between intra-cellular translation 
and several oncogenic cellular pathways, a Western Blot analysis was also carried 
out to determine the ability of 12 in altering the expression and activity of several 
oncogenic proteins, upon treatment with KB-3-1 cells. Furthermore, in attempts to 
investigate potential cellular targets of 12 in KB-3-1 cells, a relatively new target 
identification approach called DARTS was also employed [95]. In a similar 
context, yet for representative examples (16 and 17) of another distinct group of 
chalcogen-containing naphthoquinones, a TrxR-inhibition assay was carried out to 
assess a possible role of this mammalian cellular enzyme (TrxR) as part of a 
further elucidation of the biochemical mode of action of 16 or 17 against tumour 
cells [151]. In the end, in addition to their anti-cancer effects, 10-12 were also 
subjected to a preliminary anti-microbial assay in order to obtain hints about a 
possibility of their cytotoxicity, if any, against microbial strains as well [146].  
2.4.2.1 Cell type and media  
The mammalian cell cultures and their corresponding media that were 
used for the cytotoxicity assay and related in-vitro assays are listed in Table 2.4. 
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Cell line Origin Medium Manufacturer Supplements 
L-929 Transformed mouse 
fibroblast 
MEM Gibco 10% FBS (Lonza) 
KB-3-1 Human cervix 
carcinoma 
DMEM Lonza 10% FBS (Gibco) 
MCF-7 Breast carcinoma DMEM Gibco 1X Non essential 
amino acids (Gibco) 
1.5% insulin (Gibco) 
10% FBS (Lonza) 
PC-3 Prostate carcinoma F-12K Gibco 10% FBS (Lonza) 
Table 2.4 List of mammalian cell lines and their respective growth media used for in-
vitro cell-based assays. 
2.4.2.2 Cell culture   
 Studies with mammalian cell cultures were performed under sterile conditions. 
The respective media (listed in Table 2.4) required were warmed to 37°C prior to use. 
Cells were cultured in cell culture flasks in an incubator at 37°C and 10% CO2. The 
volume of media required for cells varies as per the size of culture flasks like 10 mL for 
25 cm
2
and 30 ml for 75 cm
2
 flasks. Adherent cells like L-929 and KB-3-1 were 
harvested and passaged upon 80-90 % confluency. The latter involved the scraping or 
trypsinisation of thecell layer followed by suspension of the cells by repeatedpipetting 
up and down with a sterile disposable plastic pipette. Upon attaining confluency, all cell 
lines were passaged by trypsinisation. To trypsinise the cells, the culture media was 
removed followed by rinsing of the cell surface with EBSS, followed by addition of 1 
mL of trypsin (0.1 %). Then, the flasks were incubated at 37 °C for 3 min. The 
trypsinisation was stopped by removing the trypsin and replaced with a fresh culture 
medium. Subsequently, an aliquot of the freshly prepared cell-suspension was 
transferred to a new cell culture flask and diluted with a fresh medium.  
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2.4.3 Cell-based assays 
2.4.3.1 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide  (MTT) assay      
The anti-proliferative activity of the compounds screened against mammalian 
cell lines was measured using the standard MTT assay with minor modifications [144]. 
This assay was carried out in the laboratory of Dr. Florenz Sasse (Helmholtz Centre for 
Infection Research, Braunschweig, Germany).In each well of a 96-well micro-titre 
plates 60.0 µl of serial dilutions of the compounds were added to 120.0 µl of suspended 
cells (around 5 x 10
4
 cells ml
-1
). The final concentrations which were assessed ranged 
approximately within 37 µgml
-1- 0.2 ng ml-1. After five days of incubation with the 
compound, the metabolic activity of the cells in each well was determined using the 
MTT dye. 20.0 μl of MTT solution (at an approximate concentration of 5 mg ml-1 in 
PBS) was added in each well to a final concentration of 0.5 mg ml
-1
 and incubated for     
2 h. In principle, MTT is reduced by dehydrogenases of viable cells to form purple-
coloured formazan crystals. The precipitate was washed with 100.0 μl of PBS followed 
by dissolution of the formazan crystals in 100.0 μl isopropanol (containing 
approximately 0.4 % HCl). Absorbance of the resulting solutions was measured 
spectrophotometrically at a wavelength of 595 nm using a plate reader. 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
(2E,4Z)-(4,5-dimethylthiazol-2-yl)-
3,5-diphenylformazan
N
N+N
N
S
N
Br
mitochondrial reductase N
H
N
N
S
N
 
Figure 2.6 Reduction of MTT into insoluble formazan crystals by viable cells. 
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2.4.3.2 Cell-Titre Glo ATP assay  
The ATP levels of a cell are widely recognised as a parameter of its viability 
[17]. The cytotoxic effects of compound screened against KB-3-1 cancer cells were also 
measured using the Cell Titre-Glo® assay [147] at Helmholtz Centre for Infection 
Research, Braunschweig.As per the describedprocedure, around 1 x 10
4
 cells per well 
were seeded in a 96-well micro titre plate, grown overnight and then treated with serial 
dilutions of the compounds. The final volume in each well was maintained at 100.0 µl. 
Cells treated with methanol served as negative control. After either 24 or 48 h of 
incubation, the compound-treated cells were mixed with 100.0 µl of Cell Titre-Glo 
reagent and incubated in the dark at 37 °C for 30 min. The plates were then left in the 
dark or wrapped in aluminium foil to normalise to room temperature.  
N
S
S
N CO2HHO
ATP + O2
N
S
S
N
-O O-
+ AMP + CO2 + light
     
Figure 2.7 Scheme of generation of luminescence as part of the intra-cellular ATP 
analysis assay. Figure has been adopted from [147]. 
The plates were shaken on a shaker for one minute and centrifuged briefly. The 
luminescence which correlates to the ATP levels in the cell was measured 
spectrophotometrically using a plate reader. 
2.4.3.3 Apoptosis assay- Cell Death detection ELISA assay 
The apoptosis assay was carried out in the laboratory of Dr. Florenz Sasse 
(Helmholtz Centre for Infection Research, Braunschweig, Germany) in cooperation 
with Ms. Bettina Hinkelmann. Based on the quantitative sandwich enzyme 
immunoassay principle, the detection of cell death using an ELISA was performed to 
quantify the pro-apoptotic activity of the screened compounds. This particular method 
relies on the detection of histone-associated DNA fragments (mono- and 
oligonucleosomes) generated by apoptotic cells [145]. In accordance with the 
procedure, equivalent number of KB-3-1 cells were plated in 96-well culture plates 
(around 6 x 10
3
 per well) in serum-supplemented DMEM medium and allowed to 
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adhere overnight. At the time of sample collection, confluent cells were washed with 
PBS and treated overnight with serial dilutions of the screened compounds.Cells were 
dissociated gently using EDTA (0.1 M in PBS) and pelleted along with floating cells 
(mostly apoptotic cells) collected from the conditioned media. The cell pellets were 
used to prepare the cytosolic fractions that contained the smaller fragments of DNA. 
 
Figure 2.8 Mechanism of analysis of apoptosis analysis by the ELISA technique. 
Figure has been adopted from [145]. 
Equal volumes of these cytosolic fractions were incubated in anti-histone 
antibody-coated wells (96-well plates) and histones (from the DNA fragments) were 
allowed to bind to its corresponding antibody. The peroxidase-labelled mouse 
monoclonal DNA antibodies were used to localize and identify the bound fragmented 
DNA by photometric detection using ABTS as the substrate. 
2.4.3.4 Caspase-3/7 activation assay      
Since caspase 3 and caspase 7 are essential for executing apoptotic cell death, a 
caspase 3/7 Glo-assay kit was utilised to measure their presence in KB-3-1 cells [57, 
148]. This assay was carried out in the labs of Helmholtz Centre for Infection Research, 
Braunschweig, Germany. 
The Caspase-3/7 Assay employs a pro-luminescent substrate with an optimized 
bifunctional cell lysisactivity buffer for caspase-3/7 (DEVDase) activity assays. As per 
the manufacturer´s instructions, approximately 2 x 10
4 
cells per well were plated in 96-
well micro-titre plates and allowed to adhere overnight in a humidified environment at 
37 °C and 5 % CO2. Apoptosis was induced by treating the cells with the selected 
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compounds in a dose-dependent manner for 12 h and 24 h respectively. Cells treated 
with DMSO alone were considered as negative control. After treatment, the freshly 
prepared caspase glo-reagent was added to the each well such that the final volume was 
around 200 µl per well (resulting in cell lysis). 
 
N
S
S
N
COOHHN
caspase-3/7
N
S
S
N
COOHH2N
Z-DEVD  +
UltraGlo Luciferase
Mg2+
Light
+  ATP  +  O2
Z-DEVD
 
Figure 2.9 Basis of assessing caspase 3/7 stimulation using Cell-titre Glo assay. 
The plates were adjusted to room temperature for 30 min before recording 
luminescence using a plate reader. The amount of luminescence quantified was 
proportional to the level of caspase 3/7 activation in KB-3-1 cells.  
2.4.3.5  Translation assays 
Based on the significant activity of compound 12 against several tumour cell 
lines in general and PC-3 cells in particular (in the MTT assay), an in-vitro and in-cell 
translation assay was carried out in order to determine the translation-modulatory 
efficiency of compound 12 in mammalian cells. For this purpose, rabbit reticulocyte 
lysates and KB-3-1 cells were selected as experimental systems for this purpose. The 
former cell-free system is commonly employed as a translation-enriched system to 
"rank" chemical libraries in order of their translation-inhibiting or translation-promoting 
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ability. For carrying out an in-cell translation assay, a KB-3-1 cell line was used in order 
to assess a possible link between the translation-modulatory effects of 12 with its 
apoptosis-inducing ability in KB-3-1 cells.  
Both the cell-free and in-cell translation assays are based on the quantification 
of alterations in the generation of bioluminiscence in the compound-treated translation 
systems where the bioluminiscent levels are in direct proportion to the translational 
activity. This bioluminiscence, in a translation system, can be generated upon the 
expression of a luciferase enzyme (firefly luciferase, as in this study) which catalyses 
the oxidation of luciferin (present in the translation system) by a multi-step process to 
produce light which can be subsequently measured. In the in-cell translation system, this 
firefly luciferase enzyme has been introduced via a reporter gene pRL-SV40 (which 
encodes the luciferase enzyme).Therefore, a comparison of the extent to which the 
luciferase enzyme is expressed in the compound-free and compound-containing 
translation system can be used to determine a compound's effect on the translational 
activity of the system. 
N
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N COOHHO
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S
S
N
-O O-
+     light
luciferase
Luciferin Oxy-luciferin
           
Figure 2.10 Luciferase-catalysed generation of bioluminiscence as a basis of 
measurement of the translational activity in cell-free and in-cell translation systems. 
2.4.3.5.1 In-vitro translation assay  
The in-vitro translation inhibition assay was carried out at Helmholtz Centre 
for Infection Research, Braunschweig, Germany. This assay was performed using the 
Flexi Rabbit Reticulocyte Lysate system, as per the manufacturer's instructions [154]. In 
this cell-free system, the rabbit reticulocytes which are prepared from New Zealand 
white rabbits containthe cellular components which are necessary for protein synthesis 
(tuna, ribosome’s, amino acids, initiation, elongation and termination factors) thus 
serving as a translation-enriched system. Briefly, about 500 ng of firefly luciferase 
mRNA was combined with 17.5 µl of rabbit reticulocyte lysate, 0.3 µl each of 1 mM of 
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Met- and Leu- amino acid mixtures, 0.7 µl of 2.5 M KCl, 10 U RNasin, 3.3 µl of 
nuclease free water and 1.0 µl of a methanolic solution of compound (to yield an 
approximate compoundconcentration ranging within 0.1 - 10 µg ml
-1
). An equivalent 
volume of methanol was added in place of the compound to serve as negative control. 
The reaction mixtures were incubated at 30 °C for 90 min, followed by measurement of 
the luminescence in a plate reader by mixing 2.0 µl of the mixture with 10 µl of the 
firefly luciferase substrate in a 96-well microtitre plate. 
2.4.3.5.2  In-cell translation inhibition assay     
Confluent KB-3-1 cells were trypsinised and quantified using a cell counter. 
These cells were resuspended to obtain a final concentration of around 1×10
5
 cells ml
-1
. 
100.0 µl of this cell suspension was plated in each well of a 96-well plate and allowed 
to adhere overnight. The following day, the medium in each well was exchanged with 
around 100 µl of fresh medium and the cells were incubated at 37 °C for 1 h. In the 
meantime, approximately 48 µg of pRL-SV40was mixed with 480.0 µl of DMEM and 
incubated for 5 min. To this mixture, PEI (96.0 µl, 1 µg ml
-1
) was added, mixed gently 
and incubated at room temperature for 15 min. At the end of the incubation period, the 
96-well plate (containing KB-3-1 cells) was removed from the incubator and 85.0 µl of 
the media was aspirated from each well. Then, 6.5 µl of a mixture ofpRL-SV40 and PEI 
(kindly provided by Dr. Yazh Muthukumar) was added to each well and incubated for 
30 min at37 °C. Finally, around 100 µl of fresh medium was added and incubated for 
another 48 h to achieve maximal transfection. 
The in-cell translation assay was carried out in accordance with a procedure as 
described previously [188]. Briefly, the medium from the 96-well plate containing the 
transfected KB-3-1 cells was replaced by a fresh medium followed by treatment with 
serial dilutions of the compound under investigation (0.1-100 µg ml
-1
). The plate 
containing treated cells was incubated for 3 h. Cells were then lysed with 1x lysis 
buffer. Finally, in a 96-well microtitre plate, 5.0 µl of the cell lysate was mixed with 10 
µl of the assay buffer and the luminescence was measured using a plate reader. In 
principle, the intensity of luminiscence corresponds to the level of protein translational 
activity in the cells. 
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2.4.3.6  Immunodetection of modulations in intracellular signalling 
pathways 
2.4.3.6.1 Preparation of buffers      
a) SDS running buffer (10x) 
A 10x SDS running buffer was prepared by dissolving 288.1 g of glycine, 60.4 
g tris baseand 20.5 g SDS in approximately 1.8 l of double distilled water. This buffer 
was subsequently diluted by 10 fold in double distilled water to obtain the working form 
of the buffer.  
b) TBS buffer (10x)                                                       
This was prepared by dissolving 160.6 g NaCl, 4.3 g KCl and 12.2 g Tris 
basein nearly 2.0 l of double-distilled water. The working TBS solution was prepared by 
diluting the 10x TBS buffer to 1x with double distilled water. Afterwards, TBS(T) 
buffer was prepared by adding 1.0 ml of Tween-20 (surfactant) to 1 l of 1x TBS buffer. 
c) Blotting buffer        
The blotting buffer was prepared by mixing equivalent volumes of aqueous 
solutions of approximately 25 mM of Tris-HCl and 192 mM glycine.  
2.4.3.7  Western Blot analysis 
2.4.3.7.1 SDS-PAGE 
SDS PAGE was performed by using a 4-20 % tris-HCl gradient gel (Bio-Rad, 
Munich, Germany). Treated cells were lysed using MPER cell lysis buffer (Thermo 
Fisher Scientific, Dreieich, Germany) and supplemented with 100 x Halt 
protease/phosphatase inhibitor(Pierce, Thermo Fisher Scientific, Dreieich, Germany) 
before keeping the lysate in an eppendorf under ice-cold conditions for 15 min. This 
was followed by centrifugation of the lysate at 1 x 10
4 
rpm for 10 min. The protein 
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content in the upper layer of the lysate was subsequently quantified using the BCA 
Protein Assay kit. 
Approximately 80 µg of protein from the KB-3-1 cell lysate was subsequently 
mixed with 5.0 µl of 4x SDS loading dye (Carl Roth, Karlsruhe, Germany) and 
incubated at 96 °C for 10 min. The protein samples were then loaded into wells of an 
SDS gel which was placed in an electrophoresis tank containing freshly prepared SDS 
buffer. A protein marker was also loaded into one well to determine the extent of 
electrophoresis. Electrophoresis was carried out at 150 V for around 1.5 h i.e. until the 
loading dye reached the bottom-end of the gel. 
2.4.3.7.2 Protein-transfer 
Proteins from the SDS PAGE gel were transferred onto a nitrocellulose 
membrane by a semi-dry Western Blot method. Briefly, a nitrocellulose membrane and 
six Whatman filter papers (6 x 9 cm) were soaked in 1x blotting buffer (containing 
nearly 20 % methanol) under mild shaking conditions. After 30 min of shaking, the 
nitrocellulose membrane, sandwiched between double-layered Whatman filter papers, 
was placed onto the transfer apparatus. The transfer was allowed to proceed at 15 V and 
0.5 mA for 30 min.  
2.4.3.7.3 Blocking and incubation with antibodies   
After completion of protein transfer, the nitrocellulose membrane was 
incubated for 2 h with 5 % non-fat milk prepared in TBS(T) buffer, at room 
temperature, to block unspecific binding sites. The membrane was then washed shortly 
once with TBS (T). After preparation of the prescribed dilutions of each antibody as per 
the manufacturer´s instructions, the antibody solutions were added to the membrane, 
followed by incubation at room temperature for 2 h or overnight at 4°C. The primary 
antibody solution was removed and the membrane was washed three times with TBS 
(T). The blot was then incubated with 10 ml of TBS (T) containing roughly 1 % BSA 
and 0.5 µl of secondary antibody conjugated to HRP. The membrane was washed with 
TBS (T) again and prepared for chemi-luminiscent detection. 
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2.4.3.7.4 Detection       
Supersignal West Pico® or Supersignal West Femto® chemiluminescence 
detection kit (Thermo Fisher Scientific, Bonn, Germany) was used for the detection of 
the intensity of the protein bands. For this purpose, the nitrocellulose membrane was 
incubated with a mix of Enhancer and Stable Peroxide Buffer, in equal volumes, for 
approximately 5 min. The membrane was afterwards transferred onto an X-ray cassette. 
In a dark room, an X-ray film was placed onto the cassette and exposed for 1 - 5 min. 
Finally, the film was developed using an X-ray film processor (Optimax, Protec, 
Germany). 
2.4.3.8 Drug-affinity responsive target stability (DARTS)approach  
For the identification of probable interactions of compounds with cellular 
proteins, the DARTS experiment was carried out in KB-3-1 cells according to the 
method of Lomenick et al. with minor modifications as specified below [95]. 
2.4.3.8.1 Preparation of cell lysate      
KB-3-1 cells were cultured to 70-80% confluency in a 75cm
2
 cell culture flask. 
The cells were trypsinised and centrifuged. The cell pellet was washed once with PBS 
and centrifuged again. The pellet was resuspended in 800.0 µl of M-PER lysis buffer 
(Thermo Fisher Scientific, Dreieich, Germany). Afterwards, the cell lysates were 
subjected to cell lysis on ice for 15 min. After that, the tubes were centrifuged, the 
supernatant of lysate was collected and the protein content was quantified using BCA 
Protein assay kit. Aliquots of the cell lysate containing around 100 µg of protein content 
were treated with 1.0 µl of serial dilutions of the compound (0.333 mM - 0.03 µM) in 
methanol and kept on a shaker at 700 rpm under ice-cold conditions. Then, each aliquot 
was digested with 0.1 % pronase at 37°C. The digestion was stopped after 30 min by 
addition of 5 µl of 4x loading dye (Carl Roth, Karlsruhe, Germany) followed by 
incubation of the protein lysate at 95 °C. 
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2.4.3.8.2 Detection  
The protein samples were separated on SDS-PAGE using 4-20 % Tris-HCl gels 
(Bio-Rad, Munich, Germany) and were subjected to Western Blot analysis, adopting the 
previously described procedure as mentioned in Section 2.4.3.7. 
2.4.3.9 Ligand binding affinity assay 
The ligand binding affinity assay was carried out in co-operation with 
DiscoverX (California, USA). This assay serves as a platform which employs a novel 
and proprietary active site-directed competition binding assay to quantitatively measure 
interactions between the compounds under investigation and specific cellular proteins, 
as ERK2 in this particular study. This robust and reliable assay technology does not 
requireATP and thereby determines the correct thermodynamic interaction affinity of a 
given compound (as 12 in this study) with a recombinant ERK2 protein as opposed to 
the IC50 values which are measured by more traditional methods and are often imprecise 
as they may depend on the ATP concentrations.  
For the ERK2-binding assay, a full-length recombinant ERK2 kinase 
(accession number NP_620407.1) was used. A six-point serial dilution of the compound 
under investigation (compound 12, as in this study) was prepared in DMSO at 100 x 
final analysis concentration  and subsequently diluted to 1x in the assay (final DMSO 
concentration of 1%). Binding constants (Kds) were calculated with a standard dose-
response curve using the Hill equation: 
 
In accordance with the established protocol, the Hill Slope was set to -1 and the 
background was minimised to 0.The binding interactions for each concentration of the 
compound under investigation was analysed in terms of the percentage, relative to                      
the control (DMSO) and calculated according to the following equation: 
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test compound signal - positive control signal
negative control signal - positive control signal
x  100
 
Where test compound = compound 12 (in this study); negative control = DMSO (100 % 
control); positive control = control compound (0 % control). 
2.4.3.10 Anti-microbial studies  
2.4.3.10.1 Microbial strains and their growth media used for anti 
microbial analysis 
The microbial strains used for a primary analysis of the anti-microbial activity 
of the most active organoselenium compounds (10-12) in this study are provided in 
Table 2.6. 
Table 2.6 Strains used for anti-microbial analysis 
Microorganism  Abbreviations  Source  
Escherichia coli  E. Coli  Ciba-Geigy, Basel 
Micrococcus phlei M. phlei  HZI Collection  
Micrococcus luteus M. luteus  HZI Collection  
Candida albicans C. albicans  DSM 1386  
Paeonia anomala (Pichia) P. anomala  DSM 70263  
Saccharomyces cerevisiae  S. cerevisiae Euroscarf  
Botrytis cinerea B. cinerea DSM 877  
For inoculation of bacteria and fungi, EBS and MYC media were used, 
respectively. All nutrients for the media were purchased from Sigma-Aldrich 
(Industriestrasse, Germany) and Carl Roth (Karlsruhe, Germany). 
For the agar media (agar diffusion assay), 15 gl
-1
of Muellor-Hinton agar 
(Sigma-Aldrich GmbH, Industriestrasse, Germany) was added. The medium was 
prepared in double-distilled water and autoclaved immediately. The autoclaved media 
were then stored at 4°C before further use. 
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Table 2.7 Composition of media for inoculation of microbial strains 
Medium Composition 
EBS medium (pH 7.0) Casein Peptone (5 g l
-1
), Protease peptone 
(5 g l
1
) , Meat extract (1 g l
-1
), Yeast 
extract (1 g l
-1
), HEPES (10 g l
-1
) 
MYC medium ( pH 7.0) (10 g l
-1
 glucose, 10 g l
-1 
phytone peptone 
and 50 mM HEPES) 
 
2.4.3.10.2 Selection criteria of microbial strains used as a part of 
this study 
Amongst the fungal strains, Saccharomycescerevisiae, Botrytis cinerea, 
Candida albicans and Paeonia anomala (also called Pichia) were selected for anti-
microbial screening of the relevant compounds. For several centuries, S. cerevisiae has 
been used in the production of food and alcoholic beverages. Although this form of 
yeast is not acutely pathogenic to healthy individuals, it has been reported to yield its 
virulence in immune compromised patients by secretion of pro-inflammatory cytokines 
[171].  On the other hand, B. cinerea causes critical pre-and post-harvest diseases in 
agronomically important crops, in addition to a disease called winegrower´s lungs that 
induce an allergic reaction to the lungs, resulting in breathing problems. Although 
commonly found within the digestive tracts of a healthy human body, C. albicans is 
known to exert its pathogenic effects through a disease called "Candidacies" that infects 
the mouth, throat and various other parts of the body. Pichiahas also been recognized as 
a pathogenic fungal strain since it is notorious for causing morbidity and morbidity in 
neonatal and immune compromised infants [172].      
Amongst the bacterial strains, extensive research is being carried out against 
the pathogenic gram-negative bacterium Escherichia Coli. This pathogen has been 
reported in numerous instances to cause urinary tract infections, in addition to 
occasional fatality from severe anaemia or kidney failure. Usually found to inhabit the 
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skin microflora and serve as a commensal microorganism, Micrococcus luteus has also 
been reported to induce several infections in the form of intracranial abscesses, 
pneumonia and meningitis. Mycobacterium phlei, on the other hand, is a not-so-easily 
diagnosable bacteria that has been associated with inflammation of the foot. M. phlei 
has recently been reported for the first time to be also involved in cardiac-device related 
infections [173]. Therefore, in consideration of the pathogenic characteristics of these 
strains, we endeavoured to identify possible inhibitory potential of selected compounds 
against these strains in an agar-diffusion assay. This assay was carried out in the 
laboratory of Dr. Florenz Sasse at Helmholtz Centre Braunschweig.The antibiotics 
oxytetracyclin (OTC) and nystatins were included in these assays as positive controls. 
2.4.3.10.3 Handling of microorganisms  
All microbiological studies were carried out under sterile conditions. The 
bacteria and fungi were not maintained as a continuous culture. Whenever required, the 
cells were revived from frozen samples (kept at -20 °C). Fungi were stored at 4°C as 
spore-suspension cultures. To revive each microbe, its frozen culture was placed in a 
fresh medium and inoculated overnight at 30 °C. The next day, the optical density (OD) 
of the microbial suspension was determined at a wavelength of 600 nm (bacteria) or   
548 nm (fungi) using a spectrophotometer. 
2.4.3.10.4 Agar diffusion assay 
A disk-diffusion susceptibility analysis was carried outaccording to the method 
of Wang et al. with minor modifications to determine the sensitivity or resistance of 
pathogenic microbial strains towards the compounds under investigation [146]. For 
performing the inoculation of bacteria and fungi, EBS and MYC media were used. The 
medium (with Mueller-Hinton agar) was heated in a microwave-oven until the agar had 
melted, followed by adjustment of the temperature to 50 °C in a water bath. Afterwards, 
the selected bacterial or fungal strains were added to the agar-containing medium at a 
final OD of 0.01 and 0.10 for the bacteria and fungi, respectively. Under a laminar flow 
hood, 15 ml of the inoculated medium (with agar) was then poured into 90 mm sterile 
Petri dishes (TPP, Trasadingen, Switzerland) and allowed to solidify. Then, a filter-
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paper disk (Schleicher & Schuell GmbH, Dassel, Germany) of 6 mm diameter was 
impregnated with a relevant compound under investigation (20 µl of a 1.0 mg ml
-1 
stock 
solution) and air-dried under the laminar air flow hood. Afterwards, the filter-paper disk 
was placed on the inoculated plate by using flame-sterilized forceps. The Petri dishes 
were subsequently incubated at 30 °C in an incubator for 1-2 d, depending on the speed 
of growth (usually 1 d for bacteria and 2 d for fungi). The diameter of the resulting 
inhibition zones around the disk served as an indicator of the anti-microbial potential of 
the compounds screened. 
2.4.3.11 Thioredoxin Reductase (TrxR) enzyme-inhibition assay 
In order to investigate into additional cellular targets of chalcogen-containing 
naphthoquinones (16 and 17) in an attempt to further elucidate their biochemical mode 
of action against tumorigenic cells, a TrxR enzyme inhibition assay was carried out. The 
TrxR enzyme is well-documented to behave as a natural cellular antioxidant and has 
been frequently reported as a prime target of several chemotherapeutic drugs that induce 
ROS-mediated death in tumour cells. In due consideration of this fact and a previous 
report by Jacob et al. highlighting the induction of ROS-mediated apoptosis in tumour 
cells by organochalcogen compounds like 16 and 17, the TrxR enzyme inhibition assay 
was carried out using a modified micro-plate reader based assay to assess possible 
modulatory effects of 16 and 17 on mammalian TrxR enzyme [151]. Briefly, a rat-
recombinant Thioredoxin Reductase-1 was acquired from IMCO Corporation Ltd., AB 
(Sweden). 0.04 U ml
-1
 concentrations of the mammalian enzyme were prepared in 
double-distilled water. As per the procedure, to every 25.0 µl aliquot of the enzyme 
solution, 25.0 µl of potassium phosphate buffer (PBS, pH7.0) containing the sample 
compound in serial dilutions, or DMSO (vehicle control) was added. The resulting 
solutions (maintaining a final DMSO concentration of 0.5 % v/v) were incubated with 
moderate shaking at 37°C in a 96-well micro-titre plate for 75 min. 225.0 µl of a 
reaction mixture, prior to adding in each well, was prepared by mixing PBS (500.0 µl, 
pH 7.0), EDTA solution (80.0 µl, 100.0 mM, pH 7.5), BSA solution (0.05% w/v, 20.0 
µl), NADPH solution (100.0 µl, 20.1 mM) and double distilled water (300.0 µl).This 
was followed by the initiation of the reaction by the addition of 25.0 µl of a 20.0 mM 
concentrated ethanolic solution of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB). After 
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proper mixing, the formation of 2-nitro-5-thiobenzoic acid (5-TNB) was monitored 
spectrophotometrically using a microplate reader at a wavelength of 405 nm at 10 s 
intervals for 6 min. The increase of 5-TNB concentration over time followed a 
linear trend and the enzymatic activity was calculated from the increase in 
absorbance per second. For each test compound, non-interference with the assay 
components was confirmed by a negative control experiment using an enzyme-free 
solution. The IC50 value was calculated as the concentration of the compounds 
decreasing the enzymatic activity of the untreated control by 50 % and was given 
as the mean of values obtained from three individual experiments (± SD).  
2.5 Non-cellular assays  
2.5.1 Characterization of redox properties employing the 
electrochemical method of cyclic voltammetry   
Cyclic voltammetry has been used to define the general redox properties 
of biologically active selenium-containing compounds. It is a particularly useful 
method to estimate the oxidation and reduction potential of such selenium-
containing molecules and to investigate reversible and irreversible aspects of 
electron transfer. The electrochemical method uses a reference electrode, a 
working electrode and a counter electrode that in combination are referred to as a 
three-electrode setup. An electrolyte is added to the test solution to ensure 
sufficient conductivity.  
In this particular case, the electrochemical experiments were carried out 
using a CHI 604D electrochemical work station (CH Instruments, USA) linked to a 
glassy carbon electrode. This electrode served as the working electrode with a 
standard Ag/AgCl (SSE) reference and a platinum wire counter electrode. The 
reference electrode was calibrated against the [Fe (CN) 6]
4-
/Fe (CN) 6]
3-
 redox pair. 
The experiments were performed in acetonitrile containing 0.1 M TBAPas the 
supporting electrolyte at a scan rate of 100.0 mV s
-1
. All experiments were 
performed at room temperature.  
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2.5.2 Anti-oxidant assays 
2.5.2.1 Diphenyl-(2,4,6-trinitrophenyl)iminoazanium (DPPH) Assay 
In order to determine the general antioxidant behaviour and the radical-
scavenging potential of the selected organoselenium compound in particular, a standard 
DPPH radical scavenging assay was carried out according to previously established 
protocols, with minor modifications [149]. In this assay, a non-physiological but a 
stable free radical called DPPH is employed. Due to a strong absorption exhibited by 
DPPH at a wavelength of 517 nm, this radical displays an intense violet colour in 
solution which becomes colourless or pale yellow upon neutralization by electron-
donating molecules. This property enables a visual or spectrophotometric analysis of the 
alteration in the levels of DPPH before and after a treatment with a compound under 
investigation.  
a) Preparation of DPPH reagent        
A 300 µM stock (approximate) of a methanolic solution of DPPH reagent 
(Sigma-Aldrich, Steinheim, Germany) was prepared freshly at the time of experiment 
by dissolving 1.2 mg of DPPH in 10.1 ml of absolute methanol. The solution was kept 
in the dark at all times to avoid any photochemical degradation.  
b) Assay protocol        
In each well of a 96-well microtitre plate, a methanolic solution of DPPH 
reagent (~300 µM, 200.0 µl) was treated with 
40.0 µl of serial dilutions of the organoselenium 
compounds, ascorbic acid (positive control) and 
methanol (negative control) in a concentration 
range (125-1000 µg ml
-1
). The final mixture 
(containing DPPH and the sample/ methanol) was 
allowed to react at room temperature in the dark 
for 30 min. A blank assay was run initially only with the DPPH reagent to confirm its 
N N
O2N
O2N
NO2
Figure 2.11 Structure of DPPH radical
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stability under experimental conditions. After the incubation, the decrease in absorbance 
was measured spectrophotometrically at a wavelength of 517 nm using a plate reader. In 
principle, a decrease in absorbance is directly proportional to the extent of quenching 
(or scavenging) of DPPH radicals. The methanol treated wells were considered as 
negative control whereas the wells containing untreated DPPH radicals were considered 
as blank control. The radical-scavenging effect of the compounds was calculated as per 
the following formula- 
% DPPH scavenging ability = [Abs (blank) – Abs(compound at 1mM)/Abs(blank)] x 100 
2.5.2.2 Ferric reducing ability of plasma (FRAP) assay   
This assay was carried out in accordance with previously established 
procedures with minor modifications [150]. To perform this assay, a FRAP reagent mix 
was prepared using freshly produced constituent reagents.      
a) Preparation of FRAP assay reagents 
An approximately 300 mM of acetate buffer (pH 3.6) was prepared by 
dissolving 3.1 g of sodium acetate 
(trihydrate) in 16 ml of glacial 
acetic acid and distilled water was 
added to obtain a final volume of 
1.0 l. The buffer was stored at 4
°
C, 
prior to use. 10.6 mM stock solution 
of 2,4,6-tripyridyl-s-triazine (TPTZ) 
was prepared freshly by dissolving 
0.1 g of TPTZ in HCl (30.0 ml, ~40 
mM). The 40 mM HCl solution required for this purpose was prepared by diluting 
3.6 ml of concentrated HCl (36% w/v) with double-distilled water to obtain a final 
volume of 1.0l. Furthermore, 20.6 mM stock solution of ferric chloride was also 
prepared by dissolving 0.1 g of FeCl3·6H2O in 20 ml of double-distilled water. The 
final FRAP reagent, required for this assay, was prepared by mixing TPTZ solution 
N
N
N
N N
N
Figure 2.12 Structure of 2,4,6-tripyridyl-s-triazine (TPTZ)
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(2.5 ml, 10.6 mM) and FeCl3 solution (2.5 ml, 20.6 mM) with acetate buffer        
(25 ml, ~300.0 mM, pH 3.6). The final FRAP reagent mixture was prepared afresh 
at the time of experiment. 
b) Assay protocol 
The assay was performed in a 96-well microtitre plate. For the 
determination of the antioxidant potential, a blank reading with only FRAP reagent 
(300.0 µl) was taken initially at a wavelength of 594 nm. Subsequently, in each 
well of the microtitre plate, the freshly prepared FRAP reagent (300.0 µl) was 
mixed with serial dilutions of a benchmark standard (ascorbic acid) or the 
methanolic solutions of the compounds under investigation (63-1000 µg ml
-1
,    
40.0 µl). In order to run a negative control assay, an equivalent volume of 
methanol (negative control) was also treated simultaneously with the FRAP 
reagent. The first absorbance reading (at 594 nm) was taken immediately after 
addition of FRAP reagent to samples (at time t = 0 min). The mixture was then 
allowed to incubate at 37°C for 10 min before absorbance values were measured. 
The absorbance values obtained from methanol-treated FRAP reagent were 
considered as negative control. Values from the negative control were subtracted 
from values corresponding to compound-treated wells in order to obtain the 
reducing effect of the compounds on the FRAP reagent. Calibration of the 
experiment was carried out by plotting standard curves that were obtained from 
treatment of FRAP reagent with serial dilutions of an aqueous solution of 
FeSO4·7H2O. The antioxidant potential of a screened molecule was calculated as 
it’s FRAP value with reference to the absorbance values given by the FeSO4 
solution. This value was expressed in µmol equiv of Fe
2+
l
-1
. In principle, a higher 
FRAP value indicates a greater anti-oxidant potential of the screened samples. 
Henceforth, the mean and standard deviations of FRAP values from individual 
experiments were calculated to obtain a measure of the reducing activity of the 
compounds under investigation. 
 
 
Chapter 2              Materials and Methods 
78 
 
2.6 Statistical analysis  
Student’s t-test has been used to analyze the difference between the means of 
the treated groups and the control group. Differences with a p value < 0.05 have been 
considered statistically significant and have been symbolically expressed as 
*
 for            
p < 0.05 and as 
# 
for p < 0.001. The data has been presented as the mean of 
valuesobtained from individual experiments ± Standard Deviation (SD). SD has been 
expressed as error bars. 
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Chapter 3  
Results 
3.1 Chemical synthesis  
During the past several years, numerous articles have delved into investigating 
the promising effects of organoselenium compoundsin combating cancer, in addition to 
a plethora of several other oxidative stress-related disorders [105, 136]. Such potentially 
chemotherapeutic compounds and a cascade of active metabolites associated with them 
have also been well documented to play a significant role in exploiting the acute 
susceptibility of cancercells towards intra-cellular redox alterations.  
3.1.1 Synthesis of heteroaryl group-conjugated monoselenides  
In accordance with the popular saying, "Two is always greater than one", 
several reports in the literature havehighlighted a higher chemotherapeutic efficacy of 
organodiselenides in comparison to monoselenides [153]. Although this observation has 
been supported strongly by the facile generation of active selenium metabolites in the 
former due to a facile cleavage of a selenium-selenium bond in comparison to selenium-
carbon bond in the latter, certain measures have been undertaken to enhance the anti-
cancer efficacy of several monoselenides. In principle, this could be achieved partially 
by enhancing the intra-cellular penetration efficacy of monoselenides. Since 
lipophilicity has often been observed to serve as a key to enhance cellular uptake and 
cytotoxicity against tumour cells, successful attempts have been made to generate a 
section of aryl monoselenides with hydrophobic alkyl groups of varying chain-lengths.  
The primary protocol that was employed for the synthesis of alkyl-substituted 
selenopyridines involved the reductive hydrolysis of 2,2’-dipyridyl diselenide with 
hydrazine hydrate or sodium borohydride to furnish a reactive 2-pyridyl selenolate 
species in-situ [141]. This was followed by a facile nucleophilicsubstitution of the 
Chapter 3  Results 
 
80 
 
reactive selenolate anion with haloalkanesto yield a range of alkyl-substituted 
selenopyridines as yellow oily liquids. 
 
  
Figure 3.1 Representation of alkyl-functionalized monoselenopyridines 
Similar to organodiselenides, the alkyl-substituted monoselenides were also 
obtained in moderate yields with a significant degree of stability at 4°C even after two 
months. In addition, these monoselenides along with the heteroaryl diselenides   
(Section 3.1.1) were observed to be resist photolytic degradation under visible light.    
3.1.2 Synthesis of heteroarene-conjugated diselenides  
Amongst the various categories of organoselenium compounds, (di)aryl 
diselenides have been reported in literature to exhibit an ability to disrupt the redox-
statusof tumour cells and hence trigger or stimulateseveral redox-related signaling 
pathways [152]. Theredox-altering feature of such compounds has beenrelated to the 
presence of a physiologically labile and redox-active dichalcogenide bridge that serves 
as a precursor to a series of bio-active primary and secondary metabolites. With regard 
to the synthesis of organodiselenides, a plethora of phenyl-substituted diselenides have 
been synthesized and analysed previously by several research groups. In contrast, the 
chemical synthesis of several heteroarene-substituted diselenides was successfully 
carried out in this study in order to broaden the existing information of the biological 
efficacy of diaryl diselenides. A popular methodology that was adopted for the 
formation of pyridine or pyrimidine-substituted diselenides (13-15) involved a halogen-
selenium exchange reaction between halogen-functionalized heterocycles and sodium 
diselenide (Na2Se2) or sodium hydrogen selenide (NaHSe). The latter species were 
initially prepared in-situ by the alkali-mediated reduction of elemental selenium in DMF 
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or ethanol [140-142]. This was followed by the critical step involving a halogen-
selenium exchange reaction which proceeded smoothly via a nucleophilic substitution 
of the halogen (attached to the aromatic ring) with the nucleophilic selenium (as in 
NaHSe/Na2Se2) followed by aerial oxidation to furnish a range of heteroaryl diselenides 
as solids. Dipyridyl diselenide (15) that has served as a precursor for the synthesis of the 
alkyl-functionalized monoselenides (1-9) was alsoprepared by this methodology [141]. 
On the other hand, pyridine carbaldehydes were employed as precursors for the 
synthesis of heteroarene-conjugated methylenyl diselenides (10-12). The key step in this 
synthetic scheme involved the reduction of pyridine carbaldehydes by sodium hydrogen 
selenide. The latter was prepared in-situ upon the reduction of elemental selenium by 
sodium borohydride.  
 
 
 
 
 
 
Figure 3.2 Representation of heteroarene-conjugated diselenides 
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This reaction was carried out under the catalytic action of piperidine hydrogen 
chloride. The corresponding selenoaldehyde thus formed was subsequently oxidized to 
yield the desired products (10 and 11) in quantitative yields. A similar synthetic 
methodology was also utilised for preparing 12 from a quinoline-functionalized 
carbaldehyde. The compound 12 was characterised by its unique diselenide bond that 
constitutes a part of a closed ring system. In addition, the electronic environment of the 
two selenium moieties that constitute the diselenide bridge in 12 was apparently 
asymmetric which could also probably provide an interesting reactivity. Accordingly, it 
was hypothesized that due to a probable ring strain, this diselenide bridge could react 
rather readily and hence, causes a significant biological activity, in part due to an 
apparently facile cleavage under physiological conditions. 
All the heteroaryl diselenides were synthesized under tolerable experimental 
conditions. The yields were moderately high in all cases with a high level of purity. In 
addition, most of these compounds were also observed to be significantly stable after 
isolation and purification. Only in case of 11, a certain degree of degradation was 
observed upon standing at room temperature for more than a week. This was apparently 
due to the exclusion of selenium as a black powder from 11. However, no such 
exclusion of selenium was observed upon storage of 11 at 4°C upto three weeks. 
Interestingly, therelated compound 10 was observed to be fairly stable even when kept 
at room temperature for a month. 
3.1.3 Synthesis of chalcogen-containing naphthoquinones 
 In addition to the heteroarene-functionalized diselenides and monoselenides, 
two selenium and tellurium-containing naphthoquinones (16 and 17 respectively) were 
also re-synthesized with an aim to further elucidate their mode of chemotherapeutic 
action against tumorigenic cell lines. The synthetic protocol leading to these compounds 
was a straight-forward scheme which involved the facile nucleophilic substitution of 
phenyl selenolate/tellurolate, prepared in-situ, with halogen-functionalized 
naphthoquinones to yield black-coloured solids [143]. 
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Figure 3.3 Representation of chalcogen-containing naphthoquinones 
These compounds were isolated in favourable yields with a high level of 
purity. In addition, these compounds were stable at room temperature for at least two 
months. Similar to the behaviour of monoselenides and diselenides, both these 
compounds were also observed to resist photochemical decomposition under visible 
light. 
Overall, in this current study, organoselenium compounds have been 
employedas the prime focus of attention in comparison to their sulfur and tellurium 
containing analogues. This has been apparently due to their relatively higher biological 
activity over organo-sulfur compounds, on one hand and a relatively stable chemical 
profile in comparison to organotellurides, on the other.   
3.2 Physico-chemical characterization of synthesized compounds 
3.2.1 
1
H and 
13
C NMR analysis 
The 
1
H NMR spectrum of pyridine-substituted selenoalkanes (1-9) consisted of 
peaks of the aromatic protons (corresponding to the pyridine ring) in the downfield 
region of 6.7 - 8.2 ppm as doublets or singlets depending upon the position of the 
methyl group which is attached directly to the pyridine ring. The ethylene group (from 
the hexyls side-chain) which is attached directly to the selenium moiety was 
consistently observed as a triplet peak at 3.0 ppm, followed by the relatively upfield 
shifts of remaining methylene peaks of the alkyl groups as multiplets between 1.2 - 1.8 
ppm. In contrast, in case of the allylic side chain, the methylene group which is directly 
bonded to the selenium atom appeared relatively downfield as a doublet at 3.7 ppm due 
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to splitting by the adjacent allylic protons. The 
1
H NMR spectra thereby displayed a 
change in the resonance of the hydrogen atoms of the ethylenegroup (attached directly 
to selenium) depending upon a variation in the nature of the conjugated alkyl side-chain. 
The terminal methyl group of the functionalized alkyl side-chain appeared up-field (3, 6 
or 9) as a triplet at 0.8 ppm. In contrast, the methyl group attached directly to the 
pyridine ring appeared in a relatively downfield region at 2.2 ppm. The terminal allylic 
protons appeared in close separation from each other within the range of 4.9 - 5.3 ppm. 
Although both these protons are attached to the same carbon, a difference in their 
conformational arrangement could apparently lead to a difference in their splitting 
patterns. In addition, the non-terminal allylic protons resonate at a more downfield shift 
compared to their terminal counterparts at 6.0 ppm. This could most probably be due to 
their splitting by multiple adjacent protons, in addition to their closer proximity to a 
more electronegative selenium atom. In line with the alkyl-functionalized 
monoselenopyridines, the aromatic protons of the (di)aryl diselenides (10-15) also 
resided in the downfield region within 6.8 -8.4 ppm.  On the contrary, the protons of the 
methylene group which are attached directly to the selenium moiety (Se-CH2) resonated 
at 3.7 ppm (in case of 10 or 11) and at 4.6 ppm (in case of 12). The relatively downfield 
shift in case of 12 could apparently be due to a relatively higher electronegative effect 
of the quinoline ring in comparison to the pyridine ring (10 or 11) [142]. 
1
H NMR characterization of (16) and (17) displayed the resonating region of 
the aromatic protons of the naphthoquinone ring system between 7.8 - 8.0 ppm. Further, 
in case of 16 or 17, the downfield peaks lying within 7.2 - 7.8 ppm corresponded to the 
aromatic protons of the benzene ring(s) which are attached directly to the selenium or 
tellurium moiety, respectively. In case of compound 17, the non-aromatic protons 
corresponding to a methyl group which is attached directly to the naphthoquinone ring 
appeared at an upfield shift of 1.9 ppm. With respect to their 
13
C NMR analysis, 
compounds 1-9 shared a common set of peaks corresponding to the carbon atoms of the 
pyridyl ring (120.0-160.0 ppm). The carbonatom of the methylenegroup which is 
attached directly to selenium appeared upfield at 30 ppm. On the other hand, the carbon 
peaks corresponding to the remaining methylene groups of the hexyl alkyl chain 
appeared in the region between 20 - 30 ppm. 
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Table 3.1 
1
H and 
13
CNMR spectra data of compounds, synthesized as part of this study 
Compound 1H NMR (, ppm) 13C NMR (,ppm) 
Monoselenides 
1* 8.2 (d, 1H), 7.0 (s, 1H), 6.7 (d, 1H), 2.3 (s, 3H), 
0.9 (s, 3H) 
155.5, 149.3,146.8, 130,121, 20.6, 7.7 
2* 8.4(dd, 1H), 7.1 (dd, 1H), 7.2 (dd, 1H), 6.0 (m, 
1H), 5.2 (dd, 1H), 5.1 (m, 1H), 3.8 (d, 2H), 2.1 
(s, 3H),  
154.7, 146.3, 139.5, 137.1, 135.8, 
121.4, 115.8, 28.7, 20.6 
3 8.3(dd, 1H), 7.3 (dd, 1H), 7.0 (dd, 1H), 6.1 (m, 
1H), 5.3 (dd, 1H), 5.0 (m, 1H), 3.9 (d, 2H), 2.2 
(s, 3H), 
155.4, 147.0, 136.1, 135.1, 133.3, 
119.9, 116.7, 27.6, 19.6 
4* 8.2 (d, 1H), 7.1 (d, 1H),6.8 (dd, 1H), 2.3 (s, 3H), 
0.7 (s, 3H) 
155.6, 146.7, 135.4, 132.8, 118.8, 19.8, 
4.9 
5 8.2 (d, 1H), 7.2 (s, 1H), 6.7 (d, 1H),  3.1 (t, 2H), 
2.2 (s, 3H), 1.6- 1.7 (m, 2H), 1.2-1.4 (m, 6H), 
0.8 (t, 3H) 
155.5, 149.5, 146.6, 125.9, 121.3, 96.2  
31.4, 30.3, 29.7, 25.7, 22.6, 20.7, 14.1 
6 8.2 (d, 1H), 7.2 (d, 1H),  6.7 (d, 1H), 3.2 (t, 2H), 
2.2 (s, 3H), 1.6- 1.7 (m, 2H), 1.2-1.4 (m, 6H), 
0.8 (t, 3H) 
156.2, 146.9, 135.7, 133.2, 119.5, 
96.2,31.5, 30.2, 29.8, 25.4, 22.6, 19.7, 
14.1 
7* 7.8-7.9(d,1H),7.6-7.7(t, 1H), 6.9-7.1(m, 1H), 0.8 
(s, 3H) 
158.3, 149.8, 140.9, 121.8,114.5,7.06 
8* 7.9 (dd, 1H), 7.7 (dd, 1H), 6.9 (dd, 1H), 5.9 (m, 
1H), 4.9 (m, 1H), 4.7(m, 1H), 3.5 (d, 2H) 
160.5, 145.5, 143.2, 121.6, 113.3, 31.9, 
26.3, 22.9, 13.6 
9 8.1(m, 1H), 7.8 (m, 1H), 7.1(m, 1H), 2.9-3.0 (m, 
2H), 1.3-1.7 (m, 4H), 1.2-1.3 (m, 4H),  0.9 (t, 3H) 
162.6,161.2,145.4, 143.4, 121.9, 113.4, 
31.2, 29.8, 29.4, 26.7, 22.5, 14.0 
Organodiselenides 
10 8.5(d, 2H), 7.1(d, 2H), 3.8 (s, 2H) 150.0, 147.8, 124.0, 30.6  
11 8.5 (d, 1H), 8.4(d,1H),7.5(m, 1H), 7.2(m, 1H), 
3.7(s, 2H) 
149.8, 148.4, 136.2, 134.6, 123.3, 28.8 
12* 7.9-7.8 (d,1H ), 7.7-7.6(m, 2H), 7.5-7.4 (m, 1H), 
7.3 (s, 1H), 4.6(s, 2H) 
165.4, 135.3, 131.7, 130.0, 129.7, 
127.9,127.4, 126.6, 124.9, 31.4 
13* 8.3-8.2 (d, 1H), 7.6-7.5 (d, 1H) 167.9, 161, 158.8, 118.7 
14 6.6 (s, 1H), 2.3 (s, 6H) [140] 168.9, 167.3, 116.9, 23.9 [140] 
15*  7.8-7.7 (d, 2H), 7.5-7.4 (m, 2H), 7.1-7.0 (m, 
2H), 8.4-8.3 (d, 2H) 
154.2, 137.5, 121.0, 123.0, 149.5 
Chalcogen-containing naphthoquinones 
16*  7.9 (dd, 2H), 7.8 (dd, 2H), 7.5 - 7.4 (m, 4H), 7.3 - 
7.2 (m, 6H) 
178.3, 151.8, 134.0, 132.4, 132.2, 
131.1, 129.4, 127.6, 126.8  
17 * 8.0.- 7.9 (m, 1H), 7.9 (dd, 1H), 7.8 (dd, 2H), 7.8 - 
7.7(m, 1H), 7.4 - 7.3 (m, 1H), 7.3 - 7.2 (m, 2H), 
1.9 (s, 3H) 
 183.7, 180.7, 153.1, 141.4, 138.5, 
134.2, 133.7, 131.6, 131.2, 129.5, 
128.2, 126.6, 126.5, 115.0, 20.5 
* NMR spectra data is in accordance with the published literature values [140-143] 
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In contrast, the allylic carbon atoms appeared at a relatively much higher 
chemical shift in the region between 120-135 ppm. The carbon atom of the terminal 
methyl group of the hexyl side chain and the methyl group attached directly to the 
pyridine ring appeared rather upfield at around 14 ppm and 22 ppm, respectively.In case 
of the (di)aryl diselenides, similar trends in shifts were found for the aromatic carbon 
atoms corresponding to the heteroaryl moiety (10-12). With respect to their 
13
C spectra 
analysis, 10 and 11 shared a similar set of peaks corresponding to the aromatic carbon 
atoms between 120 - 150 ppm. In case of 12, the peaks corresponding to the aromatic 
carbon atoms of quinoline ring also appeared downfield within a similar region (120-
160 ppm). 
The carbon signal corresponding to the methylene groups, which are attached 
directly to selenium, appeared upfield at around 30 ppm (for 10, 11 and 12). With 
respect to their 
13
C spectra analysis, 16 and 17 shared a similar set of carbon peaks due 
to the presence of a common naphthoquinone and benzene ring system (115 - 185 ppm). 
The peak corresponding to the carbon of the methyl group (in case of 17) could be 
observed at 20.5 ppm [143]. 
3.2.2 
77
Se NMR and elemental analysis  
 In the current studies, due to a primary biological focus on the most potent 
compounds 10, 11 and 12, 
77
Se NMR and elemental analysis of these relevant 
compounds were further carried out to ensure their high synthetic purity, which is 
essential to obtain a clear and comprehensive understanding of their biological efficacy.  
Table 3.2 
77
Se NMR and elemental analysis of compounds 10, 11 and 12 
 
 
Compound 
 
 
77
Se (δ, ppm) 
Analytical Data 
% found (Theoretical%) 
C H N 
10 283.0 40.98 (42.12) 3.40 (3.54) 7.81 (8.19) 
11 274.8 40.16 (42.12) 3.41 (3.54) 7.89 (8.19) 
12* 409.8, 369.9 39.76 (40.16) 2.24 (2.36) 4.50 (4.68) 
* Data is in accordance with the published literature values [142] 
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3.2.3  Mass spectrometric analysis  
On the basis of the results from a primary cytotoxicity screen, the mass 
spectrometric analysis of the three most potent compounds (10- 12) was also carried out 
to reconfirm their synthetic purity prior to their further biological evaluation. In case of 
compound 10 and 11, distinct mass peaks corresponding the mass of the complete 
molecules were observed at 345 (m/z). In addition, characterisitc peaks corresponding 
to a pyridyl group attached to a selenium atom were also observed at 173 (m/z). This 
peak has been observed due to the apparent cleavage of the CH2-Se bond upon injection 
in a high intensity electron beam.In case of 10 and 11, another peak in addition to its 
original mass peak was also observed at 253 (m/z). This peak could correspond to the 
formation of a diselenide species attached to a single pyridinyl ring                          
[Aryl-CH2-Se-Se]
+
. In case of 12, only the mass peak corresponding to the complete 
molecule was observed. The mass spectrometric data of representative compounds 10, 
11 and 12 has been listed in Table 3.3. 
Table 3.3 Mass spectral analysis of 10, 11 and 12. 
Compound m/z[molecular ion, relative intensity] 
10 345([C12H12N2Se2]
+
,54%), 253([C6H6NSe2]
+
,39%), 
173([C6H6NSe]
+
, 87%) 
11 345([C12H12N2Se2]
+
, 
63%),253([C6H6NSe2]
+
,35%),173([C6H6NSe]
+
, 96%) 
12
*
 301([C10H7NSe2]
+
,40%), 302 ([C10H7NSe2+1]
+
,20%). 
* Data is in accordance with the published literature values[142] 
3.2.4  X-ray structure elucidation of compound, 11 
Orange coloured crystals of diffraction quality were grown by the slow 
evaporation of compound 11 after being dissolved in a solvent mixture of 
dichloromethane and hexane (1: 4). To have a better understanding of the structural 
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details, the molecular structure of 11 was unambiguously established by single crystal 
X-ray diffraction analysis. The single crystals were chosen from a crop of crystals 
mounted on glass fibres.The corresponding structural data was collected on Bruker 
Smart Apex and Bruker Smart diffractometer using graphite monochromated Mo 
Kradiation {(0.71069 Å) and (0.71073 Å)} for the cell determination and intensity data 
collection. The crystal structure was solved by direct methods (SHELX-97) and 
(SHELX-2013) and refined by the full matrix least squares method. 
A perspective view and the atomic-numbering scheme of 1,2-bis{(pyridin-4-
yl)methyl}diselane (11) is shown in Figure 3.4.  
 
Figure 3.4 Perspective view of 1, 2-bis{(pyridin-4-yl)methyl}diselane (11) showing the 
atomic-numbering scheme 
The crystallographic data reveals that compound 11 crystallizes into 
monoclinic, P2 (1)/c space group with the following cell parameters. 
      Cell parameters 
a = 13.569(3) b = 7.8407(15) c = 11.984(2) 
α = 90.00 β = 109.101(4) γ = 90.00 
     
The selected bond distances and bond angles are presented in Table 3.4. Relevant 
information regarding the data collection and refinement parameters (Table 2.2, 
Chapter 2) supports the structural framework of compound 11. 
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Table 3.4: Selected bond distances [A
°
], bond angles [
°
] and torsional angles [
°
] of 1,2-
bis{(pyridin-4-yl)methyl}diselane (11) 
Se(1)-Se(2) 2.305(3) Se(1)-C(1) 1.94(4) 
N(1)-C(4) 1.30(6) N(1)-C(5) 1.18(5) 
C(3)-C(4) 1.32(7) C(5)-C(6) 1.40(6) 
C(1)-C(2) 1.27(5) C(7)-C(8) 1.36(5) 
C(1)-Se(1)-Se(2) 100.8(11) C(7)-Se(2)-Se(1) 100.6(12) 
C(2)-C(1)-Se(1) 114(2) Se(2)-C(7)-C(8) 114(3) 
C(1)-Se(1)-Se(2)-C(7) 179.1(10) Se(1)-Se(2)-C(7)-C(8) -72(3) 
Se(2)-Se(1)-C(1)-C(2) -76(4) C(3)-C(2)-C(1)-Se(1) 101(4) 
 
The Se-Se bond length has been found to be 2.305 Å which relates well with the 
corresponding distances reported for other diselenides, ranging from 2.29 to               
2.39 Å(Pauling scale). The C–Se bond distances of 1.997 Å [C(7)−Se(1)] and         
1.995 Å [C(6)−Se(2)] in the structure are in agreement with the literature values.The 
expanded short contacts view of 11 reveals intermolecular N···H, Se···Se and Se···H 
interactions. 
3.3 Cytotoxicity studies 
3.3.1 Primary cytotoxicity of organo-selenium compounds 
against mammalian cell lines 
Due to the presence of a redox-active and physiologically labile diselenide 
moiety, organodiselenides have been frequently proposed to furnish, intracellularly, a 
greater level of biologically-active metabolites like selenols with relative "ease", in 
comparison to monoselenides. This, in turn, has been observed in the significantly 
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higher level of anti-tumour efficacy of the former, in both in-vitro and in-vivo 
experiments, relative to their monoselenide counterparts [153].   
In the past, several reports have highlighted the biological efficacy of a 
plethora of phenyl-substituted diselenides against tumorigenic cell lines. However, there 
is lack of information regarding the biological efficacy of heteroaryl-substituted 
diselenides. In due consideration of the natural occurrence of N-containing heterocyclic 
moieties like pyridine or pyrimidine rings in biologically active substances, the present 
studies were aimed at investigating the anti-tumour efficacy of such hetero-aryl 
conjugated diselenides (10-15), thereby shifting the attention from the routine synthesis 
and biological analysis of diphenyl diselenide and its derivatives. On the other hand, in 
view of the concept that an enhancement in the ability of monoselenides to enter cells 
via an enhanced lipophilicity could possibly lead to an enhancement in their cytotoxicity 
against tumour cells and possibly bridge the difference between the anti-tumour efficacy 
of organodiselenides and monoselenides. Attempts were made to introduce a 
characteristic amphiphilicity into these rather poorly active monoselenidesvia 
functionalization with hydrophobic alkyl chains of varying carbon lengths. This led to 
the synthesis of a number of alkyl-functionalized monoselenides (1-9). The design and 
synthesis of some of the monoselenides and diselenides were carried in the research 
group of Prof. K.K. Bhasin (Department of Chemistry, Panjab University, Chandigarh, 
India). 
Further, in order to carry out a comparative analysis of the anti-tumour efficacy 
of organoselenium compounds on a relatively broader scale, several chalcophenes 
provided by Dr. Pavel Arsenyan (Latvian Institute of Organic Synthesis, Aizkraukles 
21, Riga LV-1006, Latvia) were also included in the primary screen. This facilitated in 
establishing a comparison between the anti-cancer activities of three distinct different 
groups of organo-selenium compounds, namely monoselenides, diselenides and 
selenophenes. Here again, it must be mentioned that organoselenium compounds have 
been selected for study over organosulfur compounds due to their relatively higher anti-
tumour efficacy [153]. In addition, organoselenium compounds have been reported to 
have a safer pharmacological profile in comparison to organotellurium compounds. 
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In view of the above arguments, representative examples of the synthesized 
organodiselenides and alkyl-functionalized monoselenides were screened for their anti-
proliferative ability against a spectrum of tumorigenic cell lines. Amongst the tumour 
cell lines, KB-3-1, PC-3 and MCF-7 cell lines were selected, since these tumour cell 
lines are fairly robust and therefore, can clearly distinguish between of the 
chemotherapeutic potential of toxic and non-toxic molecules.  Due to the inclusion of an 
MCF-7, a breast cancer cell line, ARS-01, an FDA-approved organo-chalcogen drug 
used in the treatment of breast carcinoma has been included as a benchmark compound 
in the primary screening. In addition, a transformed mouse fibroblast cell line (L-929) 
was alsoselected in order to observe a selectivity of any of the screened compounds 
towards tumorigenic cells.  
 The primary screening of the diverse range of organselenium compounds against 
the selected mammalian cell lines were carried out by means of a standard MTT assay, 
as described in Section 2.4.3 [144]. This assay was carried out in the laboratory of Dr. 
Florenz Sasse (Helmholtz Centre for Infection Research, Braunschweig, Germany). 
Briefly, this assay is based on the principle of conversion of a commercially available 
MTT dye into insoluble formazan crystals by the activity of dehydrogenase enzyme in 
viable cells. In accordance with this principle, viability of treated cells was calculated 
with respect to the corresponding solvent-treated cells. The IC50 values that represent the 
concentration of the compound needed to elicit half of the maximum biological 
response are depicted in Table 3.5 for the screened compounds.  
3.3.1.1 In-vitro chemotherapeutic effects of heteroarene-substituted 
monoselenides and diselenides  
According to the results presented in Table 3.6, the best inhibitory activities against 
the selected tumourigenic cell lines were displayed by the aryl (di)selenides. Amongst the 
representative examples of the synthesized (di)aryl diselenides viz.,10, 11 and 12 displayed 
the maximum anti-proliferative potential against the selected mammalian cell lines. On the 
other hand, compounds 13, 14 and 15 also displayed a moderate anti-cancer activity which 
was still higher as compared to the one of the alkyl-substituted monoselenopyridines (1-9).  
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Table 3.5 IC50 values (µM) of organoseleniumcompounds against mammalian cell 
lines
(a) 
obtained from a standard MTT assay. Values have been expressed as mean      
IC50 ± SD.*p < 0.05; 
#
p < 0.001 compared with solvent-treated cells. n = 3. 
Compound L-929 KB-3-1 PC-3 MCF-7 
1 >37 35.5± 1.5 34.3 ± 1.5 >37 
2 >37 >37 31.8 ± 1.9 >37 
3 >37 31.1± 1.5 >37 >37 
4 >37 34.8± 1.6 31.6 ±  1.6 >37 
5 >37 >37 34.5 ± 1.8 >37 
6 >37 >37 >37 >37 
7 30.3 ± 1.4 31.1 ± 1.6 >37 >37 
8 >37 >37 31.4 ± 1.1 >37 
9 >37 >37 30.1 ± 1.3 >37 
10 0.4 ± 0.1
#
 0.4 ± 0.2
#
 0.6 ± 0.3
#
 0.8 ± 0.3
#
 
11 0.7 ± 0.4
#
 0.4 ± 0.1
#
 0.9 ± 0.3
#
 n.d. 
12 0.6 ± 0.3
#
 0.8 ± 0.4
#
 0.02 ± 0.3
#
 n.d. 
13 10.5 ± 1.1
*
 17.5 ± 1.8
*
 18.6 ± 1.7
*
 16.8 ± 1.1
*
 
14 15.1 ± 1.6
*
 18.5 ± 1.3
*
 16.1 ± 1.3
*
 18.6 ± 1.9
*
 
15 6.4 ± 1.3
#
 16.3 ± 1.4
*
 18.8 ± 1.6
*
 17.5 ± 1.4
*
 
ARS-01 
(positive control) 
9.1 ± 1.1
#
 5.3 ± 0.7
#
 5.8 ± 0.6
#
 3.5 ± 0.8
#
 
(a)
L-929: transformed mouse fibroblasts; KB-3-1: humancervix carcinoma; PC-3: prostate 
carcinoma; MCF-7: breast carcinoma. n.d. - not determined 
In accordance with the results obtained from the MTT assay, compound 12 
displayed a significantly high activity against several tumorigenic cell lines. Based on the 
results obtained from the MTT assay, the inhibitory values of 12 against the selected 
mammalian cancer cell lines were found within the sub-micromolar range. Prostate cancer 
cells, in particular, displayed an acute sensitivity towards this compound (IC50 = 0.02 ± 0.3 
µM). Compound 12 also yielded a significant inhibitory activity against cultured KB-3-1 cells 
(IC50 = 0.8 ± 0.4 µM). The dose-response curves of 12 against KB-3-1 cells have been 
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demonstrated in Figure 3.5. It also displayed a certain level of toxicity even against L-929 
(IC50 of 0.6 ± 0.3 µM), thereby indicating an apparently low selectivity towards cancer cells 
and a risk of general toxicity against mammalian cells. 
 
Figure 3.5 Dose-response curves of compound 12 (grey curve) and an "equivalent 
volume" of DMSO (black curve) against KB-3-1 cells, in-vitro, in an MTT assay 
following a 5 d incubation.IC50 = 0.8 ± 0.4 µM for 12. Activities have been plotted as 
the mean values ± SD. *p < 0.001versus DMSO-treated cells. n = 3. 
In line with the results obtained for 12 in the MTT assay, the IC50 values of the 
isomeric diselenides 10 and 11 against the selected mammalian cell lines were also 
observed within the sub-micromolar range. The anti-cancer activity of 11 was slightly 
less compared to 10. Amongst the tumorigenic cell lines, both 10 and 11 exerted a 
similar inhibitory activity against human cervix carcinoma (KB-3-1) cells, in-vitro, with 
an IC50 of 0.4 ± 0.2 µM, and 0.4 ± 0.1 µM, respectively. Further, 10 yielded a relatively 
higher inhibitory activity against PC-3 cells (IC50 of 0.6 ± 0.3 µM) compared to 11    
(IC50 of 0.9 ± 0.3 µM). However, on similar lines with12, both10 and 11 apparently did 
not exhibit a selectivity towards tumorigenic cells. The dose-response curves of 10 and 
11 against KB-3-1 cells have been demonstrated in Figure 3.6. 
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Figure 3.6 Dose-response curves of 10 (light grey curve), 11 (dark grey curve) and an 
equivalent volume of DMSO (black curve) against KB-3-1 cells, in- vitro, in an MTT 
assay following a 5 d incubation. 10 and 11 exert a similar IC50 of 0.4 ± 0.2 and 0.4 ± 
0.1 µM, respectively. Relative activities have been plotted as the mean values obtained 
from individual experiments ± SD. *p < 0.001compared to DMSO-treated cells. n = 3. 
As poined out earlier, the significant intra-cellular efficacy of diselenides has 
been attributed to the facile generation of active selenols upon enzymatic cleavage of 
the diselenide bond (Figure 3.7). An interaction of the proteins (which are active in 
their oxidized form) with these strongly nucleophilic selenols has been reported to 
trigger the opening up of the disulfide bonds of such proteins, thereby resulting in the 
formation of an activated selenyl sulfide intermediate. The latter has been proposed to 
undergo subsequently a facile reaction with GSH to form glutathione-protein mixed 
sulfides which finally undergoes a further reduction to form an inactivated protein thiol. 
An inactivation of several oncogenic proteins that are redox-activated in their oxidized 
state, thereby, could contribute to the anti-proliferative potential of diselenides via 
redox-cycling. In contrast, due to the absence of physiologically labile diselenide bonds 
in monoselenides, the ease of formation of active metabolites like methyl selenol are 
apparently far less. As a consequence, the anti-tumour efficacy of monoselenides has 
been relatively weak, as observed in the present studies. 
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Figure 3.7 Mechanism of organodiselenide-catalysed inactivation of redox-regulated 
proteins [97]. 
The alkyl-functionalized monoselenides, in contrast,  irrespective of variation 
in chain length, were apparently ineffective towards inhibiting the proliferation of the 
selected tumour cells. These monoselenides displayed an average IC50 of 30 µM against 
the selected tumour cell lines, which is far beyond a significant benchmark value 
assigned to potential chemotherapeutic molecules. The not-so promising results 
obtained with respect to these alkyl-functionalized mono selenides, apparently due to 
their poor activity and/or penetration ability into cells, were in concordance with results 
recorded previously in the literature for certain monoselenides [153]. A variation in the 
carbon chain-length of the conjugated alkyl side group appeared to induce a minimal 
alteration in activity, counting against the notion that modulation of lipophilicity may 
improve the biological activity significantly. 
3.3.1.2 In-vitro chemotherapeutic efficacy of selenophenes: First 
insights 
 In addition to organo-monoselenides and diselenides of N-containing 
heterocyclic ring systems, a third chemotype belonging to a unique group called 
"selenophenes" were also subjected to a comparative cytotoxicity analysis using a 
standard MTT assay. These compounds basically involve a selenium (or sulfur in case 
of ARS-01) moiety that is integrated into a "stable" aromatic system (Figure 3.8).  
Chapter 3  Results 
 
96 
 
ARS-01
SOH
OH
O
O
N
HCl
 
ARS-02
SeOH
OH
O
O
N
HCl
 
ARS-03
O O
Se
N
Br
HCl
 
ARS-04 
O O
Se
Br N
HCl
 
ARS-05 
O O
Se
Br
N
O
O
HCl
 
ARS-06
O O
Se
Br
N
OH
O
HCl
 
Figure 3.8 Chemical structures of ARS-01 (raloxifene), ARS-02 (the selenium 
analogue of raloxifene) and various other selenophenes. 
These compounds (ARS-02 to ARS-06) had been supplied by Dr. Pavel 
Arsenyan (Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, 
Latvia) for a first-hand report on the biological efficacy of these newly synthesized 
molecules. In this case, raloxifene (ARS-01) which is an FDA approved anti-cancer 
drug and shares a close structural similarity with the selenophenes (ARS-02, in 
particular) was included as a reference compound to facilitate a comparative analysis of 
the chemotherapeutic efficacy of the screened compounds with the anti-cancer drug.
 Based on the results obtained from an MTT analysis, raloxifene (ARS-01) 
and its selenium-substituted analogue (ARS-02) displayed the highest anti-
proliferative potential against the selected cell lines. Whereas ARS-01 
demonstrated a maximum sensitivity against MCF-7 cells (IC50 of 3.5 ± 0.8 µM), 
ARS-02 yielded a weaker effect against the same cell line                                         
(IC50 of 10.7 ± 1.4 µM).Compound ARS-02, however, displayed its maximal 
inhibitory active selenium moiety in ARS-02 compared to a sulfur moiety in ARS-
01, the latter apparently displayed a better inhibitory potential against the selected 
tumour cell lines. 
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Table 3.6 IC50 values of various selenophenes obtained against mammalian cell lines
(a) 
obtained from a standard MTT assay. Inhibitory values have been calculated as mean 
IC50 values ± S.D. *p < 0.05;
 #
p < 0.001 versus DMSO-treated cells. n = 3. 
Compound L-929 KB-3-1 PC-3 MCF-7 
ARS-01 
(positive control) 
9.1 ± 1.1
#
 5.3 ± 0.7
#
 5.8 ± 0.6
#
 3.5 ± 0.8
#
 
ARS-02 12.6 ± 0.9
*
 7.1 ± 1.1
#
 11.7 ± 0.8
*
 10.7 ± 1.4
*
 
ARS-03 13.1 ± 1.5
*
 21.1 ± 1.8 18.6 ± 1.3 22.6 ± 1.6 
ARS-04 19.5 ± 1.4 17.1 ± 1.8 22.4 ± 1.5 31.3 ± 1.8 
ARS-05 11.5 ± 1.3
*
 10.6 ± 1.8
*
 21.1 ± 1.5 34.6 ± 1.4 
ARS-06 11.8 ± 1.1
*
 10.8 ± 1.8
*
 16.4 ± 1.5 35.6 ± 1.6 
(a)
L-929: transformed mouse fibroblasts; KB-3-1: human cervix carcinoma; PC-3: prostate 
carcinoma; MCF-7: breast carcinoma. 
The remaining four selenium-containing coumarin derivatives (ARS-03 to 
ARS-06) displayed an average activity against the selected tumour cell lines in the 
higher micromolar range (IC50 = 10 - 35 µM). These four selenophenes, however, 
have displayed a relatively high activity towards KB-3-1 cells, in comparison to 
the other selected cell lines. Although the exact reason behind the higher 
susceptibility of KB-3-1 cells towards selenophenes remains unclear, it can be 
assumed that KB-3-1 cells, in comparison to the other tumour cells, are probably 
more sensitive to redox-active changes that could be mediated by these 
selenophenes.  
Amongst 10, 11 and 12 that exhibited the maximum anti-cancer activity in 
the MTT assay, 12 have a unique feature of belonging to the category of aliphatic 
and aromatic diselenides. This implies that one selenium atom in 12 is attached to 
a quinoline (aromatic) ring and the other selenium atom is attached to a methylene 
(aliphatic) group. This feature is due to the cyclic framework of this particular 
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heterocyclic diselenide. Interestingly, this heterocyclic diselenide (12) also 
exhibited a very strong inhibitory potential (IC50 = 0.02 ± 0.3 µM) against the 
fairly stable prostate cancer (PC-3) cells. Although 10 and 11 have also exhibited 
potent inhibition of PC-3 cells in addition to other tumour cell lines, the promising 
anti-proliferative ability of 12 stands out in comparison to the other analysed 
molecules in this study.  Therefore, in due consideration of its significantly low 
inhibitory value registered against PC-3 cells to its overall significant inhibitory 
effect against other tumour cells as well, 12 was eventually selected for a more-
detailed biological study with attempts to comprehend its molecular and cellular 
mode of biochemical action against tumorigenic cells. Nevertheless, 10 and 11 
were also studied in parallel due to an interest in these compounds and for an 
overall comparison. It must also be mentioned that these three compounds 10, 11 
and 12 which were synthesized by a similar synthetic methodology also share a 
common biologically active functionality in the form of a methylene group 
attached to a selenium atom. 
In conclusion, as evident from the results, aryl diselenides (10-15) 
demonstrated a much higher chemotherapeutic efficacy in-vitro than the alkyl-
substituted monoselenides (1-9) and the chalcophenenes (ARS-01 - ARS-06). On 
the basis of their potent inhibitory values, compounds 10, 11 and 12 were further 
investigated for their biochemical mode of action against tumour cells. Results 
regarding the same have been discussed in the subsequent sections.  
3.3.2 Comparative evaluation of compounds 10, 11 and 12 for their 
biological activity in KB-3-1 cells 
As has been reported in the previous section, compound 12, in addition to 
compounds 10 and 11, exhibited a significant inhibitory activity against the selected 
tumorigenic cell lines in-vitro in the sub-micromolar range. In consideration of such 
findings, 10, 11 and 12 were selected for a more in-depth biological analysis. 
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3.3.2.1 ATP (Cell viability assay) 
 As observed in the MTT assay, 12 displayed a significant inhibitory activity against 
KB-3-1 cells. To further validate this observation, compound 12 was subjected to an ATP 
assay in order to investigate and quantify the decline in ATP levels in KB-3-1 cells upon 
treatment with 12. 
In addition to cellular dehydrogenase activity that has been quantified using the 
MTT assay, intracellular ATP levels are also widely recognised as a parameter of cell 
viability. In principle, when cells lose their membrane integrity, they also lose the ability to 
synthesize ATP and endogenous ATPases rapidly deplete any remaining ATP from the 
cytoplasm [147]. Therefore, to analyse the effects of the heterocyclic diselenide (12) upon 
ATP levels in KB-3-1 cells, a firefly luciferase-assisted ATP assay was employed using the 
Cell-titre Glo assay kit. This is one of the most commonly applied and commercially available 
methods for estimating cell viability in high content screening applications [147]. In 
accordance with the manufacturer´s instructions, this assay was carried out in the laboratory 
of Dr. Florenz Sasseusing KB-3-1 cells at two different time points (24 h and 48 h).  
According to the results, 12 displayed a decrease in the ATP levels in KB-3-1 cells 
in a concentration and time-dependent manner. Whilst the intracellular ATP levels had not 
decreased significantly after the first 24 h of incubation (IC50 = 4.5 ± 0.7 µM), 12 was 
observed to induce a significant decline in the ATP levels of KB-3-1 cells                                  
(IC50 = 0.6  ±  0.3 µM) after 48 h (Figure 3.9). This value was close to the inhibitory value 
obtained previously for 12 against KB-3-1 cells using the MTT assay. 
Similar to compound 12, both 10 and 11 also caused a decline in the ATP levels of 
KB-3-1 cells in a concentration and time-dependent manner. As can be seen from Figure 3.9, 
the ATP levels of KB-3-1 cells did not decrease significantly after the first 24 h of incubation 
with either 10 or 11. The IC50 values after 24 h of incubation were observed at 4.0 ± 0.7µM 
and 9.5 ± 0.9 µM respectively. However, after 48 h of incubation, both 10 and 11 caused a 
significant decline in the ATP levels of KB-3-1 cells with a 50 % inhibitory value of               
1.0 ± 0.4 µM and 2.5 ± 0.7 µM respectively. 
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a) 
 
b) 
 
Figure 3.9 Concentration-dependent effect of 10 (white bars), 11 (dark grey bars), 12 (light 
grey bars) and equivalent volume of DMSO (black bars) on ATP levels in KB-3-1 cells 
treated for (a) 1 d and  (b) 2 d. Untreated KB-3-1 cells correspond to the control. 
Luminescence, proportional to relatively intra-cellular ATP levels, was measured using a 
plate reader. Curves are plotted from mean values. Obtained from individual experiments ± 
S.D. *p <0.05; #p < 0.001 versus DMSO-treated cells. n = 3. 
To conclude, compounds 10, 11 and 12 were observed to exert a significant 
decline in ATP levels of KB-3-1 cells after 48 h incubation. Although 10 and 12 were 
found to display a similar activity at either time intervals (1 d or 2 d), 11 appeared to be 
slightly less active especially after 1 d treatment with KB-3-1 cells. Although 10 and 11 
are structural isomers, it could be possible that a poorer chemical stability of the latter in 
the biological medium could attribute to its relatively low activity. 
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3.3.2.2 Apoptosis assay:  Cell-Death Detection ELISA Assay  
 The apoptosis assay studies were carried out at Helmholtz Centre for Infection 
Research, Braunschweig, Germany. 
Based on the quantitative sandwich enzyme immuneassay principle, an ELISA 
assay for the detection of tumour cell death was performed to quantify the apoptotic 
index of compounds by detecting histone-associated DNA fragments (mono- and 
oligonucleosomes) generated by the apoptotic cells [145]. In accordance with the 
previous assays, KB-3-1 cell lineswere used to investigate the molecular mode of cell 
death. The enrichment of mono- and oligonucleosomes released into the cytoplasm of 
KB-3-1 cells by treatment with a compound was quantified in terms of "apoptotic 
index" of the compound. This index also serves as a direct parameter for comparing the 
apoptotic potential of different compounds.  In principle, a higher apoptotic index 
signifies a greater extent of fragmentation of cellular DNA and therefore, higher levels 
of apoptosis. 
 According to the results obtained in this study, 12 was observed to 
induce apoptosis in KB-3-1 cells in a dose-dependent manner. The extent of apoptosis 
induced by 12 was observed to be maximal at a concentration of 30 µM.At this 
concentration, 12 demonstrated a maximum apoptotic index of 9.5 ± 0.6. As can be seen 
in Figure 3.10, therewas a sharp increase in the apoptotic potential of 12 within the 
concentration range of 10 µM to 30 µM. In contrast, equivalent volumes of DMSO 
(negative control) exhibited a negligible induction of apoptosis, in comparison to 
12.Similar to 12, both 10 and11 were also analysed for their potential to induce 
apoptosis in KB-3-1 cells. According to the results displayed in Figure 3.10, both 
isomeric diselenides potently induced apoptosis in KB-3-1 cells in a dose-dependent 
pattern. The apoptotic indices of 10 and 11were observed to be considerably high, even 
at concentrations as low as 17 µM (apoptotic index of 8.5 ± 0.5 and 8.4 ± 0.3, 
respectively). At a lower concentration of 5.6 µM, compound 10 wasobserved to 
possess an apoptotic index of 7.1 ± 0.3, in contrast to a rather low apoptotic index of 3.9 
± 0.7 for 11. Therefore, 10 demonstrated a higher efficacy in inducing apoptosis at 
lower concentrations as compared to its isomer 11. 
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a) 
 
b) 
 
 
Figure 3.10 Induction of apoptosis by (a) compound 12 (white bars) and (b) compound 
10 (dark grey bars) and 11 (white bars), after subtraction of effects caused by equivalent 
volumes of DMSO in KB-3-1 cells in a concentration-dependent manner. The apoptotic 
index (also called enrichment factor) represents the ratio of fragmented DNA in treated 
cells relative to untreated cells (control bar). Bars have been plotted from mean values ± 
S.D. *p < 0.05; 
#
p < 0.001 versus untreated cells. n = 3. 
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To conclude, both 10 and 11 demonstrated a potent induction of apoptosis in 
KB-3-1 cells. Compound 10 apparently exhibited a relatively higher apoptotic potential 
compared to 11 or 12, particularly at the lower concentrations used. Therefore, it is 
evident that 10, 11 and 12 exert their anti-proliferative effects against KB-3-1 cells via 
an induction of apoptosis. 
3.3.2.3 Caspase 3/7 activation assay  
 It has been reported that selenium-containing molecules mediate apoptosis in 
tumour cells. Depending upon the chemical nature of species, selenium-containing 
compounds induce apoptotic mode of cell death with or without the aid of caspases [57, 
104]. In order to better comprehend the mechanism of apoptosis induced in compound-
induced KB-3-1 cells, a caspase 3/7 assay was carried out to confirm the potential 
involvement of caspases 3 and 7 in mediating apoptotic cell death in KB-3-1  
Figure 3.11 Degree of activation of caspases 3/7 in KB-3-1 cells upon treatment of   
KB-3-1 cells with different concentrations of 12, after subtraction of effects caused by 
equivalent volume of DMSO. Caspase 3/7 activity levels, after an incubation of 12 with 
KB-3-1 cells for 12 h (dark grey bars) and 24 h (white bars), are in direct proportion to 
the recorded luminiscence values. Caspase activity corresponding to untreated cells 
(control) has been arbitrarily normalized to 10.0. Bars have been plotted from mean 
values ± S.D.*p < 0.05; 
#
p < 0.001 versus untreated cells. n = 3. 
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cells and quantifying the extent of its activation upon compound treatment [148]. This 
assay was carried out at Helmholtz Centre for Infection Research, Braunschweig, using 
a commercially available Caspase3/7 Glo assay kit. Briefly, in accordance with the 
manufacturer´s instructions, KB-3-1 cells were incubated with serial dilutions of the 
compounds in 96-well micro-titre plates for 12 h and 24 h. After the treatment, the 
Caspase Glo-reagent (prepared freshly) was added to compound-treated KB-3-1 cells 
resulting in a luciferase reaction with the production of luminiscence. The amount of 
generated luminescence was quantified using a plate reader. In principle, the amount of 
luminiscence generated is proportional to the degree of activation of caspase 3/7 in KB-
3-1cells.  
Results from this assay pointed towards a concentration and time-dependent 
stimulation in caspase3/7 activity in KB-3-1 cells upon treatment with 12. The 
stimulation of caspase3/7 was more pronounced after 24 h incubation relative to 12 h 
incubation. This was evident from an approximately 5-fold and 4-fold increase in the 
activation of caspase 3/7 in KB-3-1 cells upon incubation with 30 µM of 12 relative to 
incubation with 1 µM of 12 for 12 h and 24 h, respectively. 
 Similar to 12, both 10 and 11 induced astimulation in the activation of caspase 
3/7 in KB-3-1 cells in a concentration and time-dependent manner. Upon an increase in 
the concentration from 1.8 µM to 52 µM, both 10 and 11 induced an approximately 3-
fold and 4-fold increase in the activation of caspase 3/7 after treatment with KB-3-1 
cells for 12 h and 24 h, respectively. The ability of the isomers 10 and 11 to stimulate 
caspase 3/7 activity in KB-3-1 cells was similar with 10 being relatively more effective 
than 11. Similar to 12, stimulation of caspase 3/7 by 10 or 11 was more pronounced 
after 24 h incubation, relative to 12 h incubation.  
 To sum up, the results that were obtained from the cellular assays in-vitro, 
amongst the screened compounds 10, 11 and 12 demonstrated the highest activity 
against tumour cells. This was evident from an appreciable decline in the 
dehydrogenase activity and ATP levels of cultured cervix carcinoma (KB-3-1) 
cellsupon treatment with 10, 11 or 12 at concentrations in the sub-micromolar range. 
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a) 
 
b) 
 
Figure 3.12 Degree of activation of caspases 3/7 in KB-3-1 cells upon its treatment 
with different concentrations of 10 (dark grey bars) and 11 (white bars), after 
subtraction of effects caused by DMSO. Caspase 3/7 activity levels, after an incubation 
of 10 and 11 with KB-3-1 cells for (a) 12 h and (b) 24 h, are in direct proportion to 
recorded values. Caspase activity corresponding to untreated cells (control) has been 
arbitrarily normalized to 10.0.*p < 0.05; 
#
p < 0.001 versus untreated cells. n = 3. 
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Further, in accordance with the results obtained from the ELISA assay and 
caspase 3/7 assay, these compounds (10-12) demonstrated a significant induction of 
apoptosis in KB-3-1 cells via stimulation of caspase 3/7 activity. Since 10 and 11 are 
isomers of each other, both these compounds share an identical chemical composition 
and subsequently a similar biological activity. Further, on a close introspection of their 
chemical structures, these three compounds (10, 11 and 12) possess a rather labile and 
reactive functional moiety comprising of a selenium atom attached to a methylene 
group. Since such a functional moiety has also been observed in various biologically 
active organoselenium compounds like SEM or Sec, it could be hypothesized that this 
characteristic chemical functionality could attribute to somewhat similar, yet 
significantly high biological activities of these compounds. 
3.3.2.4  Translation inhibition assays 
 Since the up-regulation of protein translation has emerged as a critical aspect 
for proliferation and survival of cancer cells, this study explored any possible 
suppressive effects of 12 towards the intra-cellular translational machinery of such cells.  
For this, two models of translation were selected: a rabbit reticulocyte system and a KB-
3-1 cell model. These experiments were, therefore, designed to establish a potential 
correlation between the anti-proliferative effects of 12 against mammalian cells, on the 
one hand, and possible down-regulatory effects on the protein-translationalefficiency of 
mammalian cells on the other. A particular emphasis on KB-3-1 cells was made in one 
of these assays since this type of tumour cells were also used as part of the previous 
studies. 
3.3.2.4.1 In-vitro protein translation inhibition assay 
This assay, involving a rabbit reticulocyte system which is enriched with 
essential amino acid mixtures and several translation-enhancing components, is 
frequentlyemployed to screen small molecules and extracts on the basis of their 
translation-inhibiting or promoting efficacy [154]. The inhibitory activity of the 
screened compounds is measured by means of a luciferase activity output assay. In 
principle, an expression of the luciferase enzyme, which is encoded within reporter 
genes like Renilla (which has been used in this study), is measured in the cell-free rabbit 
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reticulocytes to quantify the translational activity of the reticulocyte system after 
treatment with the compounds of interest. A lower luciferase activity corresponds to a 
greater inhibition of translation of the respective system. 
As is evident from the results depicted in Figure 3.13, compound 12 caused a 
decline in the translational activity of the reticulocyte system in a concentration-
dependent manner. The maximum inhibitory activity of 12 which was observed at its 
highest concentration selected (10 µg ml
-1
 or 33.3 µM) was comparable to the inhibitory 
potency of the standard inhibitorof translation cycloheximide at its highest 
concentration selected (10 µg ml
-1 
or 35.5 µM).  
 
Figure 3.13 Inhibition of protein synthesis in an in-vitro rabbit reticulocyte system by 12 
(white bars) and cycloheximide (dark grey bars), a standard translation inhibitor and used 
as a benchmark positive control. Recorded values, displayed as mean values ± SD, are in 
direct proportion to translation efficiency. Luminescence values corresponding to untreated 
cells (control) have been normalized to 100. *p < 0.05; 
#
p < 0.001 versus untreated KB-3-1 
cells. n = 3. 
 
In addition, both 12 and cycloheximide caused a 43.6 ± 1.8 % and 61.3 ± 2.1 % 
inhibition of translational activity of the reticulocyte system at concentrations as low as 
0.3 µM (0.1 µg ml
-1
) and 0.4 µM (0.1 µg ml
-1
), respectively. In contrast, methanol (as 
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negative solvent control) was found to exert negligible effects on the inhibition of the 
translational efficiency of the reticulocyte system. 
3.3.2.4.2 In-cell translation inhibition assay 
 In line with the encouraging results obtained in the eukaryotic rabbit 
reticulocyte system, the translation-inhibitory potential of 12 was analysedfurther in 
KB-3-1 cells. 
 
Figure 3.14 Inhibition of protein synthesis by 12 (white bars) and cycloheximide (light 
grey bars; positive control) in KB-3-1 cells after transfection with pRL-SV40 vector 
expressing Renilla luciferase. Recorded values, displayed as mean values ± SD, are in 
direct proportion to translation efficiency. Luminiscence of methanol-treated cells has 
been normalized to 100. The histograms are plotted as mean values. Error bars indicate 
± S.D. *p < 0.05; 
#
p < 0.001 versus methanol-treated cells. In remaining cases, p > 0.05, 
n = 3. 
In accordance with the procedure described in Section2.4.3.5.2, prior to 
treatment of KB-3-1 cells with 12,KB-3-1 cells were transfected with a suitable plasmid 
(in this case, pRL-SV40) by using polyethyleneimine (PEI) as the transfection agent 
(kindly provided by Dr. Yazh Muthukumar). This was followed by treatment of the 
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transfected KB-3-1 cells with different concentrations of 12, cycloheximide (as positive 
control) and an equivalent volume of methanol (as negative solvent control). Following 
incubation for 4 h, the transfected KB-3-1 cells were lysed with 1x Passive Lysis Buffer 
and then mixed with a luciferase assay buffer. Based on the same principle as used in 
the in-vitro translation assay, the luminescence generated upon expression of the 
luciferase enzyme in KB-3-1 cells was quantified by using a plate reader. The intensity 
of the recorded luminiscence is directly proportional to the level of protein translational 
activity of the KB-3-1 cells. 
As evident from the results displayed in Figure 3.14, both 12 and 
cycloheximide were observed to induce a similar dose-dependent decrease in the 
translational efficiency of transfected KB-3-1 cells. Apart from the maximum 
attenuating effects exerted by both compounds at 100 µg ml
-1 
(333.3 µM and 355.8 µM 
for 12 and cycloheximide, respectively), both 12 and cycloheximide drastically 
suppressed the translational efficiency of KB-3-1 cells by 71.7 ± 3.9 % and                  
68.4 ± 4.3 %, respectively even at a low concentration of 3.3 µM (1 µg ml
-1
) and 3.5 
µM (1 µg ml
-1
), respectively. In contrast, methanol, under similar experimental 
conditions, did not display any inhibitory activity in the transfected KB-3-1 cells. 
Therefore, the hypothesis that 12 inhibits protein translation in KB-3-1 cells 
may well explain its potent anti-proliferative potential against tumorigenic cells, in 
general, and against KB-3-1 cells in particular.   
3.3.2.5 Identification of 12-mediated inhibition of oncogenic pathways 
in KB-3-1 cells by immunoblot analysis 
 During the past decade, several reports have demonstrated that specificintra-
cellular pathways in tumorigenic cells also behave as agonists of protein translation [85, 
28]. This implies that these specific pathways, when mutated or over-activated, 
stimulate higher levels of protein translation, as in the case of tumour cells. This, in 
turn, is reflected by an uncontrolled proliferation and enhanced survival of tumour cells. 
Amongst such signalling pathways, the ERK and mTOR-mediated signalling pathways 
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have been reported to individually or synergistically contribute to intra-cellular protein 
translation [86, 28]. 
 In due consideration of the potent inhibitory potential of 12 on protein 
translationagainst KB-3-1 cells, in this study, attempts were made to explore 
modulatory effects of 12 on the mTOR and ERK-mediated signalling pathways. Such 
modulatory effects may well antagonize the protein translation of KB-3-1 cells. 
 
Figure 3.15 Western Blot analysis depicting changes in phosphorylation status of 
signalling proteins within the MAPK pathway induced in KB-3-1 cells, after treatment 
with 30 µM and 3 µM of compound 12. Maximum dephosphorylation is visible at 
highest concentration of 30 µM. GAPDH serves as the loading control. Methanol-
treated KB-3-1 cells are taken as a negative control. 
Western blot analysis was carried out to determine alterations in the expression 
of critical proteins within the above mentioned pathways in 12-treated KB-3-1 cells. 
Methanol-treated KB-3-1 cells served as a negative solvent control. As can be observed 
from Figure 3.16 which displays the intensities of the protein bands following gel-
electrophoresis of the compound/methanol-treated KB-3-1 cell lysates, there was a 
significant dephosphorylation and hence deactivation of oncogenic c-Raf in KB-3-1 
cells upon treatment with 12 in a concentration-dependent manner.  
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a) 
 
   
b) 
 
 
Figure 3.16 Quantitative evaluation of phosphorylation status of a) c-Raf (white bars), MEK 
1/2 (light grey), ERK 1 (dark grey), ERK 2 (medium grey) and p90RSK (black) and (b) 
GAPDH protein (loading control) derived from Western-Blot analysis of 12-treated KB-3-1 cell 
lysate. Band-intensities have been quantified using Gel-Quant.NET 1.8.2. Error bars indicate     
± S.D. *p < 0.05; 
#
p < 0.001 versus methanol-treated cells. n = 3. 
This protein, which forms the head of the ERK-mediated MAPK cellular 
pathway and has been frequently reported to be over-activated via hyper-
phosphorylation in tumour cells, was observed to be de-phosphorylated by 
approximately 70 % in KB-3-1 cells upon treatment with 12 at 30 µM relative to a 
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negligible dephosphorylation observed in case of methanol-treated cells [53].However, 
upon a 10-fold decrease in the concentration, the phosphorylation status of c-Raf was quite 
similar to that observed in case of methanol-treated KB-3-1 cells. Therefore, 12 was 
observed to modulate the phosphorylation status and hence activity of oncogenic c-Raf 
protein in KB-3-1 cells at a minimum concentration of 30 µM with an apparently negligible 
down-regulatory effect at 3 µM. 
A similar down-regulatory effect was also observed in the phosphorylation status 
and activity of the downstream substrate of c-Raf, namely MEK1/2. As in the case of c-Raf, 
higher levels of the phosphorylation state of the MEK isoforms, namely MEK1 and MEK2, 
have been reported in cancer cells [48]. Since the MEK isoforms are widely recognised as a 
direct substrate of c-Raf, alterations in their phosphorylation status of the latter have been 
observed to exert a direct impact on the phosphorylation state and activity of MEK 1/2.As 
demonstrated in Figure 3.15 and Figure 3.16, 30 µM of compound 12 induced a down-
regulation in the expression of phosphorylated MEK1/2 by nearly 60 % of the 
phosphorylated levels of MEK 1/2 observed in case of methanol-treated KB-3-1 cells. 
However, there was no such observable decrease by 12 at a lower concentration of 3 µM 
when compared to the effects induced by an equivalent amount of methanol (negative 
solvent control).  
As observed for c-Raf and MEK1/2, a similar trend was also observed in case of 
the proteins ERK1/2which act as downstream substrates of MEK1/2. As discussed in 
Chapter 1, the ERK1/2 proteins have been observed to be over-activated in tumour cells 
and also recognised to promote protein translation in tumorigenic cells [36]. As observed in 
Figure 3.15, the phosphorylation status and the activity of ERK1/2 proteins also 
experienced a down-regulation in KB-3-1 cells, upon treatment with 12 in a dose-dependent 
manner. In a slight contrast to its modulatory effects exerted against c-Raf and MEK1/2 
particularly at a higher dosage, 12 appeared to effectively attenuate the phosphorylation 
status of ERK2 not only by approximately 80 % at a higher concentration of 30 µM but 
even at a lower concentration of just 3 µM by nearly 50 % of the phosphorylation status of 
ERK2 visible in case of methanol-treated cells (Figure 3.15 and Figure 3.16). On the other 
hand, at a concentration of 3 µM the phosphorylation status of ERK1 was apparently not 
suppressed significantly. Interestingly, inspite of the fact that both ERK1 and ERK2 
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proteins exist intracellularly as isoforms and share a close structural and biochemical 
similarity, 12 was seen to dephosphorylate and hence deactivate ERK2 to a greater extent in 
comparison to ERK1 in KB-3-1 cells [178].  
Further downstream, a direct substrate of ERK2, p90RSK, was also observed to be 
dephosphorylated by nearly 60% upon treatment of KB-3-1 cells with 30 µM of 12 
compared to an inappreciable dephosphorylation observed in case of methanol-treated cells. 
A lower concentrations of 12 (3 µM), however, displayed a negligible decline in the 
phosphorylation state and hence activity of p90RSK, when compared to the same in 
methanol-treated KB-3-1 cells. Like ERK1/2, p90RSK has also been widely considered as 
an oncogene due to its over-activation via hyper-phosphorylation in cancer cells. As 
discussed earlier, hyper-phosphorylated p90RSKwhich is commonly found in tumorigenic 
cells has not only been reported to inhibit apoptosis but also enhance protein translation 
[70]. 
In addition to the ERK-mediated MAPK signalling pathway, 12 was also observed 
to attenuate the activation of critical proteins within the mTOR-mediated pathway     
(Figure 3.17). 
 
Figure 3.17 Western Blot analysis depicting changes in phosphorylation status of signalling 
proteins within the PI3K-mediated pathway induced in KB-3-1 cells upon treatment with 
different concentrations of 12. Maximum dephosphorylation is visible at the highest 
concentration of 30 µM. GAPDH serves as the loading control. Methanol-treated KB-3-1 cells 
are taken as a negative control. 
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The catalytic sub-unit of PI3K protein, p85, that forms the head of this 
signalling pathway and has been frequently reported to be hyper-phosphorylated in 
tumour cells experienced a nearly 60% decline in its phosphorylated levels in KB-3-1 
cells upon teatment with 30 µM of 12 in comparison to the phosphorylated levels 
observed in case of methanol-treated cells [74].  
As discussed in Chapter 1, an over-activation of the downstream substrates of 
PI3K protein, namely Akt and mTOR proteins, via hyper-phosphorylation has also been 
commonly implicated in the genesis of cancer [30]. According to the results displayed 
in Figure 3.17 and Figure 3.18, 30 µM of compound 12 exerted a marked decrease in 
the phosphorylation status of both Akt and mTOR proteins in KB-3-1 cells by around 
70%of the protein levels detected in methanol-treated cells. A lower concentrations of 
compound 12 (3 µM), however, did not demonstrate any appreciable decline in the 
phosphorylation state and activity of either Akt or mTOR, when compared to the same 
in methanol-treated KB-3-1 cells. 
Upon treatment of KB-3-1 cells with 12 at the highest concentration of 30 µM, 
the phosphorylation level of a downstream substrate of mTOR, 4E-BP1, decreased to 
nearly 40% in comparison to the level noticed in case of methanol-treated KB-3-1 cells. 
As described previously, hypo-phosphorylated (or dephosphorylated) 4E-BP1protein 
has been reported to behave as an intracellular translation antagonist by binding to eIF4 
(translation-promoting protein). This leads to a reduced formation of translation-
promoting complexes and a subsequent induction in tumour cell death via a decrease in 
the rate of intracellular synthesis of proteins [26]. 
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 a) 
 
 b) 
 
Figure 3.18 Quantitative evaluation of phosphorylation status of a) p-85 (white bars), 
Akt (light grey), mTOR (dark grey) and 4E-BP1 (black) and (b) GAPDH protein 
(loading control) derived from Western-Blot analysis of 12-treated KB-3-1 cell lysate. 
Band-intensities have been quantified using Gel-Quant.NET 1.8.2. Error bars indicate    
± S.D.*p < 0.05; 
#
p < 0.001 versus methanol-treated cells. n = 3. 
Therefore, the hypothesis that 12 inhibits the ERK-mediated and mTOR-
mediated signalling pathway in KB-3-1 cells which also involves the suppression in 
phosphorylation and activity of anti-apoptotic proteins like p90RSK may well explain 
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the significant apoptosis-inducting potential of 12, in addition to the confirmation of a 
direct cross-talk between these two oncogenic pathways and the translational system in 
KB-3-1 cells. 
3.3.2.6  Drug Affinity Responsive Target Stability (DARTS) 
In consideration of the significant anti-proliferative activity demonstrated by 
12 via caspase-mediated apoptosis in KB-3-1 cells, a target-identification approach 
called DARTS was also carried out in search of potential cellular targets of 12 in        
KB-3-1 cells [95]. 
 
Figure 3.19 Protection of ERK2 in the KB-3-1 cell lysate after a dose-dependent 
incubation with 12 with the cell lysate. Susceptibility of ERK2 to proteolysis has 
decreased drastically after subsequent digestion of KB-3-1 cells with pronase, when 
treated with the highest dose of 12 (333.3 µM). 
In line with its protocol, KB-3-1 cell lysates were prepared freshly and 
equivalent amounts of protein from different aliquots of the cell lysates were treated 
with varying concentrations of 12 and an equivalent volume of methanol (solvent 
negative control) under ice-cold conditions. After incubation for 2 h under ice-cold 
conditions, these proteins were digested with pronase enzyme (0.1 µg ml
-1
) for 30 min. 
One aliquot of 12-treated cell lysate was left undigested as a control. After an 
incubation of the proteins with pronase for 30 min, the digested proteins were loaded 
onto a polyacrylamide gel. Equivalent amounts of these proteins were separated by 
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electrophoresis followed by probing of the proteins for the presence of ERK2 by using 
the Western Blot technique. 
a) 
 
b) 
 
 
Figure 3.20 Quantitative evaluation of band intensities of (a) ERK2 protein and (b) GAPDH 
protein (loading control) derived from Western-Blot analysis of 12-treated KB-3-1 cell lysate, 
using the DARTS approach. Band-intensities have been quantified using Gel-Quant.NET 1.8.2. 
Error bars indicate ± S.D. *p < 0.05; 
#
p < 0.001 versus undigested cells. n = 3.  
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As has been seen in Figure 3.19, ERK2 appeared to be "protected" in the 
protein lysate of KB-3-1 cells treated with 333.3 µM of 12. The intensity of protected 
ERK2 protein band was observed to be similar to that observed in case of undigested 
cell lysate, which served as control.  
In addition, the intensity of protected ERK2 protein band increased in a 
concentration-dependent manner. In a sharp contrast, methanol (negative control) was 
unable to "protect" ERK2 from pronase-mediated digestion. As a result, in the 
methanol-treated KB-3-1 cells, there was no visible detection of protection of ERK2. 
Therefore, 12 seems to "protect" and therefore interact with ERK2, prior to enzymatic 
digestion by the protein-degrading pronase enzyme.   
3.3.2.7 Binding affinity assay 
Binding affinity assays represent a powerful screening tool and are ideally 
suited for the analysis of compounds in preclinical and clinical development.  This assay 
isemployed to provide a robust kinome-wide affinity profile which may reveal 
unanticipated opportunities that could extend the therapeutic potential or potential off-
target liabilities.  
In order to provide further evidence to strengthen the ERK2-protecting findings 
perceived previously in the DARTS approach, this binding affinity assay was carried 
out to determine the binding ability of 12 towards ERK2. This assay was carried out in 
co-operation with DiscoverX (California, USA). In accordance with this assay, 6-point 
serial dilutions of 12 were prepared in 100 % DMSO at 100 x final analysis 
concentration  and subsequently diluted to 1x in the assay (final DMSO concentration of 
1%) were incubated with a full-length recombinant ERK2 kinase (accession number 
NP620407.1) followed by a quantification of any possible binding of QD with the 
protein. This was calculated in terms of binding constant (Kd) from a standard dose-
response curve using the Hill equation. TheKd value obtained for 12 from a dose-
response curve was calculated to be approximately 3.7 µM. Interestingly, this value 
coincided with the concentration at which 12 displayed an inhibition of activated ERK2 
in the cell lysate from KB-3-1 cells using the Western Blot analysis technique. DMSO, 
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on the other hand, displayed a negligible quenching of the ERK2 signal, under the same 
experimental condition. 
 
Figure 3.21 Kd binding affinity assay of ERK2 against 12.The Kd, calculated from the 
dose-response curve, using the Hill equation, is ~3.7 µM. The Kd value generated in this 
study is proposed to be a true thermodynamic constant that reflects the binding affinity 
of 12 for native ERK2 protein. A dip in ERK2 levels (Y axis) indicates binding to 12. 
DMSO (0.1 %; negative control) displayed negligible dip in ERK2 levels, under similar 
experimental conditions.Curves have been plotted from mean values ± SD. 
3.3.2.8 Anti-microbial studies 
In consideration of the close association between cancer and infection, apart 
from an investigation into the anti-cancer mode of action of the most potent compounds 
10, 11 and12 with a deeper analysis into the molecular and cellular mode of action of 
12, theanti-microbial effects of these three compounds were also investigated against a 
panel of selected pathogenic strains using an agar-diffusion assay [146]. The agar assay 
was carried out in the laboratory of Dr. Florenz Sasse. Briefly, this assay involves the 
treatment of the selected microbial strains in an agar solution with compounds of 
interest. Antibiotics, oxytetracycline (OTC) and nystatin were included as positive 
controls. In this assay, methanol served as a negative solvent control. After incubation 
of the selected microbial strains with the compounds, the diameter of zone of inhibition 
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of microbial growth was measured as an indicator of anti-microbial activity. In 
principle, a greater zone of inhibition depicts a stronger anti-microbial activity [146]. 
In this assay, 12 displayed a modest zone of inhibition against the fungal 
strains, Saccharomyces cerevisiaeand Botrytis cinerea (approximately 20 mm and        
24 mm, respectively). The inhibitory activity of 12 against the latter was comparable to 
that of Nystatin. The zone of inhibition of 12 against Paeoniaanomalaand 
Candidaalbicans, however, was relatively modest (approximately 17 mm or 12 mm 
respectively). Furthermore, 12 displayed a low to moderate level of activity against the 
selected bacterial strains, Micrococcus luteus, Mycobacterium phlei and Escherichia 
Coli. OTC and nystatin, on the other hand, displayed significant inhibitory activity 
against the selected microbial strains.  
Table 3.7  Antimicrobial activity of 10, 11 and 12. Methanol (used as negative control) 
exhibited a negligible growth inhibition zone. OTC and Nystatin served as positive 
controls. Values signify the diameter (in cm) of growth inhibition zone and is calculated 
as mean value ± SD. n = 3. n.d. - not determined. 
 
 
Similarly, 10 and 11 also exhibited moderate anti-microbial activity against the 
microbial strains under investigation. Both isomers displayed significant anti-microbial 
activity against S. cerevisiae, B. cinerea and P. anomala with inhibitory zones above   
25 mm. In contrast, 10 and 11 appeared to be rather insensitive against E. Coli with an 
inhibitory zone diameter around 6 mm and 11 mm, respectively. Compound10 and 11 
yielded a rather moderate effect against C. albicans with an inhibitory zone of 
approximately 17 and 15 mm diameter, respectively. Both isomers also exerted a 
Compd. C.    
albicans 
M.    
Luteus 
M. phlei E.Coli P.  
anomala 
S.      
cerevisiae 
B. 
cinerea 
10 1.7 ± 0.1 2.9 ± 0.1 1.5 ± 0.1 0.6 ± 0.2 3.0 ± 0.2 2.9 ± 0.1 3.1 ± 0.2 
11 1.5 ± 0.2 2.5 ± 0.1 1.6 ± 0.2 1.1 ± 0.12 2.6 ± 0.1 2.5 ± 0.2 3.4 ± 0.2 
12 1.2 ± 0.2 1.2 ± 0.2 0.9 ± 0.2 1.4 ± 0.1 1.7 ± 0.3 2.0 ± 0.2 2.4 ± 0.1 
OTC n.d. 3.51 ± 0.2 2.5 ± 0.1 2.6 ± 0.17 n.d. n.d. n.d. 
Nystatin 3.2 ± 0.2 n.d. n.d. n.d. 2.1 ± 0.3 2.6 ± 0.1 2.8 ± 0.1 
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moderate anti-bacterial effect against M. luteus, with a mean inhibition diameter 
exceeding 25 mm. Compound 10 and 11 yielded an average inhibition zone of around 
15 mm against M. phlei, in contrast. Methanol, as a negative solvent control, yielded a 
rather insignificant inhibitory activity against the selected pathogenic strains.  
3.3.2.8 Inhibition of mammalian thioredoxin reductase (TrxR) by
 selenium and tellurium-containing naphthoquinones 
Earlier research focussing on analysing the biological mode of action of the 
chalcogen-containing naphthoquinones has revealed their inducing ability to induce 
oxidative-stress (OS) in tumorigenic cell lines [121]. This behaviour has been attributed 
either to a direct or indirect generation of ROS or a possible disruption of one or more 
of the intra-cellular antioxidant defense systems, thereby resulting in OS-related cellular 
insults. Amongst the several cellular antioxidant systems, the selenoprotein thioredoxin 
reductase (TrxR) is known to play a pivotal role in maintaining the redox homeostasis 
of cells via reduction of the cysteine-containing proteins and also of GSSG [124]. It is 
now well accepted that a modulation of this enzyme may serve as an important 
therapeutic tool for killing tumour cells by employing oxidative stress [130]. Amongst 
the many chemotherapeutic agents designed so far to target this enzyme, gold-
containing compounds like auranofin and TPPG have proven to be highly potent TrxR-
binding inhibitors [151].       
In an attempt to further elucidate the underlying biochemical reasons 
responsible for induction or maintenance of OS by certain chalcogen-containing 
naphthoquinones, an investigation into the possible inhibitory effects of these 
compounds against TrxR was carried out in the laboratory of Prof. I. Ott (Department of 
Bioinorganic Medicinal Chemistry, Technical University, Braunschweig, Germany). 
The TrxR inhibition assay that has been employed in this study utilises the fact that 
TrxR has the catalytic ability to reduce the disulﬁde bonds of 5,5'-dithiobis(2-
nitrobenzoic acid) with formation of 5-thionitrobenzoic acid (5-TNB) which can be 
detected spectrophotometrically. Therefore, a compound that can modulate the activity 
of TrxR and subsequently alter the formation of 5-TNB can be identified by this assay.  
Chapter 3  Results 
 
122 
 
According to the results obtained in the TrxR-inhibition assay, 16 and 17 
demonstrated an inhibition in the activity of TrxR with an IC50of 0.6 ± 9.5 µM and 0.5 ± 
1.7 µM, respectively. In the same experiment, DMSO (negative control) displayed only 
a negligible inhibitory effect on the activity of TrxR. It must be mentioned that upon 
following the same assay protocol and under similar experimental conditions as 
employed in this study, Ott et al. have earlier reported an IC50 of approximately 0.3 µM 
for a well- known "gold standard" of TrxR inhibitor, TEPG [151]. It can, therefore, be 
said that the inhibitory potentials of the chalcogen-containing naphthoquinones 
compared favorably with that of the potent TrxR inhibitor TEPG.  
 
Figure 3.22 Inhibition of mammalian TrxR activity by chalcogen-containing 
naphthoquinones 16 (grey bars) and 17 (white bars). The catalytic reduction of DTNB, 
in the presence of TrxR, by NADPH is observed to decrease with increasing 
concentration of 16 or 17. The TrxR activity corresponding to DMSO- treatment 
(control) has been normalised to 100. Curves have been plotted with the mean values ± 
SD. *p < 0.05; 
#
p < 0 .001 versus control. n = 3. 
Interestingly, in addition to previously described cellular targets for such 
selenium and tellurium-containing compounds, TrxR-1 has been identified in this study 
as another potential cellular target of these compounds [143]. Indeed, an inhibition of 
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this particular cellular antioxidant defense, in-vitro,as seen in the case of 16 and 17, may 
also in-part explain the accumulation of intra-cellular ROS and subsequent induction of 
ROS-mediated cellular apoptosis particularly in tumorigenic cell lines. Notably, such an 
increase in ROS levels would not require a ROS-generating action of the compounds. 
An enhanced selectivity of these chalcogen-containing TrxR inhibitors towards tumour 
cells as described earlier may, therefore, be attributed to the specific environment of 
tumour-cells that is characterised by raised levels of OS. In order to maintain these OS 
levels to an extent that is sufficient for the proliferation of cancer cells and without 
posing any risk of cellular suicide, tumour cells adopt certain biochemical pathways 
including the over-expression of the natural cellular antioxidant enzymes such as TrxR. 
This is quite evident from the abnormally increased levels of TrxR found in highly 
invasive and metastatic tumours [129, 135]. Furthermore, higher levels of TrxR in 
tumour cells in comparison to normal cells have been linked to an increased resistance 
of tumour cells towards ROS-inducing chemotherapeutic agents including doxorubicin, 
cis-platin, docetaxel and tamoxifen [124].  
Under such conditions, compounds 16 and 17 may, therefore, possess a 
potential edge over commonly employed ROS-inducing chemotherapeutic agents due to 
their dual ability of inducing ROS and inhibiting the activity of ROS-removing cellular 
enzymes such as TrxR. Such an action would, therefore, not only push tumorigenic cells 
towards cellular suicide but would also lend such compounds a certain degree of 
selectivity towards cancer cells over normal cells.  
3.4 Non-cellular studies  
In order to corroborate the encouraging data obtained regarding the anti-cancer 
activity of compound 12 from the detailed mechanistic studies carried out using several 
cell-based redox assays, some relevant studies regarding the (redox) physico-chemical 
properties of such biologically active compounds were also carried out using 
electrochemistry on the one hand, and the DPPH and FRAP redox assays, on the other. 
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3.4.1  Electrochemical studies 
The electrochemical analysis of any compound is generally carried out using a 
reference electrode, working electrode, and a counter electrode, which in combination, 
are sometimes referred to as a three-electrode setup. 
Compound 12 contains a selenium-selenium bond as a part of a 5-membered 
ring, which can be reduced and oxidized electrochemically using a dropping mercury 
electrode. This electrode, however, often suffers from the disadvantage of an unwanted 
adsorption of selenium-containing molecules on the electrode surface, resulting in a 
strong interference with the mercury electrode. This may imply the formation of a 
complex between selenium and mercury, thereby resulting in a sharp "dip" in the cyclic 
voltammogram. In order to avoid such problems, a glassy carbon electrode was 
deployed, as part of these studies, to obtain the oxidation and reduction potentials of 
compound 12. 
The oxidation and reduction potentials corresponding to 12, which are clearly 
visible as signals in the cyclic voltammogram can be seen in Figure 3.23. Compound 12 
exhibited an oxidation and reduction signal in the biologically relevant range of -900 mV to 
0 mV vs. Ag/AgCl (SSE) reference electrode, corresponding to approximately a one 
electron transfer process  (ΔEp,1/2 = 3.53 RT/nF = 90.6/n mV).In addition to the reduction 
peak of 12 at around -42mV, the appearance of a larger reduction peak at around 800mV 
could probably be due to the reduction of tetrabutyl ammonium (Bu4N
+
) ions which formed 
a part of the electrolyte. As can be seen in Figure 3.23, compound 12 displayed a redox 
couple at around 100mV in the defined potential range with quasi-reversible characteristics 
with a peak current ratio (Ipa/Ipc) around 1.  
Further, 12 has exhibited an E
° 
[(Epa + Epc)/2] value of around -92 mV, which is 
much higher than the previously published E
°
 value for heteroaryl diselenides like dipyridyl 
diselenide [155]. This indicated that 12 may apparently be a rather poorly reducing 
diselenide and probably a poor anti-oxidant. 
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Figure 3.23 Cyclic voltammogram of 12 was recorded on a CHI 604D electrochemical 
analyzer (USA) at a scan rate of 100 mV s
-1
using a glassy carbon electrode as a working 
electrode and Ag/AgCl (SSE) reference electrode in acetonitrilecontaining 0.1 M TBAP 
as the supporting electrolyte. The electrochemical potentials are provided vs. SSE and 
have been calibrated with the [Fe(CN)6]
4-
/[Fe(CN)6]
3-
 redox pair. n = 3. 
Nevertheless, the electrochemical studies of 12 that were carried out on CHI 
604D electrochemical analyzer (USA) conﬁrm that 12 was able to undergo reversible 
oxidationand reduction reactions within the physiologically relevant potential range. Its 
redox activity, however, was not comparable to that depicted by several other heteroaryl 
organodiselenides reported previously in literature [155].  
3.4.2 Anti-oxidant assays 
 As reported previously in the literature, organo-selenium compounds exhibit 
rather pronounced anti-oxidant properties that are usually attributed to their low 
oxidation potentialsi.e., ability to "donate" electrons rather easily (as observed 
previously) during electrochemical analysis. As described in Chapter 2, there are 
several analytical techniques, besides basic electrochemical methods, that have been 
established to determine the antioxidant and radical-quenching potential of such small 
molecules. Amongst them, for this study, aDPPH-radical scavenging assay was selected 
as a valuable and relatively quick analytical technique to assess the radical scavenging 
capability of biologically active compounds [149]. Although DPPH is not a 
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physiological free radical, this assay surely gives a positive and conclusive idea of the 
reducing activity of compounds. 
3.4.2.1  DPPH radical scavenging assay 
From the results obtained, at a concentration of 1 mg ml
-1
(3.3 mM), compound 
12 quenched 33.5 ± 1.6% of the original DPPH content (normalized to 100%). Though 
not very significant, rather moderate radical-scavenging ability of 12 may be due to the 
nitrogen atom contained within the quinoline ring. Diphenyl diselenide, on the other 
hand, appeared to quench only 5.3 ± 0.8% of the original DPPH at the same 
concentration (1 mg ml
-1
, 3.2 mM).  
 
Figure 3.24a Concentration-dependent quenching of DPPH radicals by 12 (white bars), 
diphenyl diselenide (black bars) and ascorbic acid (grey bars; positive control). 
Equivalent amount of methanol depicted negligible DPPH quenching (methanol bar). 
DPPH content in untreated samples (control bar) has been normalized to 100 %. Bars 
have been plotted as mean values ± S.D. 
#
p < 0 .001 versus untreated sample. n = 3. 
In line with diphenyl diselenide, the other two selected isomeric diselenides, 10 
and 11, also failed to elicit any noticeable DPPH radical scavenging behaviour, even at 
the highest selected concentration of 1 mg ml
-1
. In sharp contrast, ascorbic acid which 
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isa widely known antioxidant and an important constituent of citrus fruits was able to 
sequester 72.0 ± 1.2 % of the total DPPH radicals at a concentration of 1 mg ml
-1
(5.6 
mM). 
 
Figure 3.24b Concentration-dependent quenching of DPPH radicals by ARS-01 (black 
bars), ARS-02 (white bars) and ascorbic acid (grey bars; positive control). Equivalent 
amount of methanol depicted negligible DPPH quenching (dark grey bar). DPPH 
content in untreated samples (control bar) has been normalized to 100%. Bars have been 
plotted as mean values ± S.D. 
#
p < 0.001 versus untreated sample. n = 3. 
Amongst the selenophenesscreened, only ARS-01 and ARS-02 displayed a 
significant DPPH radical scavenging activity. At a concentration of 1 mg ml
-1 
(equivalent to 1.9 mM and 1.8 mM for ARS-01 and ARS-02, respectively), these 
compounds exhibited a similar radical quenching activity of 49.5 ± 0.7%  and 47.3 ± 
1.6%, respectively. In contrast, the remaining selenophenes displayed a negligible 
quenching of the DPPH radical in the concentration range studied. As mentioned earlier, 
diphenyl diselenide (used as a reference compound) also did not exhibit any significant 
radical-scavenging ability.To sum up, amongst the chalcophenes studied, only ARS-01 
and ARS-02 have displayed an appreciable radical scavenging activity which was 
comparable to the radical-scavenging ability of a standard radical scavenger ascorbic 
Chapter 3  Results 
 
128 
 
acid. In contrast, compounds 10, 11 and 12 have not exhibited any appreciable radical-
sequestering ability in the DPPH assay. 
3.4.2.2 Ferric reducing ability of plasma FRAP assay 
The FRAP assay is a quick and rapid analytical technique to determine the 
reducing ability of samples under investigations. In principle, upon an electron-transfer 
from given compounds, the straw-coloured Fe
3+
-TPTZ complex is converted into a 
blue-coloured Fe
2+
-TPTZ complex. The formation of the latter by the relevant 
compounds can be quantified spectrophotometrically in terms of an absorbance 
measurement (at a wavelength of 594 nm). A higher level of formation of the Fe
2+
-
TPTZ complex is a measure of the reducing activity of the compounds which is 
subsequently expressed in terms of a FRAP value. In principle, a compound with a 
higher FRAP value is an indicator of its higher anti-oxidant activity.   
Using a standard spectrophotometric setup, this assay was carried out in a 96-
well microtitre plate in accordance with an established protocol but with some minor 
modifications [150]. Methanol and ascorbic acid were included as negative and positive 
control respectively, under similar experimental conditions. Results from this assay 
indicated that the reduction of the Fe
3+
- TPTZ complex by 12 was moderately enhanced 
an effect which depended on theconcentration of 12. 
In comparison to ascorbic acid (a benchmark compound) which exhibited a 
FRAP value of 2664 ± 51 µmol equiv of Fe
2+
 l
-1 
(equivalent to an absorbance =          
3.1  ± 0.2) used at aconcentration of 250 µg ml
-1
, the FRAP value of 12 was rather low 
at 221 ± 39 µmol equiv of Fe
2+
 l
-1
 (equivalent to an absorbance = 0.2 ± 0.1). 
Interestingly, at the same concentration, diphenyl diselenide displayed hardly any anti-
oxidant ability as is evident from its rather low FRAP value below 200 µmol equiv of 
Fe
2+
 l
-1
 (equivalent to an absorbance = 0.1 ± 0.1). 
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Figure 3.25 Concentration-dependent increase in the formation of Fe(TPTZ)2 upon a 10 
min incubation of FRAP reagent with the "most active" compounds- ARS-01 (dark grey 
bars), ARS-02 (light greybars), 12 (white bars) and ascorbic acid (black bars).The level 
of Fe(TPTZ)2 in the FRAP reagent left untreated or treated with methanol represents the 
control bar or MeOH bar, respectively. The increase in absorbance at a wavelength of 
594 nm corresponds to an increase in reduction of the Fe(TPTZ)3 complex to 
Fe(TPTZ)2 complex. Bars have been plotted as mean values ± S.D. *p < 0.05;               
#
p < 0.001 versus untreated sample (control). n = 3. 
Compound 10 and 11 also displayed a negligible reduction of Fe
3+
-TPTZ 
complex even at the highest selected concentration of 250 µg ml
-1
. Both 10 and 11, 
therefore, behaved in a similar manner as diphenyl diselenide by yielding a FRAP value 
below 200 µmol equiv of Fe
2+
 l
-1 
(equivalent to an absorbance = 0.1 ± 0.1 and 0.1 ± 0.2, 
respectively) at a concentration of 250 µg ml
-1
. The poor anti-oxidant effects of 10 and 
11, as observed in the FRAP assay also corresponded with their poor DPPH radical 
scavenging effects as reported in the previous section.  
Interestingly and in sharp contrast to the anti-oxidant activity of 10, 11 or 12, 
the formation of Fe
2+
-TPTZ complex was enhanced significantly by ARS-01 and    
ARS-02 in a concentration-dependent manner. At a concentration of 250 µg ml
-1
, 
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raloxifene (ARS-01) exhibited a FRAP value of 1200 ± 69 µmol equiv of Fe
2+ 
l
-1 
(equivalent to an absorbance = 1.3 ± 0.2). A similar FRAP value of 1287 ± 43 µmol 
equiv of Fe
2+
l
-1
(equivalent to an absorbance = 1.4 ± 0.1) was observed in case of the 
selenium-substituted analogue of raloxifene (ARS-02) at the same concentration 
(Figure 3.24). In contrast, the remaining selenophenes (ARS-03 to ARS-06) were less 
active. Even at the highest selected concentration of 1mg ml
-1
, these selenophenes 
(ARS-03 to ARS-06) produced a FRAP value of less than 200 µmol equiv of Fe
2+
l
-1 
(equivalent to an absorbance = 0.1 ± 0.1). Since a phenolic group has been reported to 
serve as an efficient radical scavenger via an electron-transfer mediated by phenoxide 
anions, the significantly high FRAP values of ARS-01, ARS-02 and ascorbic acid (a 
benchmark sample) could be reasonably attributed to the presence of the phenol group 
in their chemical structures [182, 183]. In contrast, this functional moiety is absent in 
the other selenophenes (ARS-03 toARS-06), that could possibly result in their poor 
radical-quenching activity.  
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Chapter 4  
Discussion 
The design and synthesis of organoselenium compounds continues to serve as a 
challenging, yet encouraging enterprise, not only in the area of pharmaceutical drug 
design but also to comprehend the biochemical aspects and diversity of this trace 
element in physiological and non-physiological systems. During the last two decades, 
remarkable synthetic progress has been seen in broadening the existing arsenal of 
compounds and the biochemical know-how of selenium, particularly regarding its 
potential uses against cancer and several other life-threatening diseases [109]. 
In view of the extensive yet mixed results regarding the biological efficacy of 
selenium, the first step in this study has been involved in the further investigation of the 
biological activity of some hitherto unexplored examples of organoselenium 
compounds. Since organic seleniumchemistry is popularly and widely recognized in the 
form of organodiselenides and monoselenides, a pool of representative examples of 
organoselenium compounds has been created of several known and unknown 
heteroaryl-conjugated monoselenides and diselenides. In addition, several lesser known 
and less widely studied selenophenes have also been included for a first-hand 
comparative analysis of their chemotherapeutic efficacy. More importantly, these efforts 
have been closely followed by studies regarding their biological activity and subsequent 
attempts to explore the underlying biochemical reasons behind any chemotherapeutic 
efficacy observed for some of the more potential candidates (especially compound 12), 
based on its modulatory biochemical effects, both at the molecular and at the cellular 
level.    
In order to perform a comparative analysis of the chemotherapeutic efficacy of 
organoselenium compounds as an initial step of this project, a diverse collection of 
alkyl-functionalized monoselenides (1-9) and heteroaryl  diselenides (10-15) have been 
synthesized by adoption of previously established synthetic procedures [140-142]. In 
the past, certain monoselenides have been observed to demonstrate a relatively poor 
anti-cancer activity in comparison to the corresponding diselenides [153]. This dramatic 
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difference in biological activity can be attributed to the redox-active and relatively labile 
diselenide bond which is not observed in case of the monoselenides. The ease of 
cleavage of a selenium-selenium bond (as in an organodiselenide) relative to a carbon-
selenium bond (as in a monoselenide), thereby resulting in a cascade of biologically 
active metabolites, is due to the lower bond disassociation energy of the former (331 kJ 
mol
-1 
versus 583 kJ mol
-1
of the latter bond [156]. Considering this aspect, it has been 
assumed that an enhancement in the ability of monoselenides to enter cells via an 
enhanced lipophilicity could also possibly lead to an enhancement in their cytotoxicity 
against tumour cells. Therefore, in this study, in order to impart a characteristic 
amphiphilicity into these rather poorly active molecules, several heteroaryl-diselenides 
have been successfully subjected to functionalization with alkyl chains of different 
carbon-chain lengths. Such alkyl-functionalized monoselenides (1-9) have been, 
however, synthesized initially on a relatively small scale in order to obtain initial inputs 
of any increased potential against tumorigenic and microbial cells. 
With regard to the organodiselenides, in order to shift from the conventional 
synthesis of phenyl-substituted (di)selenides, the synthesis of N-containing heteroaryl-
conjugated analogues has been carried out (10-15). A combination of N-containing 
heterocyclic ring system with the redox-active dichalcogenide bridge has been 
undertaken with the awareness of the presence of such ring systems as valuable 
pharmacophores found frequently in synthetic and naturally-occurring biologically 
active small molecules. Therefore, substitution of the commonly employed benzene ring 
with N-containing heterocyclic ring has been carried out in an attempt to synergize the 
biological efficacy of these heterocyclic pharmacophores with those of the diselenide 
moiety. This work has been designed and carried out in the research group of Prof. Dr. 
K.K. Bhasin (Department of Chemistry, Panjab University, Chandigarh, India). Re-
synthesis of chalcogen-containing naphthoquinones (16 and 17) has been carried out, 
primarily as a part of an on-going investigation in elucidating the biochemical reasons 
behind its ROS-induced chemotherapeutic effects against tumorigenic cells. 
In addition to these diselenides and monoselenides, selenophenes (ARS-01 to 
ARS-06) have also been included in the panel of heteroaryl-conjugated organo-
(di)selenides. These compounds contain the redox-active chalcogen moiety as a part of 
the aromatic ring rather than being attached to the ring. Such a design may, in theory, 
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provide an enhanced stability and reactivity. The latter effect, however, has not been 
apparently observed during the biological analysis. These compounds have been 
synthesized and kindly provided by the research team of our collaborator, Dr. Pavel 
Arsenyan (Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, 
Latvia). 
All the newly synthesized and re-synthesized compounds have been 
characterised by NMR spectral analysis. In accordance with the spectroscopic data, 
these compounds have been judged to possess purity greater than 95 %. In addition, 
elemental analysis and
77
Se NMR of these compounds (10, 11 and 12), that had been 
selected from a primary screening, have also been carried out to re-confirm their 
synthetic purity, prior to a more comprehensive biological investigation [142]. In 
addition, the crystal structure of compound 11 has also been solved successfully. 
As part of the main objective of this study, a comparative analysis of the 
chemotherapeutic and anti-microbial potential of mono and di-selenium-containing 
compounds, together with a study of the biological activity of certain selenophenes has 
been carried out. 
Upon a preliminary screening of the inhibitory potential of a set of alkyl-
functionalized selenoarenes, in parallel to their diselenide counterparts and 
selenophenes against tumorigenic cell lines, the alkyl-functionalized monoselenides 
have not appeared to exhibit any promising inhibitory effects against proliferation of the 
tumour cell lines selected. All the compounds (1-9) have displayed an average 
inhibitory value (IC50) exceeding 30 µM. These IC50 values have not been significantly 
high; hence these compounds are not particularly useful in the context of cancer 
research. In contrast, ARS-01, which served as apositive control, has displayed a much 
higher anti-proliferative potential against the mammalian cell lines. This indicated that 
simple introduction of a mere lipophilic character into such molecules was not 
successful. Furthermore, since alkyl groups usually do not possess any cytotoxicity of 
their own, the overall chemotherapeutic efficacy of these monoselenides has apparently 
remained unaltered. Since a hexyl- group has been the longest alkyl chain employed in 
this strategy, a future investigation into the effects of even longer alkyl chain lengths 
(like a decyl- or even a dodecyl- chain) would be interesting. In this case, however, the 
Chapter 4  Discussion 
 
134 
 
overall chemical and physiological stability of such molecules would also need to be 
assessed before further biological analysis could be carried out.  
On the other hand, representative examples of various diselenides and some of 
the selenophenes, inspite of their relatively lower degree of lipophilicity, have appeared 
to possess a far better biological activity against the tumorigenic cells selected. 
Amongst these diselenides viz.10, 11 and 12 have demonstrated a considerable anti-
proliferative ability against the tumour cell lines. The cyclic diselenide12 has been 
observed to display a promising anti-proliferative ability against several tumour cell 
lines like KB-3-1 (IC50 = 0.8 ± 0.4 µM) cells using the MTT assay. Compound 12 has 
also exhibited a similar activity (IC50 = 0.6 ± 0.3 µM) by decreasing the ATP levels of 
KB-3-1 cells after a 48 h treatment. Compound 12, however, has also exerted a certain 
level of toxicity against L-929 (IC50 of 0.6 ± 0.3 µM) cells, thereby pointing towards a 
promising, yet relatively low specificity towards cancer cells. Inspite of a certain degree 
of non-selectivity, its acute sensitivity towards PC-3 cells (IC50 of 0.02 ± 0.3 µM), in 
particular, had encouraged us to pursue further investigations to explore the possible 
biochemical reasons leading to its significant anti-tumour activity. 
Apart from 12, isomeric diselenides, 10 and 11, have also displayed a 
promising anti-proliferative activity against tumour cells like KB-3-1 (IC50 = 0.4 ± 0.2 
µM and 0.4 ± 0.1 µM, respectively) in the MTT assay. This has been further evident by 
a significant decline in the ATP levels of KB-3-1 cells after a 48 h treatment with either 
10 or 11 (IC50 of 1.0 ± 0.4 µM and 2.5 ± 0.7µM, respectively. However, the anti-
proliferative potential of 10 has been significantly higher compared to 11 towards PC-3 
cells (IC50 = 0.6 ± 0.3 µM and 0.9 ± 0.3 µM, respectively). The relatively higher anti-
proliferative activity of 10 in some cases could be possible due to its higher cellular 
uptake, as a consequence of an attenuated steric hindrance, in comparison to 11.  
Similar to compound 12, both 10 and 11 have displayed a poor selectivity towards 
tumorigenic cells by exerting cytotoxicity against L929 (IC50 = 0.4 ± 0.1 µM and         
0.7 ± 0.4 µM respectively).  
The experimental findings from the MTT cytotoxicity analysis of the 
chalcophenes have suggested that their inhibitory (IC50) values against tumour cell lines 
reside, on an average, within the sub-millimolar range. Amongst the cell lines selected, 
the chalcophenes have displayed a relatively higher activity against cervix carcinoma 
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(KB-3-1) cells. Raloxifene (ARS-01), an FDA approved drug for treating metastatic 
breast cancer and used in this study as a positive control, has exhibited the highest 
activity amongst all chalcophenes studied. ARS-02 has also demonstrated considerable 
cytotoxicity against tumour cell lines with a maximum inhibitory effect against KB-3-1 
and MCF-7 cells (IC50 = 7.1 ± 1.1 µM, and 10.7 ± 1.4 µM respectively). Interestingly, 
in spite of their close chemical similarity, ARS-01 has been relatively more active 
against KB-3-1 and MCF-7 cells (IC50 = 5.3 ± 0.7 µM and 3.5 ± 0.8 µM, respectively) 
compared to ARS-01.In many previously published articles, the cytotoxicity of 
organoselenium compounds has been demonstrated to be superior to one of their sulfur-
containing analogues [159].  
Due to the relatively higher anti-cancer activity of ARS-01 in comparison to 
that of ARS-02, it appears that the selenium moiety in these selenophenes may not 
necessarily play a predominant role in the anti-tumour effects of these compounds. In 
contrast, ARS-03 - ARS-06 have exhibited a rather average anti-proliferative potential 
against the cancer cell lines. These compounds, however, have displayed the maximum 
activity towards KB-3-1 cells with a mean IC50 exceeding 10 µM. These 
selenopheneshave also appeared to be hardly active against MCF-7 cells with an 
average IC50 exceeding 20 µM. Upon critical observation of the structural differences 
between ARS-01 or ARS-02, on the one hand, and the remaining selenophenes      
(ARS-03 - ARS-06), on the other, it is quite probable that the relative biological 
inactivity of the latter could be attributed partially to the absence of phenolic hydroxyl 
groups in their chemical structure. These phenolic groups endow an appreciable level of 
redox activity on their own and are widely recognised to attenuate tumour proliferation 
by interfering with tumour-associated oxidative stress [160, 161]. This argument could 
be verified further by the observation of an enhanced radical scavenging effect by ARS-
01 and ARS-02, in comparison to a rather poor effect exhibited by the other 
selenophenes (ARS-03 to ARS-06) in the DPPH and FRAPS redox assays. This 
matterhas been discussed in the section dealing with non-cellular based assays. 
To sum up, the redox-active diselenides (10, 11 and 12), on one hand, and 
selenophenes ARS-01 and ARS-02, on the other hand, have exhibited the highest 
activity against tumour cell lines. The significant activities of the latter can be attributed 
to the raloxifene motif in ARS-01 that bears an "almost identical" resemblance to the 
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chemical structure of ARS-02.  On the basis of a "ranking" in anti-cancer activity, 10, 
11 and 12 have been subsequently selected for further analysis of their mode of action 
against such tumorigenic cells. The activity of these compounds against cancer cells, in 
general, and KB-3-1 cells, in particular, has been discussed in greater detail in the 
subsequent cell-based assays.  
In the past couple of decades, basic anti-cancer research has generated 
remarkable advances in our comprehension of the etiology of cancer biology. These 
investigations have also led to the unraveling of new biochemical mechanisms which 
may be useful to combat this life-threatening disease. Among the most prominent of 
these advances is the realization that the apoptotic pathway, comprising of several pro- 
and anti-apoptotic enzymes and signalling pathways, has a profound effect on the 
malignant phenotype. Earlier, during the 1970s, pathologists noticed that radiation and 
chemotherapy can induce cell death with morphological features of apoptosis. It was not 
until the late 1990s, however, that it was established that anticancer agents prevent 
carcinogenesis by induction of apoptosis, in addition to the notion that disruption of the 
apoptotic cellular path contributes to the reduced chemo sensitivity of malignant cells 
[165]. 
During apoptosis, cellular DNA degradation occurs few hours prior to 
breakdown of the plasma membrane. Therefore, DNA degradation into mono and 
oligonucleosomes is an important indicator of the stage of apoptotic cell death. 
Induction of apoptosis is considered as an important cellular event that has been taken 
into account for the therapeutic effects of organoselenium compounds against cancer 
[16]. To confirm that the treatment of KB-3-1 cells with the most active 
organodiselenides (10-12) leads to apoptotic cell death, a possible degradation of 
nuclear DNA of KB-3-1 cells into nucleosomal fragments has been assessed in this 
study by employing the cell-death detection ELISA assay. The results have indicated 
that chemotherapeutic diselenides 10, 11 and 12 exert their chemotherapeutic effects 
against KB-3-1 cells in-vitro by a concentration-dependent induction of apoptosis, 
which is characterized by the fragmentation of the nuclear DNA that serves as a 
hallmark of apoptosis [112]. Therefore, apoptosis has served as a prominent molecular 
mode of action of these diselenides. 
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Caspases form a family of endoproteases that provides a critical link in the cell 
-regulatory networks which control apoptosis-mediated cell death. Stimulation of the 
general activity of the executioner caspases-3 and 7 is prevented by their production as 
inactive procaspase dimers. The latter must be cleaved first by the initiator caspases. 
Upon activation, these pro-apoptotic caspases trigger a cascade of signalling events that 
lead to controlled degradation of cellular components, via apoptosis [57]. This is evident 
from previous reports that highlight the role of activated caspase 3/7 in promoting 
cleavage and subsequent activation of a pro-apoptotic factor BAD that serves as a more 
potent inducer of cytochrome c release and apoptosis [61]. The importance of caspase-3 
in the etiology of cancer has been reflected in reports concerned with its mutation in the 
MCF-7 breast cancer cell line [167]. Caspase-7 is another effector that is also important, 
with respect to caspase-3 in executing apoptosis, especially in the cells with deficient or 
under-expressed caspase-3. 
In order to better comprehend the mechanism of compound-induced apoptosis 
in KB-3-1 cells, it was considered interesting to investigate whether this type of 
apoptosis is caspase-mediated or not. There have been numerous reports in the past 
regarding the mixed role of caspases in apoptotic cell death induced by various 
selenium-containing compounds [134]. Depending upon the cell type, several prominent 
selenium-containing compounds like sodium selenite, ebselen and methyl selenol have 
been reported to induce cell death with or without the activation of caspases [104,106]. 
In this assay, compound 10, 11 and 12 have been observed to induce significant levels 
of apoptosis in KB-3-1 cells in-vitro via stimulation of activity of pro-apoptotic caspase 
3/7in a concentration and time-dependent manner.Therefore, it can be hypothesized that 
the significant activity of the organodiselenides (10-12) observed previously in the MTT 
and ATP assays, particularly against KB-3-1 cells, could be attributed to their ability to 
induce caspase-mediated apoptosis in such type of cancer cells. 
In addition to apoptosis, protein translation represents another complex set of 
biochemical reactions involving the interaction of a large number of factors that 
catalyze the assembly of ribosomes, mRNA templates and amino-acylated tRNAs. As 
the role of a non-regulated, out-of-control protein synthesis in tumorigenesis becomes 
even better understood, the therapeutic potential of drugs targetingprotein synthesis 
becomes even more evident [20]. In this regard, there has also been increasing evidence 
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to support the theory thatapoptosis leads to modifications in the phosphorylation status 
of several translation factors like eIF4E binding proteins (4E-BPs) in mammalian cells 
[19].A caspase-dependent cleavage of such translation initiation factors has been well-
documented to increase the rate of protein degradation, thereby playing a major role in 
the inhibition of protein translation in apoptotic cells. This concept has led us to 
investigate whether the broad anti-proliferative activity exerted by the selenium-
incorporated heterocyclic compounds (like 12), via caspase-mediated apoptosis in     
KB-3-1 cells in-vitroalso impacted on intra-cellular protein synthesis. 
In this regard, there have been several reports highlighting the inhibition of 
protein translation by several organoselenium compounds such as methyl selenocysteine 
(MSC) and methyl seleninic acid MSA, both of which are potential precursors of the 
active metabolite, methyl selenol [117]. In the past, a number of clinical trials, including 
the SELECT and NPCT trials of organic selenium, have also indicated that translational 
control could potentially constitute an important theme for future drug development. 
Many previous studies, involving the translation-modulatory potential of active 
selenium metabolites like methyl selenol and naturally occurring compounds like 
methyl selenocysteine have given a fresh thrust to the application of organic selenium 
compounds for therapeutic intervention, particularly against prostate cancer [176]. 
As a result of the significant anti-cancer activity of 12 in-vitro, in particular 
against prostate carcinoma cells (IC50 = 0.02 ± 0.3 µM), this organoselenium compound 
has been studied in more detail in an attempt to elucidate its molecular mode of action, 
especially in the context of protein synthesis. For this purpose, two experimental models 
of translation, a rabbit reticulocyte system and a KB-3-1 cell model have been selected. 
An in-vitro rabbit reticulocyte lysate system has been utilized as a cell-free translation 
system to measure the inhibitory potential of 12 in the context of protein translation. 
Prepared from New Zealand white rabbits, the rabbit reticulocyte system has been used 
widely as a standard procedure to "rank" chemical compounds in order of their 
translation inhibitory potential [174]. The in-vitro translation inhibition assay has been 
performed in the labortory of Dr. Florenz Sasse. As can be concluded from the results 
provided in Section 3.3.2.4.1, compound 12 has potently inhibited protein translation in 
the rabbit reticulocytesystem in-vitro with an approximately 43% inhibition at 0.3 µM. 
Cycloheximide has also been appreciably active with a roughly 61% inhibition at a 
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similar concentration of 0.4 µM. Methanol, in contrast, has not exhibited any down-
regulatory effects on the translational efficiency of the rabbit reticulocytes. Such an 
inhibition may imply that 12 may either act directly on the translational machinery or 
alternatively may share methyl selenol as a common metabolite, with previously studied 
organoselenium compounds such as SeMC. Under physiological conditions, the 
cleavage of the methylenated selenium in 12 could indeed result in the formation of 
methyl selenol. Therefore, it is quite possible that the methylenated selenide moiety 
could serve as the active pharmacophore, responsible for the anti-tumour and 
translation-inhibiting efficacy of 12. 
Based on the potential translation inhibiting potential demonstrated by 12 on 
the eukaryotic system, the modulatory effects of 12 towards the translation efficiency of 
KB-3-1 cells have also been investigated. Similar to their translation inhibiting activity 
in the rabbit reticulocytes, both 12 and cycloheximide (benchmark compound) have 
been found to potently attenuate the translation activity of KB-3-1 cells. Although this 
effect has been observed to be maximumat the highest selected concentrations, both 12 
and cycloheximide have also been observed to considerably inhibit translation in KB-3-
1 cells by roughly 71% and 68% even at lower concentrations of approximately  3.3 µM 
and 3.5 µM, respectively. These results have clearly indicated that the anti-proliferative 
potential of 12 against KB-3-1 cells can be attributed to the disruption of its intra-
cellular translational machinery. Hence, compounds like 12 that deprive tumour cells 
from the proteins necessary as an indispensable "fuel" for their proliferation and 
survival could, in the future, form a part of an effective anti-tumour strategy [177]. 
Several reports in the literature have attributed the anti-cancer effects of active 
selenium metabolites such as methyl selenol to their inhibitory effects against several 
oncogenic biochemical pathways [110, 111]. Amongst them, the ERK-mediated and 
mTOR-mediated cellular pathways, when over-activated, have been observed to either 
individually or synergistically contribute to tumour cell proliferation and survival by 
promoting intra-cellular protein translation, on one hand,  and /or suppressing apoptosis, 
on the other [36, 120].  In order to find a similar link between the translation-inhibiting 
and apoptosis-inducing ability of 12 with a probable modulation of such intracellular 
signalling pathways in KB-3-1 cells, Western Blot analysis of 12-treated KB-3-1 cells 
has been carried out at Helmholtz Centre. 
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Results from the Western Blot analysis have revealed that 12 demonstrates a 
significant down-regulatory effect on the activity of the Raf-mediated signalling cascade 
(also called MAPK signalling cascade), in KB-3-1 cells. This has been evident from a 
concentration-dependent decrease in the phosphorylation status of core proteins 
constituting this pathway, such as c-Raf and its downstream substrates MEK1/2, 
ERK1/2 and p90RSK in 12-treated KB-3-1 cells. These proteins when activated via 
phosphorylation have been reported to trigger a chain of cellular events by regulating 
the activity of several transcription and translation factors, thereby contributing to 
cellular proliferation and survival [70]. A mutation or over-activation of any of these 
MAPK proteins, as observed by their hyper-phosphorylation, has been implicated in a 
majority of cancer cells [36, 152]. 
As discussed in Chapter 1, in light of the recent success in the clinical 
development of several inhibitors of protein kinases, components of the Raf-mediated 
signalling cascade have been a "hot" subject of research and drug discovery efforts. Of 
these, ERK1 and ERK2 have attracted considerable research interest because of their 
over-activation and critical involvement in the regulation of protein translation and 
cellular apoptosis in tumour cells [120]. Furthermore, latest studies on this intensetopic 
have reported that ERK2, in addition to its downstream substrate p90RSK, apparently 
plays a lead actor in promoting cellular proliferation whereas ERK1 plays a lesser and a 
rather mixed role towards sustaining cellular survival [79, 80].Therefore, as has been 
observed in this study, a pronounced deactivation of ERK1/2 in KB-3-1 cells by 12 with 
a drastically more pronounced effect on ERK2 may, therefore, contribute partially to 
this compound´s potential anti-proliferative and translation-inhibitory ability. 
In addition to the ERK-mediated MAPK pathway, compound 12 has also 
exerted its down-regulatory effects on the activation of the PI3K-Akt-mTOR signalling 
pathway. As discussed in Chapter 1 and elsewhere, mTOR-mediated signalling is 
frequently over-activated in tumorigenic cell lines. The core nodes constituting this 
signalling pathway, namely PI3K, Akt and mTOR, thereby serve as potential cancer 
promoters due to genetic mutations, in tumorigenic cells [115]. In addition, a close 
association of this signalling cascade with translation factors like 4E-BP1 characterizes 
it as an important protein-translation agonist [33]. As per immunoblot analysis, 12 has 
been observed to significantly reduce the phosphorylation and, therefore, the activation 
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of these critical proteins in the PI3K-mediated signalling cascade, when employed at a 
concentration of 30 µM. Compound 12 has also induced a moderate dephosphorylation 
of eukaryotic translation factor binding protein 4E-BP1 that acts as a downstream 
substrate of mTOR protein within the PI3K signalling cascade. This may contribute to 
the disruption of the eIF4F complex that is responsible for the stimulation of mTOR-
mediated cellular translation in KB-3-1 cells. 
As displayed in Figure 4.1, the results from the Western Blot analysis, 
therefore, point towards a synergistic effect of 12 on the ERK-mediated and mTOR-
mediated signalling pathways.  
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Figure 4.1 Inhibition of protein translation in association with a synergistic inhibition of 
ERK-mediated and mTOR-mediated cellular signalling by 12 in KB-3-1 cells. 
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Since these signalling pathways share an interesting cross-talk with the 
translational machinery of the mammalian cells, these findings further corroborate the 
notion of a distinct inhibition of protein translation and an anti-carcinogenic action of 
12. We can, therefore, postulate that the anti-proliferative activity of 12 against KB-3-1 
cells is a consequence of attenuated levels of protein translation in KB-3-1 cells, which 
in turn is, at least partially, the result of the simultaneous down-regulation of the 
aberrantly activated ERK and mTOR-mediated signalling cascades. 
 
 
Figure 4.2 Protection of ERK2 by 12 in KB-3-1 cells, as demonstrated by the DARTS 
approach. 
To obtain a better insight into the cellular protein(s) which may be targeted by 12, a 
well-established drug-responsive target stability (DARTS) approach has been used in this 
study [95]. During the past few years, this relatively new methodology has been often 
employed as a relatively simple and widely applicable target identification approach for 
assessing drug-binding cellular targets. Based on the principle that a protein significantly 
peters out upon proteolysis when it is drug-free, yet it is resistant to protease digestion when it 
is drug-bound. The DARTS approach has been exploited for the identification of possible 
intra-cellular target(s) of 12. As demonstrated in Figure 4.2, the results from the DARTS 
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experiment have revealed that 12 "protects" ERK2 protein from enzymatic degradation in a 
dose-dependent manner.This finding is in partial agreement with the down-regulatory effects 
of 12 on ERK2. To the best of my knowledge, this is for the first time that a selective 
protection of non-phosphorylated ERK2 (and not ERK1) by an organodiselenide has been 
found using a target-identification approach. 
As mentioned in Chapter 1, there are several reports that distinguish between 
the biochemical roles of the closely related ERK isoforms [178]. Although both of these 
isoforms share around 85% homology, ERK2 has been reported to exert a more 
prominent effect on cellular viability when compared to ERK1. Many arguments have 
been put forward to explain the distinct roles of ERK1 and ERK2 in maintaining 
cellular vitality and survival and several knock-down experiments have suggested that 
ERK2 retains the upper-hand in maintaining cell viability, when compared to ERK1 
[179]. In consideration of these arguments, a selectivity of 12 towards ERK2 resulting 
in the latter's dephosphorylation may partially explain the marked decrease in tumour 
cell survival upon incubation with 12. The reasons underlying the specific preference of 
12 for ERK2, relative to ERK1 are more difficult to fathom. They may include a 
structural preference of 12 for a particular binding motif within ERK2 which may be 
difficult in case of ERK1. An alternative argument may consider the selectivity of 
potential metabolites of 12 most likely involving methyl selenol.   
Future experiments need to investigate the exact structural and/or biochemical 
reasons behind this bias of 12 towards ERK2. It is believed that this observation could 
serve as a valuable hint for drug development involving the anti-carcinogenic effects of 
organodiselenides.Somewhat surprisingly, however, no potential interaction of 12 with 
the core proteins within the PI3K-Akt-mTOR signalling cascade have been observed 
during the course of current investigations, using this particular DARTS approach 
In order to substantiate the findings obtained previously from the DARTS 
experiment, a ligand-binding assay has been carried out, in co-operation with 
DiscoverX (USA) in order to assess the extent of thermodynamic interactions of 12 with 
a full-length ERK2 kinase.This assay has served as a platform for measuring 
quantitatively measure interactions between 12 and ERK2. In accordance with the 
results obtained, the Kd (binding affinity) value, obtained from a dose-dependent 
incubation of 12 with recombinant ERK2 protein has been calculated to be around 3.7 
Chapter 4  Discussion 
 
144 
 
µM. Interestingly, at a similar concentration, the cyclic diselenide (12) had also been 
observed to display an inhibition in activation of ERK2 in the KB-3-1 cell lysate, using 
the Western Blot analysis technique. The Kd obtained, therefore, has indicated a 
moderate interaction of ERK2 with 12. Nonetheless, this study does not provide any 
information regarding the chemical nature of the binding interactions between ERK2 
and 12. 
In a follow-up of this study, therefore, future experiments need to be designed 
in order to investigate the probable binding domains in the ERK2 protein that could 
serve as potential interaction sites for 12. Such studies may surely provide a more 
detailed in-sight into the chemical and biochemical factors that underlie the selective 
affinity to 12 towards ERK2. 
In a related context, it is well documented that tumour cells harbor higher 
levels of OS relative to normal and healthy cells [14]. This OS has been proposed to be 
utilised by cancer cells as a "driving force" for their proliferation via the activation of 
several genetic factors and signalling pathways [15]. On the contrary, "too much" 
intracellular accumulation of OS may also push tumour cells towards cellular suicide. 
This situation can be conveniently considered to a situation of giving a dose of poison 
("extra" ROS induced by an external stimulus) to a critically-sick patient (tumour cells, 
in this case). This additional dose of ROS may be effectively induced by the inhibition 
of ROS-scavenging cellular antioxidants like TrxR (in this case). The potent inhibition 
of mammalian TrxR by two selenium and tellurium-containing naphthoquinones (16 or 
17) in the sub-micromolar range, as observed in this study, has partially explained the 
ROS-inducing ability of such compounds against cancer cells. The latter effect had been 
previously reported by Jacob et al. [143]. Unlike several other anti-cancer 
organoselenium compounds like ebselen and methyl seleninate that have been reported 
to exert their redox-regulatory effects by serving as a substrate of mammalian TrxR, the 
chalcogen-containing naphthoquinones such as 16 and 17 have proved themselves as 
potential inhibitors of mammalian TrxR in the TrxR inhibition assay that has been 
carried out in the research group of Prof. Ingo Ott (Department of Bioinorganic 
Medicinal Chemistry, Technical University, Braunschweig) [151]. Future studies are 
needed to provide an explanation for the comparably high inhibitory potential of the 
tellurium-containing naphthoquinone in comparison to its selenium-containing 
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counterpart. In addition, it would also be interesting to carry out detailed structure-
activity relationship (SAR) studies of these redox-active molecules in order to identify 
the distinct pharmacophore(s) or reactive sites in these molecules which are ultimately 
responsible for inhibiting TrxR.  
In addition to a detailed investigation into the anti-cancer activities of 10, 11 
and 12 against mammalian cell lines, an anti-microbial assay of these chemotherapeutic 
compounds has been also carried out with a basic motive to explore possible wider 
spectra of their potential targets in the microbial domain. In accordance with the results, 
the anti-microbial activities of 10, 11 and 12 against the selected microbial strains have 
been observed to be rather modest. Additional experiments with many other pathogenic 
strains, however, are needed to have a broader scenario of the anti-microbial spectrum 
of such chemotherapeutic compounds, in addition to identifying precise biochemical 
reasons behind the higher activity of these compounds towards some fungal strains in 
comparison to bacterial strains, as has been observed in this study. Therefore, such 
organodiselenides may, therefore, exhibit some cytotoxic effects against mammalian 
cell lines, but are apparently not potential candidates for the future development of 
innovative redox-modulatory anti-microbial agents.  
The relationship between the electrochemical behaviour of compounds and 
their redox-regulated biological activity is very interesting. Based on this concept, an 
investigation into the relationship between the significant biological activity of 12 and 
its electrochemical characteristics has been carried out in co-operation with Dr. Joseph 
(Noorul Islam University, Tamil Nadu, India). According to the electrochemical results 
observed in this study, a high reduction potential of compound 12 may well indicate it 
to be rather oxidising which may attribute to its apoptosis-inducing activity in tumour 
cells. In contrast, the selenophenes (ARS-01 to ARS-06) have not been observed to be 
redox-active as far as the chalcogen moiety is concerned, which is surprising and 
disappointing. This may, however, be due to the "extra stability” of the chalcogen 
moiety within the aromatic framework of the selenophenes. However, the redox activity 
of the most active selenophenes ARS-01 and ARS-02 may have resulted from their 
phenolic groups which also ultimately explains their significant anti-oxidant effects, as 
observed in the DPPH and FRAP redox assays. The redox activities of ARS-01 and 
ARS-02 are probably not due to a redox modulation (in the presence of sulfur or 
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selenium) but due to their binding to specific cellular targets (like estrogen receptors as 
in the case of ARS-01) which may have no relation with the chalcogen moiety or indeed 
redox modulation [189]. The results obtained from the DPPH assay point towards a 
relatively low radical-scavenging activity of 12 at 1 mg ml
-1
 (33.5 ± 1.6 %) in 
comparison to a more significant effect displayed by ascorbic acid at 1 mg ml
-1              
(72.0 ± 1.2%). A similar result has also been obtained in the FRAP assay where a 
relatively low FRAP value (of 221 ± 39 µmol equiv of Fe
2+
 l
-1 
has been measured for 
12, in comparison to that of ascorbic acid (2664 ± 51 µmol equiv of Fe
2+
 l
-1
). Though 
not promising, the average radical-scavenging effect of 12 could probably be due to the 
presence of the electron-donating nitrogen atom of the quinoline ring. However, this 
argument has not been found to be valid in case of 10 and 11, which despite the 
presence of a nitrogen-containing pyridine ring have neither exhibited any observable 
decline in DPPH levels nor a significant reduction of the Fe(TPTZ)3 complex. Such a 
contrast in the reducing ability of 12 on the one hand, and 10 or 11 on the other is even 
more surprising despite the similar basicities (pKa ~5) of pyridine (in case of 10 or 11) 
and quinoline ring systems (in case of 12) [181].     
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Figure 4.3 Proposed mechanism of radical-scavenging activity of phenolic groups by - 
(a) One-step hydrogen transfer (reaction I) or  
(b) Electron transfer (reaction II or III) 
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The anti-oxidant activities of coumarins has been demonstrated to be due to 
their hydroxyl groups that serve directly as free radical scavengers via facile generation. 
As displayed in Figure 4.3, this radical-scavenging effect has been proposed to proceed 
either by an electron transfer (ET) from phenolate anions or by a hydrogen atom transfer 
from the phenolic hydroxyl group [182].  
Owing to a lower redox potential, however, the phenolate anion furnished by a 
phenolic group-bearing compound has been reported to harbor a higher radical-
scavenging ability compared to its parent phenolic form [183]. 
In regard to the above arguments that explain the possible mechanism of anti-
oxidative effects of phenols, it can be hypothesized that the potential radical-scavenging 
ability of ARS-01 and ARS-02 could be convincingly attributed to the presence of free 
phenolic hydroxyl groups in these molecules, that probably serve as the critical 
functionality to explain the significant DPPH radical scavenging effects for these 
compounds in addition to their significantly high FRAP values. In contrast, the 
inconsequential anti-oxidant effects of the other selenophenes (ARS-03 to ARS-06) 
could be due to the absence of phenolic hydroxyl groups and an apparently non-active 
role of the chalcogen moiety in their chemical structure.      
In consideration of the above arguments, the presence of phenolic groups in 
ARS-01 and ARS-02 could serve as a logical hypothesis for their potential anti-oxidant 
and radical-scavenging ability. In contrast, the potentially low anti-oxidant ability of the 
selenium-containing coumarins (ARS-03 to ARS-06) could be attributed to the absence 
of phenolic hydroxyl groups and an apparently non-relevant role of the chalcogen 
moiety in such molecules. 
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Conclusion and Outlook  
Remarkable progress has been made during the past few decades in expanding 
the existing knowledge of the biological action of organoselenium compounds in its 
diverse chemical and biochemical forms. Inspite of the chemical sensitivity and 
susceptibility of selenium, significant synthetic progress has been achieved in 
expanding the chemical library of organoselenium compounds, with a particular 
emphasis towards the chemical synthesis and derivatisation of naturally occurring and 
biologically active organoselenium compounds [184]. This, in turn, has provided 
biologists and biochemists with ample sources of organoselenium compounds for 
evaluating their unique biochemical mode of action of such molecules, particularly 
against cancer cells.  
In spite of the diverse nature of organoselenium compounds that have been 
analysed so far for chemotherapeutic efficacy, most of these compounds have 
apparently discharged their therapeutic effects through a common cascade of 
biologically active metabolites such as methyl selenol and hydrogen selenide. These 
compounds have been frequently reported to exert their anti-cancer effects by 
monitoring the redox-regulated transcriptional and translational pathways within the 
intracellular environment of various tumours [185]. The extent of effectiveness of these 
organoselenium compounds against cancer, however, has been observed to vary 
considerably with dosage and nature of the administered source of selenium. In this 
study, the anti-cancer activity of the main compound of study (12) has been observed to 
bear a close resemblance with that of the previously reported anti-cancer effects of 
methyl selenol in terms of its apoptosis-inducing activity, on the one hand, and its 
inhibitory effects against the translational and oncogenic ERK-mediated MAPK 
pathway, on the other [108]. On this note, an apparent selectivity of 12 towards ERK2, 
as observed in the DARTS experiment, points towards a possible affinity of naturally 
occurring organic selenium sources like SEM or SeMC towards ERK2.  
Since tumour cells are observed to thrive under high levels of oxidative stress, 
an attenuation of the latter by potential antioxidants has been proposed to serve as an 
effective strategy to counter cancer [186]. In spite of the widely discussed and 
frequently observed cross-talk between the anti-oxidant and anti-cancer effects of small 
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molecules, such a relationship has apparently not been observed in this study in case of 
compounds 10, 11 or 12. In contrast, the chalcophenes ARS-01 and ARS-02 that have 
been observed to display relatively weaker anti-cancer effects than the 
organodiselenides (10, 11 or 12) have demonstrated rather significant anti-oxidant 
properties than the latter. This may raise questions regarding the extent of contribution 
of the direct and indirect antioxidant activities of polyphenols (like ARS-01 or ARS-02) 
towards suppressing proliferation of cancer cells. In this regard, however, till date there 
is apparently no concrete and consistent link between the anti-oxidant and 
chemotherapeutic effects of small molecules.  
On the contrary, an induction of an extra pinch of oxidative stress in tumour 
cells has been an alternative and an apparently more effective strategy in the treatment 
of cancer. Thriving at a precarious level of oxidative stress, the fate of tumour cells has 
been observed to be highly susceptible to modulation in the activities of cellular anti-
oxidant enzymes like TrxR. This concept has been extensively exploited by a range of 
molecules like auranofin which have been reported to induce ROS-mediated apoptosis 
in tumour cells via inhibition of TrxR [187]. A similar mode of action has also been 
observed, during the current study, in case of chalcogen-containing naphthoquinones 
(16 and 17). In due consideration of the fact that only a few chalcogen-containing 
compounds have so far been identified as TrxR-inhibitors, with a majority of them 
serving rather as TrxR substrates, such chalcogen-containing naphthoquinones may 
serve as a potential lead in the design of futuristic TrxR-inhibiting chemotherapeutics.  
In the current situation, the exact biochemical anti-cancer effects of 
organoselenium compounds are still clouded by contradictory results and opinions. 
Inspite of selenium's promising chemotherapeutic effects observed in several in-vitro 
and in-vivo experiments, there is still a wide scope for a deeper comprehension of the 
precise biochemistry that organoselenium compounds share and ultimately may impact 
on cancer, its formation, progression and eradication.    
To sum up this study, from a diverse range of organoselenium compounds 
belonging to distinct categories of monoselenides (1-9), diselenides (10-15) and 
chalcophenes (ARS-01 toARS-06), the diselenides have exhibited the highest anti-
cancer activity in-vitro. However, such an appreciable activity of the diselenides can be 
more reasonably attributed to their cytotoxicity against mammalian cells rather than to 
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their selectivity against tumour cells. Such anti-cancer effects of the most active 
diselenides (10-12) have been observed to be an outcome of caspase 3/7 - mediated 
apoptosis which has been induced by these diselenides in cervix carcinoma (KB-3-1) 
cells. Furthermore, compound 12 hasnot only inhibited the translational machinery but 
also targeted the translation-associated Raf/MEK/ERK and PI3K/Akt/mTOR pathways 
of KB-3-1 cells. On this note, a DARTS approach has also indicated a selective 
interaction of 12 with ERK2. Inspite of their considerable anti-cancer activities, these 
diselenides (10-12) have displayed poor anti-oxidant effects. In contrast, only the 
selenophenes (ARS-01 and ARS-02) have demonstrated a significant anti-oxidant effect 
in the DPPH and FRAP redox assays primarily due to the action of the phenolic 
hydoxyl groups and apparently not due to the chalcogen moiety. 
In another context, compounds 16 and 17 which belong to a distinct group of 
chalcogen-containing naphthoquinones have been studied to act as active inhibitors of 
mammalian TrxR. This behaviour could form an additional biochemical reason to 
further explain their previously reported ROS-mediated induction of apoptosis in 
tumour cells.  
In view of the appreciable chemotherapeutic potential demonstrated by 
organoselenium compounds in a range of in-vitro and in-vivo experiments carried out 
over the last decade, it can be safely proposed that such compounds should not be 
ignored in the design and synthesis of drugs against cancer. Moreover, compared to a 
rather narrow focus on the efficacy of organoselenium compounds against primary 
tumours, more attention should be diverted towards the identification and a probable 
exploitation of the therapeutic effects of these compounds in tackling cancer 
progression and metastasis.  
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Figure 5. 
1
H (a) and 
13
C NMR of 1,2-bis{(pyridine-3-yl}methyl)diselane, 10 
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Figure 7. 
1
H (a) and 
13
C NMR of 1,2-bis{(pyridine-4-yl}methyl)diselane, 11 
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